



(11) **EP 1 346 061 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
17.12.2014 Bulletin 2014/51

(51) Int Cl.:
C12N 9/64 (2006.01) **A61K 38/00** (2006.01)
C07K 14/47 (2006.01) **C12Q 1/37** (2006.01)
C12Q 1/68 (2006.01) **G01N 33/68** (2006.01)

(21) Application number: **01978230.9**

(86) International application number:
PCT/DK2001/000695

(22) Date of filing: **19.10.2001**

(87) International publication number:
WO 2002/032953 (25.04.2002 Gazette 2002/17)

(54) **PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2)**

SCHWANGERSCHAFTSASSOZIIERTES PLASMAPROTEIN A2 (PAPP-A2)

PROTEINE PLASMATIQUE A2 ASSOCIEE A LA GROSSESSE (PAPP-A2)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(30) Priority: **20.10.2000 DK 200001571**
20.10.2000 US 241840 P

(43) Date of publication of application:
24.09.2003 Bulletin 2003/39

(60) Divisional application:
10183761.5 / 2 339 020

(73) Proprietor: **Como Biotech APS**
8000 Aarhus C (DK)

(72) Inventors:
• **OXVIG, Claus**
DK-8260 Viby J (DK)
• **OVERGAARD, Michael, Toft**
DK-9260 Gistrup (DK)

(74) Representative: **Aamand, Jesper L. et al**
Jesper Levin A/S
Vedbaek Strandvej 341
2950 Vedbaek (DK)

(56) References cited:
WO-A-00/54806 WO-A-01/75067
WO-A-01/95855

- **LAWRENCE J B ET AL:** "The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protase secreted by human fibroblasts is pregnancy-associated plasma protein-A." **PROC. NATL. ACAD. SCI.**, vol. 96, March 1999 (1999-03), pages 3149-3153, XP002902423 & **DATABASE EMBL [Online] PAPA- HUMAN, Q13219, Q08371, Q9UDK7; 16 October 2001 (2001-10-16)**
- **KRISTENSEN T ET AL:** "Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA." **BIOCHEMISTRY**, vol. 33, 1994, pages 1592-1598, XP002902424 & **DATABASE EMBL [Online] PAPA-HUMAN, Q13219, Q08371, Q9UDK7; 16 October 2001 (2001-10-16)**
- **OVERGAARD M T ET AL:** "Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor." **THE JOURNAL OF BIOLOGICAL CHEMISTRY**, vol. 275, no. 40, 6 October 2000 (2000-10-06), pages 31128-31133, XP002902425 & **DATABASE EMBL [Online] PAPA-HUMAN, Q13219, Q08371, Q9UDK7; 16 October 2001 (2001-10-16)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 346 061 B1

- OXVIG C ET AL: "Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 23, 9 June 1995 (1995-06-09), pages 13645-13651, XP002902426 & DATABASE EMBL [Online] PAPA-HUMAN , Q13219, Q08731, Q9UDK7; 16 October 2001 (2001-10-16)
- OVERGAARD M T ET AL: "Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: Expression in human reproductive and nonreproductive tissues." BIOLOGY AND REPRODUCTION, vol. 61, 1999, pages 1083-1089, XP002902427 & DATABASE EMBL [Online] PAPA-HUMAN , Q13219, Q08371, Q9UDK7; 16 October 2001 (2001-10-16)
- BONNO M ET AL: "Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta." LABORATORY INVESTIGATION, vol. 71, no. 4, 1994, pages 560-566, XP002902428 & DATABASE EMBL [Online] PAPA-HUMAN, Q13219, Q03871, Q9UDK7; 16 October 2001 (2001-10-16)
- PAGE N M ET AL: "The characterization of pregnancy associated plasma protein-E and the identification of an alternative splice variant." PLACENTA, vol. 22, 2001, pages 681-687, XP002902429 & DATABASE EMBL [Online] PAPA-HUMAN, Q13219, Q08371, Q9UDK7.; 16 October 2001 (2001-10-16)
- OVERGAARD M T ET AL: "Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 24, 16 June 2001 (2001-06-16), pages 21849-21853, XP002902430 & DATABASE EMBL [Online] Q9BXP8.; XP000000008
- FARR M ET AL: "Pregnancy-associated plasma protein-E (PAPP-E)" BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1493, no. 3, 2 October 2000 (2000-10-02), pages 356-362, XP004275781 ISSN: 0167-4781 & DATABASE EMBL [Online] Q9H4C9.; 1 March 2001 (2001-03-01)
- CHRISTIANSEN M ET AL: 'Quantification and characterization of pregnancy-associated complexes of angiotensinogen and the proform of eosinophil major basic protein in serum and amniotic fluid.' CLINICAL CHEMISTRY vol. 46, no. 8, 2000, pages 1099 - 1105, XP002902701
- OXVIG C ET AL: "Circulation human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 17, 1993, pages 12243-12246, XP002902702
- ERICKSON G F ET AL: "The physiology of folliculogenesis: the role of novel growth factors." FERTILITY AND STERILITY, vol. 76, no. 5, November 2001 (2001-11), pages 943-949, XP002902431
- GORDON C S SMITH ET AL: "Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth" THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 87, no. 4, April 2002 (2002-04), pages 1762-1767, XP002902703
- GIUDICE L C ET AL: "Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: Evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation." THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 87, no. 5, May 2002 (2002-05), pages 2359-2366, XP002902704
- WALD N J ET AL: "First trimester serum screening for down's syndrome." PRENATAL DIAGNOSIS, vol. 15, 1995, pages 1227-1240, XP002902432

Description**FIELD OF THE INVENTION**

5 **[0001]** The present invention relates to a novel polypeptide with homology to pregnancy-associated plasma protein-A (PAPP-A). The novel polypeptide according to the invention is denoted PAPP-A2. The invention further relates to novel polynucleotides comprising a nucleic acid sequence encoding such a polypeptide, or a fragment thereof.

[0002] The invention further relates to methods for using the novel polynucleotides, including fragments thereof as defined herein below, and methods for using the novel polypeptides capable of being produced from such polynucleotides.

10 **[0003]** The invention also relates to expression and purification of recombinant PAPP-A2, and to production of polyclonal and monoclonal antibodies against PAPP-A2, and to the purification of native PAPP-A2 from human tissues or body fluids.

[0004] In further aspects the invention relates to uses of PAPP-A2 as a marker for pathological states, and as a therapeutic target for drugs that modify the proteolytic activity of PAPP-A2 in pregnant as well as non-pregnant individuals.

BACKGROUND OF THE INVENTIONPregnancy-associated plasma protein-A (PAPP-A)

20 **[0005]** PAPP-A was first isolated in 1974 from pregnancy serum along with other proteins believed to be of placental origin (Lin et al., 1974, Am J Obstet Gynecol 118, 223-36). The concentration in serum reaches about 50 mg/liter at the end of pregnancy (Folkersen et al., 1981, Am J Obstet Gynecol 139, 910-4; Oxvig et al., 1995, J Biol Chem 270, 13645-51). PAPP-A was originally characterized as a high molecular weight homotetramer (Bischof, 1979, Arch Gynecol 227, 315-26; Lin et al., 1974, Am J Obstet Gynecol 118, 223-36; Sinosich, 1990, Electrophoresis 11, 70-8), but it has

25 now been demonstrated that PAPP-A primarily exists in pregnancy serum and plasma as a covalent, heterotetrameric 2:2 complex with the proform of eosinophil major basic protein (proMBP), PAPP-A/proMBP (Oxvig et al., 1993, J Biol Chem 268, 12243-6). Only about 1% of PAPP-A in pregnancy serum and plasma is present as a homodimer, as recently demonstrated (Overgaard et al., 2000, J Biol Chem). The existence of the PAPP-A/proMBP complex was revealed, in part, by the isolation of a PAPP-A and a proMBP peptide, linked together by a disulfide bond, from a digest of purified

30 PAPP-A/proMBP (Oxvig et al., 1993, J Biol Chem 268, 12243-6).

[0006] The subunits of the PAPP-A/proMBP complex can be irreversibly separated by reduction of disulfide bonds and denaturation (Oxvig et al., 1993, J Biol Chem 268, 12243-6). In reducing SDS-PAGE, the PAPP-A subunit has an apparent molecular weight of 200 kDa (Oxvig et al., 1994, Biochim Biophys Acta 1201, 415-23), and its 1547-residue sequence is known from cloned cDNA (Kristensen et al., 1994, Biochemistry 33, 1592-8). PAPP-A is synthesized as a pre-pro-protein (preproPAPP-A), including a 80-residue pre-pro-piece (Haaning et al., 1996, Eur J Biochem 237, 159-63). No proteins with global homology to PAPP-A has been reported in the literature, but PAPP-A contains sequence motifs, including an elongated zinc binding motif (HEXXHXXGXXH) at position 482-492 (numbering according to Kristensen et al., 1994, Biochemistry 33, 1592-8). This motif and a structurally important methionine residue, also thought to reside

35 in PAPP-A at position 556, are strictly conserved within the metzincins, a superfamily of zinc peptidases: astacins, adamalysins (or reprolysins), serralsins and matrixins (matrix metalloproteinases or MMP's) (Bode et al., 1993, FEBS Lett 331, 134-40; Stocker et al., 1995, Protein Sci 4, 823-40).

[0007] The proMBP subunit has a calculated peptide mass of 23 kDa (Barker et al., 1988, J Exp Med 168, 1493-8; McGrogan et al., 1988, J Exp Med 168, 2295-308). In SDS-PAGE, however, proMBP migrates as a smear of 50-90 kDa that is not visible in Coomassie-stained gels (Oxvig et al., 1993, J Biol Chem 268, 12243-6), probably due to its strong and unusual glycosylation (Oxvig et al., 1994, Biochem Mol Biol Int 33, 329-36; Oxvig et al., 1994, Biochim Biophys Acta 1201, 415-23). PAPP-A and proMBP are both produced in the placenta during pregnancy, but mainly in different cell types as shown by *in situ* hybridization (Bonno et al., 1994, Lab Invest 71, 560-6). Analyses by RT-PCR revealed that both PAPP-A and proMBP mRNA are present in several reproductive and nonreproductive tissues, although the levels are lower than in the placenta (Overgaard et al., 1999, Biol Reprod 61, 1083-9).

Clinical use of PAPP-A

50 **[0008]** Clinically, depressed serum levels of PAPP-A are increasingly being used as a predictor of Down's syndrome pregnancies (Brambati et al., 1993, Br J Obstet Gynaecol 100, 324-6; Haddow et al., 1998, N Engl J Med 338, 955-61; Wald et al., 1992, Bmj 305, 28; Wald et al., 1999, N Engl J Med 341, 461-7), and it has been shown that PAPP-A serum levels are also depressed in other fetal abnormalities (Biagiotti et al., 1998, Prenat Diagn 18, 907-13; Spencer et al., 2000, Prenat Diagn 20, 411-6; Westergaard et al., 1983, Prenat Diagn 3, 225-32).

[0009] Further, the synthesis of PAPP-A in smooth muscle cells of the coronary artery following angioplasty is increased

(Bayes-Genis et al., 2000, *Arterioscler Thromb Vasc Biol*, in press), which is currently being evaluated for potential clinical value. Data show that measurements of proMBP in pregnancy serum also have a diagnostic value (Christiansen et al., 1999, *Prenat Diagn* 19, 905-10).

5 Proteolytic activity of PAPP-A: Cleavage of IGFBP-4

[0010] Only recently, the putative metalloproteinase activity of PAPP-A has been experimentally confirmed (Lawrence et al., 1999, *Proc Natl Acad Sci U S A* 96, 3149-53). PAPP-A was partially purified from human fibroblast-conditioned medium (HFCM) and shown to be responsible for the proteolytic activity of HFCM against insulin-like growth factor binding protein (IGFBP)-4. IGFBP's, of which six have been described, are important modulators of IGF-I and -II activity (Fowlkes, 1997, *Trends Endocrinol Metab* 8, 299-306; Rajaram et al., 1997, *Endocr Rev* 18, 801-31).

[0011] IGF-I and -II are essential polypeptides with potent anabolic and mitogenic actions both *in vivo* and *in vitro*. IGF bound to IGFBP-4 cannot interact with its receptor, but bioactive IGF is released once the binding protein is cleaved. Interestingly, cleavage of IGFBP-4 by PAPP-A strictly requires the presence of IGF (Conover et al., 1993, *J Clin Invest* 91, 1129-37; Lawrence et al., 1999, *Proc Natl Acad Sci U S A* 96, 3149-53). PAPP-A secretion has also been demonstrated from osteoblasts and marrow stromal cells (Lawrence et al., 1999, *Proc Natl Acad Sci U S A* 96, 3149-53), from granulosa cells (Conover et al., 1999, *J Clin Endocrinol Metab* 84, 4742-5), and from vascular smooth muscle cells (Bayes-Genis et al., 2000, *Arterioscler Thromb Vasc Biol*, in press), all of which have known IGF-dependent IGFBP-4 proteinase activity.

20 IGFBP-5

[0012] Like IGFBP-4, IGFBP-5 cleavage has been widely reported to occur by unidentified proteinases in a number of tissues and conditioned media (Hwa et al., 1999, *Endocr Rev* 20, 761-87).

[0013] Lawrence et al. (The Insulin-like growth factor-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A; *Proc. Natl. Acad. Sci.* Vol. 96, March 1999, pp. 3149-53) discloses that purification of IGF-dependent IGFBP-4 protease from human fibroblast-conditioned medium ("HFCM") was performed, and that the proteins identified by tandem mass spectrometry was PAPP-A. PAPP-A and the IGF-dependent IGFBP-4 protease from HFCM are similar in that they are both high molecular weight glycosylated proteins that bind Zn^{2+} . The identification of PAPP-A as the IGF-dependent IGFBP-4 protease has implications for placental function and fetal development. In addition, the identification of the IGF-dependent IGFBP-4 protease as PAPP-A and the availability of pure protein and associated molecular tools now allows determination of the mechanism underlying its IGF dependence and the biological role of localized IGF-dependent IGFBP-4 proteolysis in wound healing, bone remodeling, atherosclerosis, and follicular development.

[0014] Kristensen et al. (Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA; *Biochem.*, Vol. 33, 1994, pp. 1592-98) discloses that the amino acid sequence of human pregnancy-associated plasma protein-A (PAPP-A), a component of the circulating complex with the proform of eosinophil major basic protein (proMBP), has been determined from partial protein sequencing and from sequencing of cloned cDNA. The PAPP-A monomer contains 1547 amino acid residues, but is derived from a larger precursor of placental origin. PAPP-A contains 82 Cys residues, which are all bridged, 14 putative sites for N-glycosylation, and 7 putative sites for attachment of glycosaminoglycan groups. The C-terminal part of PAPP-A contains 5 approximately 60-residue motifs related to the short consensus repeats of complement proteins and selectins. The SCRs presently known can be grouped into three classes: complement-type, class I; selectin-type, class II; PAPP-A-type, class III. PAPP-A further contains three approximately 26-residue motifs, related to the lin-notch motifs of proteins regulating early tissue differentiation, and, in addition, a putative Zn^{2+} binding site similar to that found in many metalloproteinases has been identified. Apart from these features, the PAPP-A sequence is not related to other known protein sequences.

[0015] Overgaard et al. (Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor; *The J. of Biol. Chem.*, Vol. 275, no. 40, 6 October 2000, pp. 31128-33) discloses that the authors expressed the entire 1547-residue human PAPP-A in mammalian cells. Biochemical analysis showed that the activity of rPAPP-A and pregnancy serum PAPP-A/proMBP complex differs 100-fold, demonstrating a biological role of proMBP as a proteinase inhibitor of PAPP-A, and the PAPP-A activity of pregnancy serum, inhibitable with PAPP-A antibodies, is in part due to a minor fraction of uncomplexed PAPP-A present in both pregnancy serum and plasma. Comparison of rPAPP-A with PAPP-A as present in pregnancy serum reveals a strikingly lower IGFBP-4 proteolytic activity of the PAPP-A because of proMBP, as it is bound covalently to PAPP-A in pregnancy serum. Since proMBP inhibits PAPP-A in pregnancy serum, proMBP has another biological role outside the eosinophil leukocyte from where it was originally known. It also represents a novel mode of proteinase inhibition because the enzyme is covalently bound by disulfide bonds to its inhibitor. To the authors' knowledge, no analogous example of this exists in the literature. Authors hypothesize that PAPP-A activity is not inhibited but rather controlled or regulated by proMBP; they put forth the idea that PAPP-A/proMBP represents a latent form of PAPP-A that can become active

under given circumstances, possibly at the cell surface.

[0016] Oxvig et al. (Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma; *The J. of Biol. Chem.*, Vol 270, no. 23, 9 June 1995, pp. 13645-51) discloses that the authors found serum levels of proMBP to exceed those of PAPP-A four-to-tenfold on a molar basis throughout pregnancy. After investigating proMBP in pregnancy using a proMBP-specific monoclonal antibody, the authors isolated two novel proMBP complexes. One is shown to be a 2:2 disulfide-bound complex (approximately 200 kDa) between proMBP and angiotensinogen. The other is a 2:2:2 complex (approximately 300 kDa) between proMBP, angiotensinogen, and complement C3dg. They have concluded that circulating proMBP in pregnancy is present in these three types of complexes. The authors believe that specific interactions between the complexed proteins occur in pregnancy, and they predict their interactions are important in the pathophysiology of pregnancies associated with hypertension.

[0017] Overgaard et al. (Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: Expression in human reproductive and nonreproductive tissues; *Biol. and Reprod.*, Vol 61, 1999, pp. 1083-89) discloses that To analyze the presence of PAPP-A and proMBP mRNA, the authors measured the levels of PAPP-A and proMBP mRNA in a total of 43 samples from 13 different tissues, using a sensitive semi-quantitative reverse transcription (RT) polymerase chain reaction (PCR) assay. The placenta contained the highest level measured for both PAPP-A and proMBP. The authors report that PAPP-A and proMBP mRNA is synthesized by female reproductive tissues, e.g. ovary, tuba uterina, endometrium, and myometrium from postmenopausal women in addition to the placenta. Synthesis of both mRNA also occurs in nonreproductive tissues, e.g., kidney, colon, prostate, prostate carcinoma, bone marrow cells, breast, and breast carcinoma. The amount of PAPP-A and proMBP mRNA differs greatly between tissues; term placenta has more than 200-fold higher levels than any non-placental tissue tested. This finding indicates that the main site of both PAPP-A and proMBP synthesis during pregnancy is the placenta. However, the authors found that the ratio between the specific amount of proMBP and PAPP-A mRNA in the placenta is not constant during pregnancy. The low mRNA levels of nonplacental tissues are shown by the extremely low serum concentrations of PAPP-A and proMBP antigen in nonpregnant individuals. The finding that PAPP-A mRNA is synthesized in all the examined tissues, reproductive as well as nonreproductive, was surprising to the authors, and indicated that PAPP-A functions outside pregnancy.

[0018] Bonno et al. (Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta; *Lab. Invest.*, Vol. 71, no. 4, 1994, pp.560-66) discloses that pregnancy-associated plasma protein-A (PAPP-A) is composed of PAPP-A subunits bound by disulfide bonds to equimolar amounts of proMBP molecules to form a complex, PAPP-A/proMBP. To determine the localization of the PAPP-A subunit, immunofluorescence was performed on normal placental tissues using proMBP-absorbed anti-PAPP-A antibody. Furthermore, the expression of PAPP-A mRNA was investigated by in situ hybridization. PAPP-A is localized to placental septa, anchoring villi, and the syncytia of chorionic villi, whereas MBP is localized only to septa and anchoring villi. By in situ hybridization, PAPP-A mRNA is detected in placental X cells and syncytiotrophoblasts, but MBP mRNA is localized only to placental X cells. The presence of PAPP-A mRNA and PAPP-A subunit protein in placental X cells and syncytiotrophoblasts indicates that both X cells and syncytiotrophoblasts synthesize the PAPP-A subunit, whereas only X cells synthesize proMBP.

[0019] Page et al. (The characterization of pregnancy-associated plasma protein-E and the identification of an alternative splice variant; *Placenta*, Vol. 22, 2001 pp.681-87) discloses that the authors have performed differential display and bioinformatic database mining of the placenta in an attempt to find novel diagnostic markers of pathological pregnancies. They have identified a full-length cDNA encoding the preproprotein of pregnancy associated plasma protein-E (PAPP-E); a putative metalloprotease, of 1790-residues with a putative 21-residue signal peptide. An alternatively spliced mRNA was found to encode an 826-residue precursor protein corresponding to the N-terminus of PAPP-E. Both PAPP-E variants were found to be co-expressed abundantly in the placenta and non-pregnant mammary gland with low expression in the kidney, fetal brain and pancreas. Gene structure analysis revealed that PAPP-E was encoded on 23 exons on chromosome 1 and its splice variant on the first five same exons. Authors believe that this discovery will help in the deciphering of the physiology of this new family of metzincins in not only the placenta during pregnancy, but also the mammary gland in breast cancer. Authors believe the new PAPP-E variants could have the potential for the diagnosis of pathological pregnancies including trisomies such as Down's syndrome.

[0020] Overgaard et al. (Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase; *The J. of Biol. Chem.*, Vol. 276, no. 24, 16 June 2001, pp. 21849-53) discloses that the authors have identified a novel metalloproteinase with similarity to pregnancy-associated plasma protein-A (PAPP-A), which they call PAPP-A2. Recombinant PAPP-A2 polypeptide of 1558 residues resulted from processing of a 1791-residue prepro-protein. Unlike PAPP-A, PAPP-A2 migrated as a monomer (of 220 kDa) in non-reducing SDS-polyacrylamide gel electrophoresis. The prepro-parts of PAPP-A2 and PAPP-A are not homologous, but mature PAPP-A2 shares 45% of its residues with PAPP-A. PAPP-A2 specifically cleaved IGFBP-5 at one site, between Ser-143 and Lys-144. In contrast to the cleavage of IGFBP-4 by PAPP-A that strictly requires the presence of IGF, the cleavage of IGFBP-5 by

PAPP-A2 was IGF-independent. Like PAPP-A, PAPP-A2 expression is neither limited to the placenta nor to pregnancy.

[0021] Farr et al. (Pregnancy-associated plasma protein-E (PAPP-E); *Biochimica ET Bio-physica ACTA, Gene Structure and Expression*, Elsevier, Amsterdam, NL, Vol. 1493, no. 3, 2 October 2000 pp. 356-62) discloses that the authors have cloned a full-length cDNA encoding a novel human protein from placenta cDNA. The corresponding 1542 amino acid protein sequence was termed 'pregnancy-associated plasma protein-E' (PAPP-E) as it shows a 62% homology to the human pregnancy-associated plasma protein-A (PAPP-A). Both proteins share the same domain structure and authors believe they probably form a new subfamily of metzincins. The PAPP-E gene has been assigned to chromosome 1 and is predominantly expressed in placenta. The authors still need to analyze the biological role of PAPP-E.

[0022] Christiansen et al. (Quantification and characterization of pregnancy-associated complexes of angiotensinogen and the proform of eosinophil major basic protein in serum and amniotic fluid; *Clin. Chem.*, Vol. 46, no. 8, 2000, pp. 1099-1105) discloses that the authors developed ELISAs against three different groups of proMBP-containing complexes (i.e., proMBP/Ang with or without complement C3dg, and proMBP/C3dg), and an assay to measure the total amount of all proMBP complexes, including PAPP-A/proMBP using one monoclonal antibody, 234-10, against the proMBP part of PAPP-A/proMBP and polyclonal antibodies against complement C3d and Ang. The ELISAs developed by the authors allow measurement of the concentrations of proMBP/Ang and proMBP/C3dg in various clinical conditions and support studies for the regulation of synthesis in in vitro systems. Furthermore, authors claim it will be possible to get a better understanding of the relationship between the maternal serum concentration of proMBP complexes and fetal chromosomal disease.

[0023] Oxvig et al. (Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein; *The J. of Biol. Chem.*, Vol. 268, no. 17, 1993, pp. 12243-12246) discloses that the authors found that proMBP is a constituent of circulating PAPP-A, and this is the first demonstration of this molecule in serum. They made that conclusion based on the following: 1) Tryptic peptides originating from proMBP were found in a digest of reduced and carboxymethylated PAPP-A/proMBP; 2) a disulfide-bridged peptide connecting proMBP and PAPP-A and a peptide spanning the proMBP processing site have been isolated from nonreduced PAPP-A/pro-MBP in high yield; 3) sequence analysis shows that PAPP-A/pro-MBP contains three NH₂-terminal sequences, one originating from the PAPP-A subunit, and two originating from proMBP; 4) the PAPP-A subunit can be separated from the proMBP subunit by denaturing gel chromatography of reduced and carboxymethylated PAPP-A/proMBP; 5) mAbs directed against the propeptide of MBP and against mature MBP react strongly with reduced PAPP-A/proMBP and with the material separated from the PAPP-A subunit by reducing SDS-PAGE or denaturing gel chromatography. Authors found that in the complex, one PAPP-A subunit is likely to be bound to one molecule of proMBP. Authors conclude that the physiological significance of the interaction between PAPP-A and ProMBP in pregnancy is not known, but the results reported here provide a novel basis for studying the biological roles of PAPP-A and placental MBP.

[0024] WO0054806A (INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 PROTEASE, 21 September 2000) discloses a method for screening for or diagnosing a growth-promoting state (such as restenosis, atherosclerosis, ovulation, wound healing, fibrosis, or cancer) in a non-pregnant patient, said method comprising: detecting a level of pregnancy-associated plasma protein-A (PAPP-A) in a biological sample (such as blood, urine, pleural fluid, oral washings, tissue biopsies, and follicular fluid) from said non-pregnant patient, and comparing said level of PAPP-A in said non-pregnant patient to a standard level of PAPP-A in non-pregnant patients, wherein an increase in said level of PAPP-A in said non-pregnant patient indicates the presence of said growth-promoting state. WO0054806A further discloses 1) a monoclonal antibody having specific binding affinity for PAPP-A, wherein PAPP-A is free of proMBP; 2) a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an agent that alters the protease activity of PAPP-A; 3) a method for identifying an agent inhibiting the protease activity of PAPP-A, said method comprising incubating an isolated PAPP-A polypeptide, an activator of protease activity, and a substrate of PAPP-A with said agent to determine if proteolysis of said substrate is inhibited; 4) a medical device for placement in a patient, said medical device comprising an agent that alters PAPP-A protease activity; 5) a method for making a monoclonal antibody having specific binding affinity for PAPP-A and 6) a method for detecting PAPP-A in a biological sample.

[0025] WO 0175067A (NOVEL NUCLEIC ACIDS AND POLYPEPTIDES, 11 October 2001) provides novel polynucleotides and proteins encoded by such polynucleotides, along with uses for these-polynucleotides and proteins, for example in therapeutic, diagnostic and research methods. The compositions of the present application include novel isolated polypeptides, novel isolated polynucleotides encoding such polypeptides, including recombinant DNA molecules, cloned genes or degenerate variants, especially naturally occurring variants such as allelic variants, antisense polynucleotide molecules, and antibodies that specifically recognize one or more epitopes present on such polypeptides, as well as hybridomas producing such antibodies. The compositions of the present application additionally include vectors, including expression vectors, containing the polynucleotides of the application, cells genetically engineered to contain such polynucleotides and cells genetically engineered to express such polynucleotides. The methods of WO 0175067A also provide methods for treatment which involve the administration of the polynucleotides or polypeptides of the invention to individuals exhibiting certain symptoms. In addition, the application encompasses methods for treating diseases or disorders by administering compounds and other substances that modulate the overall activity of the target

gene products.

[0026] Erickson et al. (The physiology of folliculogenesis: the role of novel growth factors; Fert. and Ster., Vol. 76, no. 5, November 2001, p. 947) discloses that the existence of PAPP-A in human follicular fluid fits the hypothesis that PAPP-A may be responsible for the IGFBP-4 protease activity known to be present in follicular fluid. PAPP-A, therefore, is a critical determinant of FSH-dependent folliculogenesis in women. The gene encoding PAPP-A is expressed in human ovaries, being restricted to granulosa cells in healthy Graafian follicles and granulosa lutein cells. The restricted pattern of PAPP-A expression in normal human ovaries suggests to the authors that PAPP-A may be a functional marker of the dominant follicle ("DF") and its product, the corpus luteum ("CL"). Authors hypothesize that the regulated expression PAPP-A might play a role in controlling survival, growth, and/or differentiation of the DF and CL by inactivating the gonadotropin antagonist IGFBP-4.

[0027] Gordon Smith et al. (Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth; The J. of Clin. Endocrinol. & Metab., Vol. 87, no. 4, April 2002, pp.1762-67) discloses that women with PAPP-A levels in the lowest fifth percentile at 8-14 week gestation had an increased risk of intrauterine growth restriction, extremely premature delivery, moderately premature, preeclampsia, and stillbirth. The strengths of the associations were similar when the test was performed before 13 week gestation or between 13 and 14 week gestation. PAPP-A has been identified as a protease specific for IGF- binding proteins. The authors conclude that adverse outcome in late pregnancy may be determined in the first trimester of pregnancy, that control of the IGF system in early pregnancy may be critical in normal placental development, and that women at high risk of adverse pregnancy outcome may be identified in very early pregnancy.

[0028] WO 0195855A (PREGNANCY-ASSOCIATED PLASMA-PROTEIN-E (PAPP-E), 20 December 2001) relates to the sequence for PAPP-E, an antibody for detecting PAPP-E, and the use of the antibody to diagnose various clinical conditions such as trisomy 13, 18, 21, or 22.

[0029] Giudice et al. (Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: Evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation; The J. of Clin. Endocrinol. & Metab., Vol. 87, no. 5, May 2002, pp. 2359-66) discloses that the authors have identified the IGF-II-dependent IGFBP-4 protease in human trophoblasts and decidualized endometrial stromal cells as PAPP-A. In addition, they investigated the regulation of PAPP-A and proMBP by insulin-like peptides. The data suggests that IGF-II likely regulates PAPP-A and proMBP in decidualized endometrial stromal cells via the type 1 IGF receptor and also via the type 2 receptor. The data demonstrate a complete enzyme (PAPP-A), inhibitor (proMBP), cofactor (IGF-II), and substrate (IGFBP-4) family at the trophoblast-decidual interface.

[0030] Wald et al. (First trimester serum screening for down's syndrome; Prenatal Diag., Vol. 15, 1995, pp. 1227-40) demonstrates that at 10 weeks gestation, there are two biochemical markers for Down's Syndrome screening: pregnancy-associated placental protein-A (PAPP-A) and the free beta-sub-unit of human chorionic gonadotrophin (free beta-hCG). When used together with maternal age, authors show that these two biochemical markers have an estimated detection rate of 62% and a 5% false-positive rate. The authors believe that ten week screening for Down's syndrome is an advance that is now technically possible, but there is still insufficient information to justify its use in routine screening practice.

SUMMARY OF THE INVENTION

Pregnancy-associated plasma protein-A2

[0031] The novel nucleic acid according to the invention has been isolated from human placenta and characterised by means of sequencing analysis. The novel nucleotide sequence encodes a new polypeptide, PAPP-A2.

[0032] The amino acid sequence of PAPP-A2 is composed of a 233-residue pre-pro-piece and a 1558-residue mature portion. The mature portion of PAPP-A2 is homologous with the mature portion of PAPP-A (approx. 45 % identity), but the prepro-pieces do not show any similarity between the two proteins. Like PAPP-A, PAPP-A2 contains conserved amino acid stretches that classify it as a putative metalloproteinase of the metzincin superfamily.

[0033] PAPP-A2 has been expressed in a mammalian expression system, and it has been demonstrated that PAPP-A2 is an active enzyme. Further, it has been shown that PAPP-A2 cleaves IGFBP-5, Insulin Like Growth Factor Binding Protein 5. In comparison, the cleavage of IGFBP-4 by PAPP-A has previously been demonstrated.

[0034] A complementary DNA (cDNA) which encodes the full length form of PAPP-A2 is identified, sequenced and isolated. The cDNA or portions of the cDNA is cloned into expression vectors for expression in a recombinant host. The cDNA is useful to produce recombinant full-length PAPP-A2 or fragments of PAPP-A2. The cDNA and the recombinant PAPP-A2 protein derived therefrom are useful in the production of antibodies, diagnostic kits, laboratory reagents and assays.

[0035] The cDNA and the recombinant PAPP-A2 protein may also be used to identify compounds that affect PAPP-A2 function. PAPP-A2 antisense oligonucleotides or antisense mimetics may be clinically useful for reducing the expression of PAPP-A2 protein and thereby antagonizing the effects of PAPP-A. Similarly, the PAPP-A2 coding sequence

can be used for gene therapy to introduce PAPP-A2 into target cells thereby enhancing the effects of PAPP-A2.

[0036] The invention furthermore pertains to PAPP-A2 for use as a therapeutic target for the reduction or elimination of IGFBP-5 proteolytic activity in a cell.

[0037] It is furthermore an objective of the present invention to provide methods for use of PAPP-A2 for diagnostic purposes.

[0038] Other features and advantages of the invention will be apparent from the following drawings and description hereof, from the following detailed description, and from the claims.

[0039] The present invention relates in one embodiment to the following aspects.

[0040] An isolated polypeptide which

(a) consists of residues 234 to 1791 of SEQ ID NO:2 and has proteolytic activity against Insulin Like Growth Factor Binding Protein 5 (IGFBP-5); or

(b) differs from the polypeptide of (a) solely by

deletion of 1 to 10 amino acid residues from, or addition of from 1 to 10 amino acid residues to, the amino terminal of the polypeptide of (a) and/or deletion of 1 to 10 amino acid residues from, or addition of from 1 to 10 amino acid residues to, the carboxy terminal of the polypeptide of (a); and/or

one or more conservative amino acid substitutions,

wherein said polypeptide of (b) is at least 95% identical to the polypeptide of (a) and has proteolytic activity against Insulin Like Growth Factor Binding Protein 5 (IGFBP-5); or

(c) consists of a fragment of SEQ ID NO:2 at least 5 amino acids in length, said fragment comprising one or more of the following regions of SEQ ID NO:2:

Cys-403 to Cys-499,

Cys-828 to Cys-881,

Cys-1048 to Cys-1115,

Cys-1390 to Cys-1396,

Cys-1459 to Cys-1464,

Cys-1521 to Cys-1525,

Cys-1590 to Cys-1595,

Cys-1646 to Cys-1653,

Cys-1729 to Cys-1733,

wherein said fragment has proteolytic activity against Insulin Like Growth Factor Binding Protein 5 (IGFBP-5).

[0041] A purified polynucleotide encoding the polypeptide described above or the complementary strand of said polynucleotide.

[0042] A recombinant DNA molecule in the form of an expression vector comprising an expression signal operably linked to the polynucleotide according to the invention.

[0043] A host organism transfected or transformed with the polynucleotide according to the invention or the recombinant DNA molecule described herein above.

[0044] A composition comprising the polypeptide according to the invention in combination with a physiologically acceptable carrier.

[0045] A pharmaceutical composition comprising the polypeptide according to the invention in combination with a pharmaceutically acceptable carrier.

[0046] A method for producing an antibody specific against the polypeptide according to the invention, said method comprising the steps of

i) providing a host organism,

ii) immunizing the host organism with a polypeptide according to the invention and

iii) obtaining said antibody.

[0047] A method for producing the polypeptide according to the invention, said method comprising the steps of

i) providing a suitable host organism,

ii) transfecting or transforming the host organism provided in step i) with the polynucleotide according to the invention, or the vector according to the invention,

iii) culturing the host organism obtained in step ii) under conditions suitable for expression of the polypeptide encoded by the polynucleotide or the vector.

[0048] A method for inhibiting and/or reducing expression of a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2 in a cell by means of anti-sense technology, said method comprising the steps of

- i) providing the complementary strand of the polynucleotide according to the invention,
- ii) transfecting or transforming a cell capable of expressing a PAPP-A2 encoding polynucleotide with said polynucleotide provided in step i),
- iii) culturing the cell obtained in step ii) under conditions suitable for hybridization of the PAPP-A2 encoding polynucleotide provided in step i) to a complementary polynucleotide in said cell, and
- iv) inhibiting and/or reducing the expression of PAPP-A2 in said cell.

[0049] A method for detecting a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2, or measuring the level of PAPP-A2, in a biological sample obtained from an individual, said method comprising the steps of

- i) obtaining a biological sample from said individual,
- ii) detecting PAPP-A2 in said sample by detecting
 - a) a polypeptide according to the invention; and/or
 - b) a polynucleotide in the form of mRNA originating from PAPP-A2 expression using the polynucleotide according to the invention, and/or
 - c) PAPP-A2 specific protease activity by detecting cleavage of IGFBP-5.

[0050] An *ex vivo* method of diagnosing a clinical condition in an individual, said method comprising the steps of

- i) performing the detection method described above on a biological sample obtained from an individual, and
- ii) diagnosing the clinical condition.

[0051] A method for identifying an agent inhibiting the protease activity of a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2, said method comprising the steps of

- i) incubating a) the polypeptide according to the invention and b) a predetermined substrate for said polypeptide, and c) a putative inhibitory agent, and
- ii) determining if proteolysis of said substrate is inhibited.

[0052] A method for identifying an agent enhancing the protease activity of a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2, said method comprising the steps of

- i) incubating a) the polypeptide according to the invention 14 and b) a predetermined substrate for said polypeptide, and c) a putative enhancer agent, and
- ii) determining if proteolysis of said substrate is enhanced.

[0053] A method for purification of a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2 or complexes of PAPP-A2 with other proteins, said method comprising the steps of

- i) providing a polyclonal or monoclonal antibody specific against the polypeptides of (a) or (b) described herein above and in claim 1, and
- ii) purifying PAPP-A2 or complexes of PAPP-A2 with other proteins by means of affinity chromatography.

DEFINITIONS

[0054] As used herein, PAPP-A2 refers to an isolated PAPP-A2 polypeptide having the amino acid sequence listed in Fig. 1 (SEQ ID NO:2), or a variant thereof as defined herein. The PAPP-A2 according to the invention, or a variant thereof, may be produced by recombinant DNA technology, or the PAPP-A2 may be naturally occurring.

[0055] A PAPP-A2 encoding nucleotide sequence refers to an isolated nucleic acid having the sequence listed in Fig. 1 (SEQ ID NO:1), or a variant thereof as defined herein.

[0056] "Active" refers to those forms of PAPP-A2 which retain the biological and/or immunological activities of any naturally occurring PAPP-A2.

[0057] "Naturally occurring PAPP-A2" refers to PAPP-A2 produced by human cells that have not been genetically

engineered and specifically contemplates various PAPP-A2s arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation, acylation, or complex formation, covalent or noncovalent, with other polypeptides.

5 [0058] An "isolated polypeptide" is a protein, or a variant or fragment thereof, which constitutes 90% or more of the protein contents of a given preparation as evaluated by standard methods known in the art of protein chemistry.

[0059] "Derivative" refers to polypeptides derived from naturally occurring PAPP-A2 by chemical modifications such as ubiquitination, labeling (e.g., with radionuclides, various enzymes, etc.), pegylation (derivatization with polyethylene glycol), or by insertion (or substitution by chemical synthesis) of amino acids (amino acids) such as ornithine, which do not normally occur in human proteins.

10 [0060] "Recombinant variant" refers to any polypeptide differing from naturally occurring PAPP-A2 by amino acid insertions, deletions, and substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, such as proteolytic activity or cell adhesion, may be found e.g. by comparing parts of the sequence of PAPP-A2 with structurally similar proteins (e.g. other metzincin family proteinases), with locally homologous proteins of known disulfide structure, or by secondary structure predictions.

15 [0061] Preferably, amino acid "substitutions" are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as, but not limited to, the replacement of a leucine with an isoleucine or valine, replacement of an aspartate with a glutamate, or replacement with a threonine with a serine, i.e., conservative amino acid replacements. Further examples and definitions falling within the meaning of the term "substitutions" as applied herein are provided in the detailed description of the invention herein below.

20 [0062] Amino acid "insertions" or "deletions" are typically in the range of from about about 1 amino acid to about 50 amino acids, such as from about 1 amino acid to about 20 amino acids, for example from about 1 amino acid to about 20 amino acids, such as from about 1 amino acid to about 10 amino acids. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a PAPP-A2 molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

25 [0063] Where desired, a "signal or leader sequence" can direct the polypeptide (full length PAPP-A2, or portions of the PAPP-A2 polypeptide) through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques.

30 [0064] A polypeptide "fragment", "portion", or "segment" is a stretch of amino acid residues of at least about 5 amino acids, often at least about 7 amino acids, typically at least about 9 to 13 amino acids, such as at least about 17 or more amino acids in various embodiments. It may also be a longer stretch of residues up to intact PAPP-A2 in length. To be active, any PAPP-A2 polypeptide or PAPP-A2 polypeptide fragment must have sufficient length to display biologic and/or immunologic activity on their own, or when conjugated to a carrier protein such as keyhole limpet hemocyanin.

35 [0065] An "oligonucleotide" or polynucleotide "fragment", "portion", or "segment" is a stretch of the PAPP-A2 encoding sequence which is useful in the expression of PAPP-A2 polypeptide fragments. It may also be a stretch of nucleotide residues capable of being used in a polymerase chain reaction (PCR) or a hybridization procedure, typically for amplifying or revealing related parts of mRNA or DNA molecules. In particular, one or both oligonucleotide probes will comprise sequence that is identical or complementary to a portion of PAPP-A2 where there is little or no identity or complementarity with any known or prior art molecule. For this purpose, such oligonucleotide probes will generally comprise between

40 about 10 nucleotides and 50 nucleotides, and preferably between about 15 nucleotides and about 30 nucleotides.

[0066] "Animal" as used herein may be defined to include human, domestic or agricultural (cats, dogs, cows, sheep, etc) or test species (mouse, rat, rabbit, etc). "Recombinant" may also refer to a polynucleotide which encodes PAPP-A2 and is prepared using recombinant DNA techniques. The DNAs which encode PAPP-A2 may also include allelic or recombinant variants and mutants thereof.

45 [0067] "Nucleic acid probes" are prepared based on the cDNA sequences which encode PAPP-A2 provided by the present invention. Nucleic acid probes comprise portions of the sequence having fewer nucleotides than about 6 kb, usually fewer than about 1 kb. After appropriate testing to eliminate false positives, these probes may be used to determine whether mRNAs encoding PAPP-A2 are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA extracted from such cells or tissues as described in (Walsh et al., 1992, PCR Methods Appl 1, 241-50). Probes may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or be chemically synthesized. They may be labeled by nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in (Sambrook et al., 1989); or (Ausubel et al., 1989).

50 [0068] Alternatively, recombinant variants encoding these PAPP-A2 or similar polypeptides may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations may also be introduced to modify the properties of the polypeptide, including but not limited to activity, interchain affinities, or polypeptide degradation or turnover rate. One example

involves inserting a stop codon into the nucleotide sequence to limit the size of PAPP-A2 so as to provide a molecule of smaller molecular weight.

[0069] "Expression vectors" are defined herein as DNA sequences that are required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic genes in a variety of hosts such as bacteria, yeast, bluegreen algae, plant cells, insect cells and animal cells.

[0070] The term "antibody" as used herein includes both polyclonal and monoclonal antibodies, as well as fragments thereof, such as, Fv, Fab and F(ab)₂ fragments that are capable of binding antigen or hapten. It includes conventional murine monoclonal antibodies as well as human antibodies, and humanized forms of non-human antibodies, and it also includes 'antibodies' isolated from phage antibody libraries.

[0071] "Ribozymes" are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of PAPP-A2 RNA sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between fifteen (15) and twenty (20) ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

DETAILED DESCRIPTION OF THE INVENTION

[0072] The present invention is defined in the appended claims.

Isolation of a nucleotide sequence encoding PAPP-A2

[0073] The present invention in one aspect relates to a novel cDNA sequence encoding a protein with global homology to pregnancy-associated plasma protein-A (PAPP-A). This protein has been denoted PAPP-A2. The complete nucleotide sequence of PAPP-A2 has been obtained from mRNA isolated from human placenta (Example 1). The complete nucleotide sequence (SEQ ID NO:1) and translated amino acid sequence (SEQ ID NO:2) of PAPP-A2 are both shown in Figure 1.

[0074] Homology of PAPP-A2 with PAPP-A is evident upon alignment of the two amino acid sequences as shown in Figure 3. PAPP-A2 and PAPP-A share approximately 45% of their amino acid residues. Sequence motifs known to be important for the function of PAPP-A (Kristensen et al., 1994, Biochemistry 33, 1592-8; Lawrence et al., 1999, Proc Natl Acad Sci U S A 96, 3149-53; Overgaard et al., 2000, J Biol Chem) are also found in PAPP-A2. Principally, PAPP-A2 contains an elongated zinc binding motif (HEXXHXXGXXH, amino acids shown by one letter code) at position 733-743 (Figure 2). This motif and a structurally important methionine residue, are strictly conserved within the metzincins, a superfamily of zinc peptidases (Bode et al., 1993, FEBS Lett 331, 134-40; Stocker et al., 1995, Protein Sci 4, 823-40).

[0075] Like PAPP-A; PAPP-A2 is synthesized as a prepro-protein. PreproPAPP-A2 has 1791 amino acids (Figure 1). There is no homology between the prepro-portions of PAPP-A and PAPP-A2. Further, the prepro-portions of the two proteins differ significantly in length. The PAPP-A2 prepro-peptide has 233 residues (Figure 3); the PAPP-A prepro-peptide has 80 residues (Haaning et al., 1996, Eur J Biochem 237, 159-63).

Uses of the nucleotide sequence encoding PAPP-A2

[0076] The nucleotide sequence encoding PAPP-A2 (or its complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use in the recombinant production of PAPP-A2 or fragments hereof, and use in generation of anti-sense DNA or RNA, their chemical analogs (e.g. PNA or LNA) and the like. Uses of nucleotides encoding PAPP-A2 disclosed herein are exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

[0077] It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of PAPP-A2-encoding nucleotide sequences, some bearing minimal homology to the nucleotide sequence of any known and naturally occurring gene may be produced. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of

naturally occurring PAPP-A2, and all such variations are to be considered as being specifically disclosed.

[0078] Although the nucleotide sequences which encode PAPP-A2 and/or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring PAPP-A2 under stringent conditions, it may be advantageous to produce nucleotide sequences encoding PAPP-A2 or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PAPP-A2 and/or its derivatives without altering the encoded amino acid sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

[0079] Nucleotide sequences encoding PAPP-A2 may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques (Sambrook et al., 1989). Useful nucleotide sequences for joining to PAPP-A2 include an assortment of cloning vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, and the like. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for the host cell.

[0080] Disclosed herein are PAPP-A2-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding PAPP-A2. Such probes may also be used for the detection of similar PAPP-A2 encoding sequences and should preferably contain at least 50% of the nucleotides from the conserved region or active site. The hybridization probes of the subject invention may be derived from the nucleotide sequences of the SEQ ID NO:1 or from genomic sequences including promoters, enhancer elements and/or possible introns of the respective naturally occurring PAPP-A2. Hybridization probes may be labeled by a variety of reporter groups, including radionuclides such as ³²P or ³⁵S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

[0081] PCR as described (U.S. Pat. Nos 4,683,195; and 4,965,188) provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes PAPP-A2. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a mixture of both and comprise a discrete nucleotide sequence for diagnostic use or a degenerate pool of possible sequences for identification of closely related genomic sequences.

[0082] Other means of producing specific hybridization probes for PAPP-A2 DNAs include the cloning of nucleic acid sequences encoding PAPP-A2 or PAPP-A2 derivatives into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides.

[0083] It is possible to produce a DNA sequence, or portions thereof, encoding PAPP-A2 and their derivatives entirely by synthetic chemistry, after which the gene can be inserted into any of the many available DNA vectors using reagents, vectors and cells that are known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into the PAPP-A2 sequences or any portion thereof.

[0084] The nucleotide sequence can be used in an assay to detect disease associated with abnormal levels of expression of PAPP-A2. The nucleotide sequence can be labeled by methods known in the art and added to a fluid or tissue sample from a patient under hybridizing conditions. After an incubation period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off, the dye is quantitated and compared with a standard. Alternatively, levels of PAPP-A2 mRNA can be measured by micro array techniques using immobilized probes. Expression in samples can also be evaluated by (semi-quantitative) RT-PCR. Expression in samples can alternatively be evaluated by techniques based on hybridization. For example, *in situ* hybridization can be used to detect PAPP-A2 mRNA. This technique has the advantage that it locates the cells that synthesize the mRNA, but also is less sensitive than RT-PCR.

[0085] Included in the scope of the invention are oligoribonucleotide sequences, that include antisense RNA and DNA molecules and ribozymes that function to inhibit translation of PAPP-A2. Antisense techniques are known in the art and may be applied herein. Both antisense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

[0086] The invention also relates to unknown PAPP-A2 genes isolated from other species and alleles of the PAPP-A2 gene, in which PAPP-A2 orthologues or homologues exists. A bacteriophage cDNA library may be screened, under conditions of reduced stringency, using a radioactively labeled fragment of the human PAPP-A2 clone described herein.

Alternatively the human PAPP-A2 sequence can be used to design degenerate or fully degenerate oligonucleotide probes which can be used as PCR probes or to screen bacteriophage cDNA libraries. The PCR product may be subcloned and sequenced to insure that the amplified sequences represent the PAPP-A2 sequences. The PCR fragment may be used to isolate a full length PAPP-A2 clone by radioactively labeling the amplified fragment and screening a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to screen a genomic library. For a review of cloning strategies which may be used, see e.g., (Ausubel et al., 1989; Sambrook et al., 1989).

Expression of recombinant PAPP-A2

[0087] In order to express a biologically active proteinase, the nucleotide sequence coding for the protein, or a functional equivalent, can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. For example, recombinant protein can be used for immunization to obtain antibodies, as a laboratory reagent, and in diagnostic kits.

[0088] More specifically, methods which are well known to those skilled in the art can be used to construct expression vectors containing the PAPP-A2 sequence and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See e.g., the techniques described in (Ausubel et al., 1989; Sambrook et al., 1989).

[0089] Further, expression vectors containing fragments of the PAPP-A2 encoding sequence may also be constructed. In particular, this may be relevant for the use of portions of the PAPP-A2 polypeptide as an antigen for immunization. In addition, the coding sequence of PAPP-A2 or fragments hereof may be cloned in frame with a coding nucleotide sequence present in the vector to result in a fusion protein or a 'tagged' PAPP-A2 protein. For example, such a fusion protein may be composed of PAPP-A2 and GST, and such tag may be a c-myc tag (for detection) and/or a histidine tag (for purification).

[0090] A variety of host-expression vector systems may be utilized to express the PAPP-A2 coding sequence or fragments hereof. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the PAPP-A2 coding sequence; yeast transformed with recombinant yeast expression vectors containing the PAPP-A2 coding sequence; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the PAPP-A2 coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the PAPP-A2 coding sequence; or animal cell systems infected with recombinant virus expression vectors (e.g., adenovirus, vaccinia virus, human tumor cells) including cell lines engineered to contain multiple copies of the PAPP-A2 DNA either stably amplified (CHO/dhfr) or unstably amplified in double-minute chromosomes (e.g., murine cell lines).

[0091] The expression elements of these systems vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage lambda, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedron promoter may be used; when cloning in plant cell systems, promoters derived from the genome of plant cells (e.g., heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter for the chlorophyll a/b binding protein) or from plant viruses (e.g., the 35S RNA promoter of CaMV; the coat protein promoter of TMV) may be used; when cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the CMV promoter, the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used; when generating cell lines that contain multiple copies of the PAPP-A2 DNA SV40-, BPV- and EBV-based vectors may be used with an appropriate selectable marker.

[0092] The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, infection, protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce PAPP-A2 protein. Identification of PAPP-A2 expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-PAPP-A2 antibodies, and the presence of host cell-associated PAPP-A2 activity.

[0093] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the PAPP-A2 expressed. For example, when large quantities of PAPP-A2 are to be produced, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include but are not limited to the E. coli expression vector pUR278 (Ruther and Muller-Hill, 1983, Embo J 2, 1791-4), in which the PAPP-A2 coding sequence may be ligated into the vector in frame with the lac Z coding region so that a hybrid AS-lac Z protein is produced. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The

pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety. In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review, see (Ausubel et al., 1989; Bitter et al., 1987, *Methods Enzymol* 153, 516-44; Rosenfeld, 1999, *Methods Enzymol* 306, 154-69).

5 **[0094]** In cases where plant expression vectors are used, the expression of the PAPP-A2 coding sequence may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV may be used (Gmunder and Kohli, 1989, *Mol Gen Genet* 220, 95-101); alternatively, plant promoters such as the small subunit of RUBISCO (Broglie et al., 1984, *Science* 224, 838-43).

10 **[0095]** An alternative expression system which could be used to express PAPP-A2 is an insect system. In one such system, Baculovirus is used as a vector to express foreign genes. The virus then grows in the insect cells. The PAPP-A2 coding sequence may be cloned into non-essential regions (for example the polyhedron gene) of the virus and placed under control of a Baculovirus promoter. These recombinant viruses are then used to infect insect cells in which the inserted gene is expressed. For example, see (Smith et al., 1983, *Mol Cell Biol* 3, 2156-65).

15 **[0096]** A variety of mammalian expression vectors may be used to express recombinant PAPP-A2 in mammalian cells. Commercially-available mammalian expression vectors which may be suitable for recombinant PAPP-A2 expression, include but are not limited to, pMC1neo (Stratagene), pXT1 (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593), pBPV-1 (8-2) (ATCC 37110), pcDNA3.1 and its derivatives (Stratagene). Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, CV-1, COS-1, COS-7, CHO-K1, 3T3, NIH3T3, HeLa, C1271, BS-C-1, MRC-5, and 293. Further, in mammalian host cells, a number of viral based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the PAPP-A2 coding sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing PAPP-A2 in infected hosts. See for example (Logan and Shenk, 1984, *Proc Natl Acad Sci U S A* 81, 3655-9). Alternatively, the vaccinia 7.5K promoter may be used. See for example (Mackett et al., 1982, *Proc Natl Acad Sci U S A* 79, 7415-9).

20 **[0097]** For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express PAPP-A2 may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with PAPP-A2 DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.

25 **[0098]** Some applications of the recombinant PAPP-A2 may require the protein to be in purified or partially purified form. Recombinantly expressed PAPP-A2 or fragments of the PAPP-A2 polypeptide can be isolated by liquid chromatography. Various methods of protein purification well known in the art include those described in for example (Scopes, 1987). Alternatively, recombinant PAPP-A2 fusion proteins or 'tagged' PAPP-A2 may be purified by affinity chromatography. Further, antibodies raised against PAPP-A2 may be used for purification by immunoaffinity chromatography.

30 **[0099]** Recombinant variant of PAPP-A2 may be produced by site directed mutagenesis. In some applications of PAPP-A2 such variants may be preferred due to for example increased protein stability, or changes in activity.

Production and uses of antibodies against PAPP-A2

35 **[0100]** The recombinant protein may be used to generate antibodies. Monospecific antibodies to PAPP-A2 can be purified from mammalian antisera containing antibodies reactive against PAPP-A2 or can be prepared as monoclonal antibodies reactive with PAPP-A2 using standard techniques.

40 **[0101]** Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for PAPP-A2. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the PAPP-A2, as described above. PAPP-A2 specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with rabbits or mice being preferred, with an appropriate concentration of PAPP-A2 either with or without an immune adjuvant. For example, antibodies specific against PAPP-A2 can be used for the purification of native and recombinant PAPP-A2, as a laboratory reagent, and in antibody based diagnostic kits.

45 **[0102]** Monoclonal antibodies (mAb) reactive with PAPP-A2 can be prepared by conventional methods, such as by immunizing inbred mice with PAPP-A2. The mice are immunized with about 0.1 mg to about 10 mg, preferably about 1 mg, of PAPP-A2 in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about

30 weeks. Immunized mice are given one or more booster immunizations of about 0.1 to about 10 mg of PAPP-A2 in a buffer solution such as phosphate buffered saline (PBS) by the intravenous (IV) route. Lymphocytes from antibody-positive mice are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner under conditions which will allow the formation of stable hybridomas. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using PAPP-A2 as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are then cloned. For details, see (Peters and Baumgarten, 1992).

[0103] In vitro production of anti-PAPP-A2 is carried out by growing the hybridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

[0104] Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique (Crowther, 1995).

[0105] The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in (Clackson et al., 1991, Nature 352, 624-8; Marks et al., 1991, J Mol Biol 222, 581-97), for example. Identified phage antibodies can be produced by expression in bacteria.

[0106] Methods such as those described above may be used to produce monospecific antibodies specific for PAPP-A2 polypeptide fragments or full-length nascent PAPP-A2 polypeptide.

[0107] PAPP-A2 antibody affinity columns can be made by adding the antibodies to a gel support, such as Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1 M ethanolamine HCl (pH 8). The column is washed with water followed by 0.23 M glycine HCl (pH 2.6) to remove any non-conjugated antibody or extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing PAPP-A2 or PAPP-A2 fragments are slowly passed through the column. The column is then washed, and the protein is eluted. The purified PAPP-A2 protein is then dialyzed against phosphate buffered saline.

[0108] Native PAPP-A2 from sources such as human plasma or serum, tissue extracts, or media from nontransfected cell lines (that endogenously secrete PAPP-A2) may also be purified by use of an antibody affinity column.

[0109] Using polyclonal or monoclonal antibodies against PAPP-A2 a number of assays may be constructed for measurement of PAPP-A2 antigen in body fluids or tissue and cell extracts. Kits based on antibodies may be used for diagnostic purposes. The assays include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent assay (ELISA) techniques, and radioimmunoassay (RIA) techniques.

[0110] For example, in one such ELISA, a sandwich assay can be constructed where antigen present in a sample is caught by immobilized polyclonal anti(PAPP-A2). Detection is then performed by the use of one or more monoclonal PAPP-A2 antibodies and peroxidase conjugated anti(murine IgG). In another assay, antigen present in a sample is caught by immobilized polyclonal anti(PAPP-A2), and detected using biotinylated polyclonal anti(PAPP-A2). For further examples and details, see (Crowther, 1995). Assays can be calibrated using purified PAPP-A2 to construct a standard curve by serial dilution. The concentration of PAPP-A2 in solution in a purified form can be accurately measured by amino acid analysis (Sottrup-Jensen, 1993, Biochem Mol Biol Int 30, 789-94).

[0111] Polyclonal antibodies may be used to inhibit the biological activity of PAPP-A2. Specifically, in analogy with the inhibition of the IGFBP-4 proteolytic activity of PAPP-A by polyclonal PAPP-A antibodies (Lawrence et al., 1999, Proc Natl Acad Sci U S A 96, 3149-53), anti(PAPP-A2) may be used to inhibit the proteolytic activity of PAPP-A2. Certain monoclonal antibodies may also be inhibitory towards the activity of PAPP-A2. Such monoclonal antibodies are likely to recognize an epitope in close proximity to the active site of PAPP-A2, but the inhibitory activity may also be based on binding to epitopes other than those close to the active site: Inhibitory monoclonal antibodies can be obtained by immunization with PAPP-A2, PAPP-A2 fragments, with peptides derived from PAPP-A2.

[0112] Inhibitory (monoclonal) antibodies may have therapeutic value in conditions of pathologies in which it may be desirable to decrease the activity of PAPP-A2.

Activity of PAPP-A2

[0113] Like PAPP-A, PAPP-A2 contains conserved amino acid stretches that classify it as a putative metalloproteinase of the metzincin superfamily (Stocker et al., 1995, Protein Sci 4, 823-40). It has been experimentally verified that PAPP-A2 does exhibit proteolytic activity by demonstrating its cleavage of insulin-like growth factor binding protein (IGFBP)-5 (Example 6.7).

[0114] In general, proteolytic activity of PAPP-A2 against potential protein substrates may be evaluated by the incu-

bation of purified or partially purified PAPP-A2 with the potential substrate under a variety of experimental conditions (such as for example temperature, buffer composition, ionic strength, and pH). Enzymatic activity of PAPP-A2 against the protein in question can be evaluated by SDS-PAGE (in which degradation or release of well defined proteolytic fragment(s) will be evident), or by high-pressure liquid chromatographic detection of released peptide(s). By means of such procedures, other substrate targets of PAPP-A2 may be identified. Incubation with a variant of PAPP-A2 where, for example, a residue in the active site has been substituted to obtain an inactive enzyme, serves as a proper negative control.

[0115] Random peptide libraries consisting of all possible combinations of amino acids attached to a solid phase support may be used to identify peptides that can be cleaved by PAPP-A2. Identification of such peptides may be accomplished by screening a peptide library with recombinant soluble PAPP-A2. Methods for expression and purification of the enzyme are described above and may be used to express recombinant full length PAPP-A2 or fragments, analogs, or derivatives thereof depending on the functional domains of interest. For further details, see (Meldal, 1998, Methods Mol Biol 87, 65-74; Meldal, 1998, Methods Mol Biol 87, 51-7). Alternatively, peptide substrates may be derived from identified protein substrates of PAPP-A2.

[0116] Alternatively, phage display of peptide libraries may be used to identify peptides that can be cleaved by PAPP-A2 (Matthews and Wells, 1993, Science 260, 1113-7).

[0117] Peptides that function as PAPP-A2 substrates may function in assays for the detection of PAPP-A2 proteolytic activity in body fluids or tissue and cell extracts. Substrate peptides may be derivatized to function in an assay based on quenched-fluorescence (Meldal, 1998, Methods Mol Biol 87, 65-74). Kits based on such, or other, techniques may be used for diagnostic purposes in pathologies where measurement of PAPP-A2 activity is relevant.

Identification of agents that modify the activity of PAPP-A2

[0118] An assay for the detection of PAPP-A2 proteolytic activity, as described above, provides a method for the identification of molecules that modify the activity of PAPP-A2. Such molecules may be, for example, peptides, derivatized peptides, hydroxamic acid derivatized peptides, small organic molecules, or antibodies.

[0119] The screening of peptide libraries can be used to discover pharmaceutical agents that act to modulate and/or inhibit the biological activity of PAPP-A2. Methods for expression and purification of the enzyme are described above and may be used to express recombinant full length PAPP-A2 or fragments, analogs, or derivatives thereof depending on the functional domains of interest. Random peptide libraries consisting of all possible combinations of amino acids attached to a solid phase support may be used to identify peptides that are able to modulate and/or inhibit PAPP-A2 activity by binding to the active site or other sites of PAPP-A2. For example, see (Meldal, 1998, Methods Mol Biol 87, 75-82).

[0120] Similarly, combinatorial chemistry may be used to identify low molecular weight organic molecules that affect the activity of PAPP-A2.

Measurement of complexes of PAPP-A or PAPP-A2

[0121] PAPP-A primarily exists in pregnancy serum as a disulfide bound 2:2 complex with the proform of eosinophil major basic protein (proMBP), PAPP-A/proMBP. In addition to the PAPP-A/proMBP complex, proMBP exists in the circulation as a disulfide bound 2:2 complex with angiotensin (ANG), proMBP/ANG, and a fraction of this complex is further complexed to a fragment of complement component C3dg (PROMBP/ANG/C3dg) (Oxvig, 1995; Christiansen, 2000).

[0122] The level of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP in body fluids of an individual may be indicative of predisposition to a clinical condition or indicative of the presence of a clinical condition. Accordingly, the present invention in one embodiment is directed towards a method of diagnosing a clinical condition or diagnosing predisposition to said clinical condition in an individual comprising the steps of

- a) providing a body sample from said individual; and
- b) measuring the level of a complex selected from the group consisting of PAPP-A/proMBP, PAPP-A2/proMBP, PAPP-A/PAPP-A2, PAPP-A/PAPP-A2/proMBP, proMBP/ANG and proMBP/ANG/C3dg in said body fluid sample; and
- c) diagnosing the clinical condition or diagnosing predisposition to the clinical condition, wherein the level of the complex above or below a predetermined value is indicative of the clinical condition or predisposition to the clinical condition.

[0123] Furthermore, the levels of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP in body fluids of a mammalian mother may be indicative of predisposition to a clinical condition or indicative of the presence of a clinical

condition in a fetus of said mother. Hence, the present invention provides methods of diagnosing a clinical condition or diagnosing predisposition to said clinical condition in a mammalian fetus comprising the steps of

- a) providing a body fluid sample from the mother of said fetus; and
- b) measuring the level of a complex selected from the group consisting of PAPP-A/proMBP, PAPP-A2/proMBP, PAPP-A/PAPP-A2, PAPP-A/PAPP-A2/proMBP, proMBP/ANG and proMBP/ANG/C3dg in said body fluid sample; and
- c) diagnosing the clinical condition or diagnosing predisposition to the clinical condition, wherein the level of the complex above or below a predetermined value is indicative of the clinical condition or predisposition to the clinical condition.

[0124] In particular, according to the present method the level of one or more of the following complexes may be determined:

- PAPP-A/proMBP
- PAPP-A2 and proMBP (PAPP-A2/proMBP)
- PAPP-A2 and PAPP-A (PAPP-A/PAPP-A2)
- PAPP-A/PAPP-A2 with proMBP (PAPP-A/PAPP-A/proMBP)
- proMBP/ANG
- proMBP/ANG/C3dg

[0125] The level of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP in a body fluid sample may be determined by any conventional method known to the person skilled in the art. For example, the level can be measured by a method comprising the use of immunospecific reagents specifically interacting with one or more components of the complex desirable to measure, such as immunospecific reagents specifically interacting with PAPP-A, PAPP-A2, proMBP, ANG or C3gd. Immunospecific reagents may for example be monoclonal antibodies, polyclonal antibodies and/or antigen binding fragments thereof, specific towards the individual components of the complex.

[0126] Such methods include but are not limited to sandwich ELISA, wherein an immunospecific reagent specifically recognising one component of the complex is employed as catching antibody and another immunospecific reagent specifically recognising another component of the complex is employed as detection antibody. The detection antibody is preferably either directly or indirectly detectable, for example the detection antibody may be directly coupled to a detectable label or the detection antibody may be capable of interacting with another agent which is coupled to a detectable label.

[0127] A detectable label may for example be a fluorescent label, a chromophore, a radioactive label, a heavy metal or an enzyme.

[0128] For example, the level of PAPP-A/proMBP complexes in a body fluid sample may be determined by sandwich ELISA using a PAPP-A specific monoclonal or polyclonal antibody for catching and a proMBP specific monoclonal or polyclonal antibody for detection or the level of proMBP/ANG in a body fluid sample may be determined by sandwich ELISA using a proMBP specific monoclonal or polyclonal antibody for catching and a ANG specific monoclonal or polyclonal antibody for detection.

[0129] The clinical condition may be any clinical condition which may be diagnosed by the level of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP or wherein predisposition may be diagnosed by the level of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP. The clinical condition may for example be selected from the group comprising Down's syndrome, preeclampsia and acute coronary syndrome, including unstable angina and myocardial infarction.

[0130] The body fluid sample may be any useful body fluid sample, such as a blood sample including a serum sample, a urine sample, a saliva sample or an amniotic fluid sample.

[0131] In particular, the level of PAPP-A/proMBP may be determined when the clinical condition is selected from the group consisting of Down's syndrome, and acute coronary syndrome including unstable angina and myocardial infarction.

[0132] In one embodiment of the present invention diagnosing Down's syndrome or diagnosing predisposition to Down's syndrome, comprises determining the level of PAPP-A/proMBP, wherein the level of PAPP-A/proMBP below a predetermined value is indicative of the Down's syndrome or predisposition to Down's syndrome.

[0133] In another embodiment of the present invention diagnosing acute coronary syndrome, including unstable angina and myocardial infarction or diagnosing predisposition to acute coronary syndrome, including unstable angina and myocardial infarction, comprises determining the level of PAPP-A/proMBP, wherein the level of PAPP-A/proMBP above a predetermined value is indicative of the acute coronary syndrome, including unstable angina and myocardial infarction or predisposition to acute coronary syndrome, including unstable angina and myocardial infarction.

[0134] In yet another embodiment the level of proMBP/ANG may be determined to diagnose predisposition to Down's

syndrome or to diagnose Down's syndrome. All the above mentioned methods of diagnosis may also be performed in combination with one or more other methods of diagnosis. In addition, more than one different diagnosis according to the present invention may be performed, for example it is possible to measure the level of more than one complex or to measure the level of one complex in different body samples.

5

Use of PAPP-A2 to generate natural proteolytic fragments

[0135] PAPP-A2 may be used to generate natural fragments of proteins that are specifically cleaved by PAPP-A2. As in the case of IGFBP-5 (see Examples 6.7 and 6.9), such fragments may have biological effects different from intact IGFBP-5. Fragments can be purified by standard chromatography after cleavage with purified PAPP-A2 (see Example 6.9).

10

Design of fragments of PAPP-A2 for expression

[0136] Because all cysteine residues found in mature PAPP-A are also found in mature PAPP-A2 (see Figure 3), the pattern of disulfide bonds can be assumed to be the same for PAPP-A2 for those common cysteine residues. Therefore, knowledge of the disulfide structure of the PAPP-A subunit (see Figure 8) can be used to rationally design fragments of PAPP-A2 in which pairing of all cysteine residues is possible. Putative domain boundaries of PAPP-A2 can be defined based on the disulfide structure shown in Figure 8. Those domains can be expressed separately or in combination. In the event that a domain contains a cysteine residue known to form an inter-chain disulfide bridge to another PAPP-A subunit or to proMBP (see Figure 8), it may be required that this cysteine is mutated to for example a serine or an alanine residue

15

20

[0137] Thus, possible boundary regions are *between* Cys-403 and Cys-499, between Cys-828 and Cys-881, between Cys-1048 and Cys-1115, between Cys-1390 and Cys-1396, between Cys-1459 and Cys-1464, between Cys-1521 and Cys-1525, between Cys-1590 and Cys-1595, between Cys-1646 and Cys-1653, and between Cys-1729 and Cys-1733 (numbering of preproPAPP-A2, as in Figure 1 and 3).

25

Pharmaceutical Compositions

[0138] Identification of PAPP-A2 as the IGFBP-5 protease provides methods for affecting growth and differentiation *in vivo* by using PAPP-A2 as a therapeutic target. Inhibitors of PAPP-A2 is believed to decrease the amount of bioavailable IGF-I and IGF-II. For example, inhibition of PAPP-A2 activity can be useful in disorders such as restenosis, atherosclerosis, and fibrosis. Activators, or agents that increase the activity of PAPP-A2, is believed to increase the amount of bioavailable IGF-I and IGF-II.

30

[0139] Agents that alter PAPP-A2 activity or that alter adherence of PAPP-A2 to cell surfaces can be incorporated into pharmaceutical compositions. Such agents may be incorporated together with agents that alter PAPP-A activity or that alter adherence of PAPP-A to cell surfaces. A combination of PAPP-A2 specific agents and PAPP-A specific agents may be more effective than traditional agents directed against PAPP-A. There is also provided a method of treatment comprising the step of administering to an individual in need thereof a combination of PAPP-A2 specific agents and PAPP-A specific agents in pharmaceutically effective amounts.

35

40

[0140] As an example, an antibody such as anti-PAPP-A2 polyclonal or monoclonal, can be formulated into a pharmaceutical composition by admixture with pharmaceutically acceptable non-toxic excipients or carriers. Such compounds and compositions may be prepared for parenteral administration, particularly in the form of liquid solutions or suspensions in aqueous physiological buffer solutions; for oral administration, particularly in the form of tablets or capsules; or for intranasal administration, particularly in the form of powders, nasal drops, or aerosols. Compositions for other routes of administration may be prepared as desired using standard methods.

45

[0141] Formulations for parenteral administration may contain as common excipients (i.e., pharmaceutically acceptable carriers) sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxethylene-polyoxypropylene copolymers are examples of excipients for controlling the release of a compound of the invention *in vivo*. Other suitable parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration may contain excipients such as lactose, if desired. Inhalation formulations may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or they may be oily solutions for administration in the form of nasal drops. If desired, the compounds can be formulated as gels to be applied intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration

50

55

Medical Devices

[0142] The disclosure also features a medical device for placement in a patient (e.g., an implant) that includes an agent that inhibits or activates PAPP-A2 protease activity. Suitable agents are readily identified using the methods described herein. The device can be impregnated with the agent or can be coated with the agent. Nonlimiting examples of inhibitors include an antibody such as anti-PAPP-A2 polyclonal or monoclonal, or a metalloprotease inhibitor such as 1,10-phenanthroline.

[0143] IGFBP-5 protease activity of PAPP-A2 is potently inhibited by 1,10-phenanthroline, but is not inhibited by tissue inhibitors of matrix metalloproteases (TIMP'S). Other inhibitors include small molecules such as derivatives of hydroxamic acid. Anti-PAPP-A2 polyclonal IgG may also inhibit IGF-dependent - or IGF-independent - IGFBP-5 specific PAPP-A2 protease activity in HFCM in a dose-dependent manner.

[0144] In addition, polypeptides (i.e., any chain of amino acids, regardless of length or post-translational modification), including modified polypeptides, can function as inhibitors. Any inhibitor of the IGFBP-5 protease activity of PAPP-A2 can be used for coating or impregnating a medical device according to the invention. Modified polypeptides include amino acid substitutions, deletions, or insertions in the amino acid sequence as compared with a corresponding wild-type sequence, as well as chemical modifications. Although protease-resistant IGFBP-5 is not an inhibitor per se of the IGFBP-5 protease activity of PAPP-A2, similar results are expected when it is used for coating or impregnating a medical device.

[0145] As an example, coating or impregnating the medical device with a PAPP-A2 inhibitor, optionally in combination with a PAPP-A inhibitor, can help prevent the development of restenosis following balloon angioplasty, or can prevent a further increase in size of an atherosclerotic plaque. Coronary angioplasty with stent placement is currently the leading therapeutic approach for coronary atherosclerosis. An important goal of angioplasty of coronary artery disease is to prevent both acute and chronic complications. Modern procedures are quite successful in eliminating immediate problems. Unfortunately, restenosis still occurs in 20-30% of stented patients. No known pharmacological intervention is available to prevent the restenosis.

[0146] Without being bound by a particular mechanism, it is thought that an increase in IGFBP-5 protease expression by coronary smooth muscle cells precedes neointimal formation in response to angioplasty in humans.

[0147] For example, enhanced PAPP-A2 activity can be useful for wound healing, fractures, osteoporosis, or ovulation. Osteoporosis or other conditions of bone loss may benefit from increased bone formation and decreased bone resorption. Agents that enhance PAPP-A2 activity can be, for example, a modified IGF, i.e., an IGF analog.

[0148] Analogs include IGF polypeptides containing amino acid insertions, deletions or substitutions, as well as chemical modifications. Amino acid substitutions can include conservative and non-conservative amino acid substitutions. Conservative amino acid substitutions replace an amino acid with an amino acid of the same class, whereas non-conservative amino acid substitutions replace an amino acid with an amino acid of a different class. Non-conservative substitutions result in a change in the hydrophobicity of the polypeptide or in the bulk of a residue side chain. In addition, non-conservative substitutions can make a substantial change in the charge of the polypeptide, such as reducing electropositive charges or introducing electronegative charges. Examples of non-conservative substitutions include a basic amino acid for a non-polar amino acid, or a polar amino acid for an acidic amino acid. Amino acid insertions, deletions and substitutions can be made using random mutagenesis, site-directed mutagenesis, or other recombinant techniques known in the art.

[0149] The medical device can be, for example, bone plates or bone screws that are used to stabilize bones, or a stent, which typically is used within the body to restore or maintain the patency of a body lumen. Blood vessels, for example, can become obstructed due to an atherosclerotic plaque that restricts the passage of blood. A stent typically has a tubular structure defining an inner channel that accommodates flow within the body lumen. The outer walls of the stent engage the inner walls of the body lumen. Positioning of a stent within an affected area can help prevent further occlusion of the body lumen and permit continued flow. A stent typically is deployed by percutaneous insertion of a catheter or guide wire that carries the stent. The stent ordinarily has an expandable structure. Upon delivery to the desired site, the stent can be expanded with a balloon mounted on the catheter. Alternatively, the stent may have a biased or elastic structure that is held within a sheath or other restraint in a compressed state. The stent expands voluntarily when the restraint is removed. In either case, the walls of the stent expand to engage the inner wall of the body lumen, and generally fix the stent in a desired position.

STATEMENTS OF DISCLOSURE

[0150] In a first aspect the present disclosure relates to a purified polynucleotide selected from the group consisting of

- i) a polynucleotide comprising nucleotides 1 to 5376 of SEQ ID NO:1, corresponding to the coding sequence of PAPP-A2, as deposited with DSMZ under accession number DSM 13783; and

EP 1 346 061 B1

ii) a polynucleotide encoding a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and

iii) a polynucleotide encoding a fragment of a polypeptide encoded by polynucleotides (i) or (ii), wherein said fragment

5 a) has a proteolytic activity specific for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5), or a derivative thereof, or any other substrate; and/or

b) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or

10 c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide; and

15 iv) a polynucleotide, the complementary strand of which hybridizes, under stringent conditions, with a polynucleotide as defined in any of (i), (ii) and (iii), said polynucleotide encoding a polypeptide having the amino acid sequence as shown in SEQ ID NO:2, or a fragment thereof, wherein said fragment

a) has a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5); and/or

20 b) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or

c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide; and

25 v) a polynucleotide comprising a nucleotide sequence which is degenerate to the nucleotide sequence of a polynucleotide as defined in any of (iii) and (iv),

and the complementary strand of such a polynucleotide.

30 **[0151]** A polynucleotide as used herein shall denote any naturally occurring polynucleotide having any naturally occurring backbone structure, as well as nucleotides known in the art as LNA (locked nucleic acid) and PNA (peptide nucleic acid).

[0152] In preferred aspects the purified polynucleotide comprises the coding sequence of PAPP-A2, nucleotides 1 to 5376, as shown in SEQ ID NO:1, or a nucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO:2.

35 **[0153]** In another preferred aspect the polynucleotide comprises a nucleotide sequence encoding a fragment of the polypeptide having the amino acid sequence as shown in SEQ ID NO:2, wherein said fragment

a) has a proteolytic activity specific for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5), or a derivative thereof, or any other substrate; and/or

40 b) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or

45 c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide

[0154] There is also provided a polynucleotide, the complementary strand of which hybridizes, under stringent conditions, with a polynucleotide according to the invention.

50 **[0155]** Stringent conditions as used herein shall denote stringency as normally applied in connection with Southern blotting and hybridization as described e.g. by Southern E. M., 1975, J. Mol. Biol. 98:503-517. For such purposes it is routine practise to include steps of prehybridization and hybridization. Such steps are normally performed using solutions containing 6x SSPE, 5% Denhardt's, 0.5% SDS, 50% formamide, 100 µg/ml denaturated salmon testis DNA (incubation for 18 hrs at 42°C), followed by washings with 2x SSC and 0.5% SDS (at room temperature and at 37°C), and a washing with 0.1x SSC and 0.5% SDS (incubation at 68°C for 30 min), as described by Sambrook et al., 1989, in "Molecular Cloning/A Laboratory Manual", Cold Spring Harbor).

55 **[0156]** The DNA sequences are used in a variety of ways. They may be used as probes for identifying homologs of uHase (e.g., homologs of huHase). Mammalian homologs have substantial sequence similarity to one another, i.e. at least 75%, usually at least 90%, more usually at least 95% sequence identity. Sequence similarity is calculated based

on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul et al. 1990 J Mol Biol 215:403-10.

5 **[0157]** Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50.degree. C. and 10.times.SSC (0.9 M saline/0.09 M sodium citrate) and remain bound when subjected to washing at 55.degree. C. in 1.times.SSC. Sequence identity may be determined by hybridization under high stringency conditions, for example, at 50.degree. C. or higher and 0.1.times.SSC (9 mM saline/0.9 mM sodium citrate). By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes may be any species, e.g. Primate species, particularly human; rodents, such as rats and mice, canines, felines, bovine, opines, equine, yeast, Drosophila, Caenorhabditis, etc.

10 **[0158]** In a further aspect there is provided a polynucleotide comprising a nucleotide sequence which is degenerate to a polynucleotide capable of hybridising to SEQ ID NO:1, or a fragment thereof.

15 **[0159]** Degeneracy as used herein is defined in terms of the activity or functionality associated with the polypeptide expressed from said degenerate polynucleotide, said polynucleotide is either i) comprising a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5); and/or ii) recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or iii) competing with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide.

20 **[0160]** In a further embodiment there is provided a polynucleotide comprising the complementary strand of a polynucleotide according to the invention.

[0161] The polynucleotide according to the invention may be operably linked to a further polynucleotide comprising nucleic acid residues corresponding to the 3' untranslated region of PAPP-A2, or a fragment thereof. As used herein the 3' untranslated region comprises nucleic acid residues 5377 to 8527 of SEQ ID NO:1.

25 **[0162]** There is also provided a recombinant DNA molecule in the form of an expression vector comprising an expression signal operably linked to a polynucleotide according to the invention.

30 **[0163]** In a further embodiment there is provided a host organism transfected or transformed with the polynucleotide according to the invention, or the vector according to the invention. The host organism is preferably a mammalian organism such as e.g. a mammalian cell line. However, a microbial eukaryote such as yeast or fungi may also be used, as may a microbial prokaryote such as Bacillus or E. coli. The person skilled in the art will know how to select expression signals, including leader sequences and/or signal peptides suitable for expression in a given cell. The person skilled in the art will also know how to determine the level of expression in a given cell by using standard molecular biology techniques.

35 **[0164]** In a further aspect the disclosure relates to an isolated polypeptide comprising or essentially consisting of the amino acid sequence of SEQ ID NO:2, or a fragment thereof, wherein said fragment

a) has a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5); and/or

40 b) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or

c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor with an affinity for said polypeptide.

45 **[0165]** In one preferred aspect of the disclosure there is also provided variants of SEQ ID NO:2, and variants of fragments thereof. Variants are determined on the basis of their degree of identity or their homology with a predetermined amino acid sequence, said predetermined amino acid sequence being SEQ ID NO:2, or, when the variant is a fragment, a fragment of SEQ ID NO:2.

50 **[0166]** Accordingly, variants preferably have at least 75% sequence identity, for example at least 80% sequence identity, such as at least 85 % sequence identity, for example at least 90 % sequence identity, such as at least 91 % sequence identity, for example at least 91% sequence identity, such as at least 92 % sequence identity, for example at least 93 % sequence identity, such as at least 94 % sequence identity, for example at least 95 % sequence identity, such as at least 96 % sequence identity, for example at least 97% sequence identity, such as at least 98 % sequence identity, for example 99% sequence identity with the predetermined sequence.

55 **[0167]** Variants are also determined based on a predetermined number of conservative amino acid substitutions as defined herein below. Conservative amino acid substitution as used herein relates to the substitution of one amino acid (within a predetermined group of amino acids) for another amino acid (within the same group), wherein the amino acids exhibit similar or substantially similar characteristics.

EP 1 346 061 B1

[0168] Within the meaning of the term "conservative amino acid substitution" as applied herein, one amino acid may be substituted for another within the groups of amino acids indicated herein below:

5 i) Amino acids having polar side chains (Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, and Cys,)

ii) Amino acids having non-polar side chains (Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, and Met)

iii) Amino acids having aliphatic side chains (Gly, Ala Val, Leu, Ile)

10 iv) Amino acids having cyclic side chains (Phe, Tyr, Trp, His, Pro)

v) Amino acids having aromatic side chains (Phe, Tyr, Trp)

15 vi) Amino acids having acidic side chains (Asp, Glu)

vii) Amino acids having basic side chains (Lys, Arg, His)

viii) Amino acids having amide side chains (Asn, Gln)

20 ix) Amino acids having hydroxy side chains (Ser, Thr)

x) Amino acids having sulphur-containing side chains (Cys, Met),

25 xi) Neutral, weakly hydrophobic amino acids (Pro, Ala, Gly, Ser, Thr)

xii) Hydrophilic, acidic amino acids (Gln, Asn, Glu, Asp), and

xiii) Hydrophobic amino acids (Leu, Ile, Val)

30 **[0169]** Accordingly, a variant or a fragment thereof may comprise, within the same variant of the sequence or fragments thereof, or among different variants of the sequence or fragments thereof, at least one substitution, such as a plurality of substitutions introduced independently of one another.

[0170] It is clear from the above outline that the same variant or fragment thereof may comprise more than one conservative amino acid substitution from more than one group of conservative amino acids as defined herein above.

35 **[0171]** The addition or deletion of an amino acid may be an addition or deletion of from 2 to 10 amino acids, such as from 10 to 20 amino acids, for example from 20 to 30 amino acids, such as from 40 to 50 amino acids. However, additions or deletions of more than 50 amino acids, such as additions from 10 to 100 amino acids, addition of 100 to 150 amino acids, addition of 150-250 amino acids, are also comprised within the present invention.

40 **[0172]** The polypeptide fragments according to the present invention, including any functional equivalents thereof, may in one embodiment comprise less than 250 amino acid residues, such as less than 240 amino acid residues, for example less than 225 amino acid residues, such as less than 200 amino acid residues, for example less than 180 amino acid residues, such as less than 160 amino acid residues, for example less than 150 amino acid residues, such as less than 140 amino acid residues, for example less than 130 amino acid residues, such as less than 120 amino acid residues, for example less than 110 amino acid residues, such as less than 100 amino acid residues, for example less than 90 amino acid residues, such as less than 85 amino acid residues, for example less than 80 amino acid residues, such as less than 75 amino acid residues, for example less than 70 amino acid residues, such as less than 65 amino acid residues, for example less than 60 amino acid residues, such as less than 55 amino acid residues, for example less than 50 amino acid residues.

50 **[0173]** "Functional equivalency" as used in the present disclosure is according to one preferred embodiment established by means of reference to the corresponding functionality of a predetermined fragment of the sequence. More specifically, functional equivalency is to be understood as the ability of a polypeptide fragment to exert IGFBP-5 specific protease activity and/or to be recognised by an antibody capable of recognising PAPP-A2 and/or to compete with PAPP-A2 for binding to a receptor having affinity for PAPP-A2.

55 **[0174]** Functional equivalents or variants of PAPP-A2 will be understood to exhibit amino acid sequences gradually differing from the preferred predetermined PAPP-A2 sequence, as the number and scope of insertions, deletions and substitutions including conservative substitutions increases. This difference is measured as a reduction in homology between the preferred predetermined sequence and the fragment or functional equivalent.

[0175] All fragments or functional equivalents of SEQ ID NO:2 are included within the scope of this disclosure, regard-

less of the degree of homology that they show to a preferred predetermined sequence of PAPP-A2 as reported herein. The reason for this is that some regions of PAPP-A2 are most likely readily mutable, or capable of being completely deleted, without any significant effect on the binding activity of the resulting fragment.

5 **[0176]** A functional variant obtained by substitution may well exhibit some form or degree of native PAPP-A2 activity, and yet be less homologous, if residues containing functionally similar amino acid side chains are substituted. Functionally similar in this respect refers to dominant characteristics of the side chains such as hydrophobic, basic, neutral or acidic, or the presence or absence of steric bulk. Accordingly, in one embodiment of the invention, the degree of identity is not a principal measure of a fragment being a variant or functional equivalent of a preferred predetermined fragment according to the present disclosure.

10 **[0177]** The homology between amino acid sequences may be calculated using well known algorithms such as BLOSUM 30, BLOSUM 40, BLOSUM 45, BLOSUM 50, BLOSUM 55, BLOSUM 60, BLOSUM 62, BLOSUM 65, BLOSUM 70, BLOSUM 75, BLOSUM 80, BLOSUM 85, or BLOSUM 90.

15 **[0178]** Fragments sharing at least some homology with fragments of SEQ ID NO:2 are to be considered as falling within the scope of the present disclosure when they are at least about 90 percent homologous, for example at least 92 percent homologous, such as at least 94 percent homologous, for example at least 95 percent homologous, such as at least 96 percent homologous, for example at least 97 percent homologous, such as at least 98 percent homologous, for example at least 99 percent homologous with said fragments of SEQ ID NO:2. In one aspect, the homology percentages refer to identity percentages.

20 **[0179]** Additional factors that may be taken into consideration when determining functional equivalence according to the meaning used herein are i) the ability of antisera to detect a PAPP-A2 fragment according to the present invention, or ii) the ability of the functionally equivalent PAPP-A2 fragment to compete with PAPP-A2 in a binding assay. One method of determining a sequence of immunogenically active amino acids within a known amino acid sequence has been described by Geysen in US 5,595,915.

25 **[0180]** A further suitably adaptable method for determining structure and function relationships of peptide fragments is described by US 6,013,478. Also, methods of assaying the binding of an amino acid sequence to a receptor moiety are known to the skilled artisan.

[0181] Conservative substitutions may be introduced in any position of a preferred predetermined fragment of SEQ ID NO:2, and it may also be desirable to introduce non-conservative substitutions in any one or more positions.

30 **[0182]** A non-conservative substitution leading to the formation of a functionally equivalent fragment of PAPP-A2 would for example i) differ substantially in polarity, for example a residue with a non-polar side chain (Ala, Leu, Pro, Trp, Val, Ile, Leu, Phe or Met) substituted for a residue with a polar side chain such as Gly, Ser, Thr, Cys, Tyr, Asn, or Gln or a charged amino acid such as Asp, Glu, Arg, or Lys, or substituting a charged or a polar residue for a non-polar one; and/or ii) differ substantially in its effect on polypeptide backbone orientation such as substitution of or for Pro or Gly by another residue; and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having a minor side chain, e.g. Ala, Gly or Ser (and vice versa).

35 **[0183]** Variants obtained by substitution of amino acids may in one preferred embodiment be made based upon the hydrophobicity and hydrophilicity values and the relative similarity of the amino acid side-chain substituents, including charge, size, and the like. Exemplary amino acid substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

40 **[0184]** In addition to the variants described herein, sterically similar variants may be formulated to mimic the key portions of the variant structure and that such compounds may also be used in the same manner as the variants of the invention. This may be achieved by techniques of modelling and chemical designing known to those of skill in the art. It will be understood that all such sterically similar constructs fall within the scope of the present disclosure.

45 **[0185]** In a further embodiment the present disclosure relates to functional comprising substituted amino acids having hydrophilic or hydrophobic indices that are within +/-2.5, for example within +/- 2.3, such as within +/- 2.1, for example within +/- 2.0, such as within +/- 1.8, for example within +/- 1.6, such as within +/- 1.5, for example within +/- 1.4, such as within +/- 1.3 for example within +/- 1.2, such as within +/- 1.1, for example within +/- 1.0, such as within +/- 0.9, for example within +/- 0.8, such as within +/- 0.7, for example within +/- 0.6, such as within +/- 0.5, for example within +/- 0.4, such as within +/- 0.3, for example within +/- 0.25, such as within +/- 0.2 of the value of the amino acid it has substituted.

50 **[0186]** The importance of the hydrophilic and hydrophobic amino acid indices in conferring interactive biologic function on a protein is well understood in the art (Kyte & Doolittle, 1982 and Hopp, U.S. Pat. No. 4,554,101).

55 **[0187]** The amino acid hydrophobic index values as used herein are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5) (Kyte & Doolittle, 1982).

[0188] The amino acid hydrophilicity values are: arginine (+3.0); lysine (+3.0); aspartate (+3.0+-.1); glutamate (+3.0+-.1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5+-.1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4) (U.S. 4,554,101).

5 [0189] In addition to the peptidyl compounds described herein, sterically similar compounds may be formulated to mimic the key portions of the peptide structure and that such compounds may also be used in the same manner as the peptides of the invention. This may be achieved by techniques of modelling and chemical designing known to those of skill in the art. For example, esterification and other alkylations may be employed to modify the amino terminus of, e.g., a di-arginine peptide backbone, to mimic a tetra peptide structure. It will be understood that all such sterically similar
10 constructs fall within the scope of the present disclosure.

[0190] Peptides with N-terminal alkylations and C-terminal esterifications are also encompassed within the present disclosure. Functional equivalents also comprise glycosylated and covalent or aggregative conjugates formed with the same or other PAPP-A2 fragments and/or PAPP-A2 molecules, including dimers or unrelated chemical moieties. Such functional equivalents are prepared by linkage of functionalities to groups which are found in fragment including at any
15 one or both of the N- and C-termini, by means known in the art.

[0191] Functional equivalents may thus comprise fragments conjugated to aliphatic or acyl esters or amides of the carboxyl terminus, alkylamines or residues containing carboxyl side chains, e.g., conjugates to alkylamines at aspartic acid residues; O-acyl derivatives of hydroxyl group-containing residues and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g. conjugates with fMet-Leu-Phe or immunogenic proteins. Derivatives
20 of the acyl groups are selected from the group of alkyl-moieties (including C3 to C10 normal alkyl), thereby forming alkanoyl species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The reactive groups preferably are difunctional compounds known per se for use in cross-linking proteins to insoluble matrices through reactive side groups.

[0192] Covalent or aggregative functional equivalents and derivatives thereof are useful as reagents in immunoassays or for affinity purification procedures. For example, a fragment of PAPP-A2 according to the present invention may be insolubilized by covalent bonding to cyanogen bromide-activated Sepharose by methods known per se or adsorbed to polyolefin surfaces, either with or without glutaraldehyde cross-linking, for use in an assay or purification of anti-PAPP-A2 antibodies or cell surface receptors. Fragments may also be labelled with a detectable group, e.g., radioiodinated by the chloramine T procedure, covalently bound to rare earth chelates or conjugated to another fluorescent moiety for
25 use in e.g. diagnostic assays.

[0193] Mutagenesis of a preferred predetermined fragment of PAPP-A2 can be conducted by making amino acid insertions, usually on the order of about from 1 to 10 amino acid residues, preferably from about 1 to 5 amino acid residues, or deletions of from about from 1 to 10 residues, such as from about 2 to 5 residues.

[0194] In one embodiment the fragment of PAPP-A2 is synthesised by automated synthesis. Any of the commercially available solid-phase techniques may be employed, such as the Merrifield solid phase synthesis method, in which amino acids are sequentially added to a growing amino acid chain. (See Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963).

[0195] Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Applied Biosystems, Inc. of Foster City, Calif., and may generally be operated according to the manufacturer's instructions. Solid phase synthesis will enable the incorporation of desirable amino acid substitutions into any fragment of PAPP-A2 according to the present invention. It will be understood that substitutions, deletions, insertions or any subcombination thereof may be combined to arrive at a final sequence of a functional equivalent. Insertions shall be understood to include amino-terminal and/or carboxyl-terminal fusions, e.g. with a hydrophobic or immunogenic protein or a carrier such as any polypeptide or scaffold structure capable as serving as a carrier.

[0196] Oligomers including dimers including homodimers and heterodimers of fragments of PAPP-A2 according to the invention are also provided PAPP-A2 functional equivalents and variants can be produced as homodimers or heterodimers with other amino acid sequences or with native PAPP-A2 sequences. Heterodimers include dimers containing immunoreactive PAPP-A2 fragments as well as PAPP-A2 fragments that need not have or exert any biological activity.

[0197] PAPP-A2 fragments according to the invention may be synthesised both in vitro and in vivo. Method for in vitro synthesis are well known, and methods being suitable or suitably adaptable to the synthesis in vivo of PAPP-A2 are also described in the prior art. When synthesized in vivo, a host cell is transformed with vectors containing DNA encoding PAPP-A2 or a fragment thereof. A vector is defined as a replicable nucleic acid construct. Vectors are used to mediate expression of PAPP-A2. An expression vector is a replicable DNA construct in which a nucleic acid sequence encoding the predetermined PAPP-A2 fragment, or any functional equivalent thereof that can be expressed in vivo, is operably linked to suitable control sequences capable of effecting the expression of the fragment or equivalent in a suitable host.
30
35
40
45
50
55 Such control sequences are well known in the art.

[0198] Cultures of cells derived from multicellular organisms represent preferred host cells. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of useful host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and WI38, BHK, COS-7, 293 and MDCK cell lines.

Preferred host cells are eukaryotic cells known to synthesize endogenous PAPP-A2. Cultures of such host cells may be isolated and used as a source of the fragment, or used in therapeutic methods of treatment, including therapeutic methods aimed at promoting or inhibiting a growth state, or diagnostic methods carried out on the human or animal body.

[0199] In particular embodiments the present invention relates to a polypeptide fragment according to the invention, wherein the PAPP-A2 fragment comprises or essentially consists of amino acid residues 234 to 1791 corresponding to the mature part of PAPP-A2, including any processing variants thereof.

Processing variants are variants resulting from alternative processing events, possibly processing events catalysed by any protease including, but not limited to, a signal peptidase and a furin. One putative cleavage site is located after position 233 is described herein below in detail. Another putative cleavage site is located after the motif RQRR (position 196 - 199 in the amino acid sequence of PAPP-A2). Processing variants shall be understood to comprise variants arising from processing in vivo when PAPP-A2 is expressed in human or animal tissue, sera or body fluids.

[0200] Mature PAPP-A2 amino acids sequences essentially consisting of the mature sequence designated in SEQ ID NO:2 (amino acid residues 234 to 1791) shall be understood in one embodiment to comprise this part of the sequence lacking between 1 to about 10 N-terminal amino acids or C-terminal amino acids, preferably 1 to 10 N-terminal amino acids, such as 2 to 8 N-terminal acids, for example 3 to 6 N-terminal amino acids.

[0201] Also included in the definition of essentially consisting of as used herein shall be the mature sequence designated in SEQ ID NO:2 (amino acid residues 234 to 1791) having in addition thereto an additional 1 to about 10 N-terminal amino acids or C-terminal amino acids, preferably 1 to 10 N-terminal amino acids, such as 2 to 8 N-terminal acids, for example 3 to 6 N-terminal amino acids. This definition of essentially consisting of shall also apply in other aspects and is not restricted to being used in connection with a particular part of PAPP-A2. The definition shall also apply to other processes PAPP-A2 polypeptides including polypeptides arising from alternative processing in tissue, sera or body fluids other than the ones from where the processed PAPP-A2 has originally been isolated.

[0202] Additionally preferred fragments comprise or essentially consists of amino acid residues 1 to 233 corresponding to the prepro part of PAPP-A2, of amino acid residues 23 to 233 corresponding to the pro part of PAPP-A2, of amino acid residues 1 to 22 corresponding to the signal peptide or leader sequence of PAPP-A2, and to such sequences operably linked to the mature part of PAPP-A2 corresponding to amino acid residues 234 to 1791 of SEQ ID NO:2.

[0203] There is also provided recombinant PAPP-A2 polypeptide, or a fragment thereof, wherein preferably the polypeptide is free of human proteins, or other proteins natively associated with said polypeptide.

[0204] In a further aspect there is provided a composition comprising i) a polynucleotide according to the invention, and/or ii) a vector according to the invention, and/or iii) a host organism according to the invention, and/or iv) a polypeptide according to the invention, in combination with a physiologically acceptable carrier.

[0205] In yet another aspect there is provided a pharmaceutical composition comprising i) a polynucleotide according to the invention, and/or ii) a vector according to the invention, and/or iii) a host organism according to the invention, and/or iv) a polypeptide according to the invention, in combination with a pharmaceutically acceptable carrier.

[0206] The invention further pertains to a method for producing an antibody with specificity for a PAPP-A2 polypeptide according to claims 1 to 14 said method comprising the steps of

- i) providing a host organism,
- ii) immunizing the host organism with the polypeptide according to claim 10, and
- iii) obtaining said antibody.

[0207] There is also provided monoclonal antibodies and polyclonal antibodies having specific binding affinity for a PAPP-A2 polypeptide according to the invention, or a fragment thereof. The antibody is preferably a monoclonal.

[0208] In a further aspect there is provided a method for producing a PAPP-A2 polypeptide according to the invention, said method comprising the steps of

- i) providing a suitable host organism, preferably a mammalian cell,
- ii) transfecting or transforming the host organism provided in step i) with a polynucleotide according to the invention, or a vector according to the invention,
- iii) culturing the host organism obtained in step ii) under conditions suitable for expression of the polypeptide encoded by the polynucleotide or the vector; and optionally
- iv) isolating from the host organism the polypeptide resulting from recombinant expression by the host organism.

[0209] In a still further aspect of the invention there is provided a method for inhibiting and/or reducing the expression of PAPP-A2 in a cell by means of anti-sense technology, said method comprising the steps of

- i) providing an anti-sense polynucleotide according to the invention,
- ii) transfecting or transforming a cell capable of expressing PAPP-A2 with said anti-sense polynucleotide provided in step i),
- iii) culturing the cell obtained in step ii) under conditions suitable for hybridization of the polynucleotide provided in step i) to a complementary polynucleotide in said cell involved in the expression of PAPP-A2, and
- iv) inhibiting and/or reducing the expression of PAPP-A2 in said cell.

[0210] The antisense polynucleotide and the complementary polynucleotide may be co-expressed from distinct polynucleotide molecules or they may be expressed from the same molecule. As an alternative to hybridization, the method may include the use of reverse transcriptase PCR technology (rt PCT technology).

[0211] In yet another aspect of the invention there is provided a method for detecting PAPP-A2, or measuring the level of PAPP-A2, in a biological sample obtained from an individual, said method comprising the steps of

- i) obtaining a biological sample from said individual,
- ii) detecting PAPP-A2 in said sample by detecting
 - a) a PAPP-A2 polypeptide, or a fragment thereof, and/or
 - b) a polynucleotide in the form of mRNA originating from PAPP-A2 expression, and/or
 - c) PAPP-A2 specific protease activity, preferably IGFBP-5 protease activity, or proteolytic activity directed against a derivative of IGFBP-5..

[0212] The method may comprise the further step of comparing the PAPP-A2 or the level of PAPP-A2 detected in step ii) with a predetermined value selected from the group consisting of

- a) a predetermined amount and/or concentration of PAPP-A2; and/or
- b) a predetermined amount and/or concentration of PAPP-A2 mRNA; and/or
- c) a predetermined PAPP-A2 specific protease activity.

[0213] The predetermined value in one embodiment will be indicative of a normal physiological condition of said individual.

[0214] The biological sample is preferably selected from the group consisting of blood, urine, pleural fluid, oral washings, tissue biopsies, and follicular fluid.

[0215] When the level of PAPP-A2 is measured as an amount of PAPP-A2 protein, the PAPP-A2 protein is preferably measured by immunochemical analysis wherein PAPP-A2 protein is detected by at least one monoclonal antibody. PAPP-A2 protein may also be detected in a complex comprising at least one additional component, preferably a polypeptide such as, but not limited to, pro-MBP (pro-Major-Basic Protein). PAPP-A2 may also be detected as a PAPP-A2 monomer or as a PAPP-A2 dimer.

[0216] Further aspects of the invention relates to an ex vivo method of diagnosing a clinical condition in an individual, said method comprising the steps of

- i) performing a method for detecting PAPP-A2 or measuring the level of PAPP-A2, and
- ii) diagnosing the clinical condition.

[0217] The clinical condition is preferably a fetal abnormality such as, but not limited to, a fetal abnormality selected from the group consisting of Trisomy 21, Trisomy 18, Trisomy 13, and Open Spina Bifida.

[0218] Additional fetal abnormalities capable of being diagnosed according to the invention is ectopic pregnancy, open

spina bifida, neural tube defects, ventral wall defects, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Monosomy X or Klinefelter's Syndrome.

[0219] In another aspect the clinical condition is an altered growth state selected from the group consisting of a growth promoting state and a growth inhibiting state, including, but not limited to, restenosis, atherosclerosis, wound healing, fibrosis, myocardial infarction, osteoporoses, rheumatoid arthritis, multiple myeloma, or cancer.

[0220] In a yet further aspect of the disclosure there is provided a method for detecting expression of a polynucleotide according to the invention in a biological sample, said method comprising the steps of

i) providing a biological sample putatively containing a polynucleotide according to the invention, and

ii) contacting the biological sample with a polynucleotide comprising a strand that is i) complementary to the polynucleotide according to the invention and ii) capable of hybridizing thereto, and

iii) allowing hybridization to occur, and

iv) detecting the hybridization complex obtained in step iii),

wherein the presence of the hybridization complex is indicative of the expression in the biological sample of the polynucleotide according to the invention, or a fragment thereof.

[0221] In a still further aspect of the disclosure there is provided a method for identifying an agent inhibiting the protease activity of PAPP-A2, said method comprising the steps of

i) incubating a) the polypeptide according to the invention, or a fragment thereof, and b) a predetermined substrate for said polypeptide or fragment, and c) a putative inhibitory agent, and

ii) determining if proteolysis of said substrate is inhibited.

[0222] The substrate preferably comprises a polypeptide that may be an internally quenched fluorescent peptide. One preferred substrate comprises or essentially consists of IGFBP-5, or a fragment thereof.

[0223] The disclosure also pertains to an inhibitory agent obtainable according to such a method for identifying an agent inhibiting the protease activity of PAPP-A2.

[0224] There is also provided the use of such provided inhibitory agents in the manufacture of a medicament for treating a clinical condition in an individual in need of such treatment.

[0225] In a still further aspect the disclosure pertains to a method for identifying an agent capable of enhancing the protease activity of PAPP-A2, said method comprising the steps of

i) incubating a) the polypeptide according to the invention, or a fragment thereof, and b) a predetermined substrate for said polypeptide, and c) a putative enhancer agent, and

ii) determining if proteolysis of said substrate is enhanced.

[0226] The substrate preferably comprises a polypeptide including an internally quenched fluorescent peptide. IGFBP-5, or a fragment thereof, is particularly preferred as a substrate.

[0227] There is also provided an enhancing agent obtainable according to the method for identifying an agent capable of enhancing the protease activity of PAPP-A2, and the disclosure also pertains to the use of such enhancing agents in the manufacture of a medicament for treating a clinical condition in an individual in need of such treatment.

[0228] In yet another aspect there is provided a method of treatment by therapy of an individual, said method comprising the step of administering to said individual i) a pharmaceutical composition according to the invention, and/or ii) the inhibitory agent according to the invention, and/or the enhancing agent according to the disclosure.

[0229] In a still further aspect there is provided a method for purification of PAPP-A2 or complexes of PAPP-A2 with other proteins, said method comprising the steps of

i) providing a polyclonal or monoclonal antibody with specific binding affinity for a polypeptide according to the invention, or a fragment thereof, and

ii) purifying PAPP-A2, or a fragment thereof, by means of affinity chromatography.

[0230] It is understood that while the invention has been described in conjunction with the detailed description thereof,

the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

BRIEF DESCRIPTION OF THE DRAWINGS

5

[0231]

10

Figure 1 shows the cDNA sequence (in 5'→3' orientation) corresponding to the mRNA that encodes preproPAPP-A2. Only the coding part of the sequence and the terminal stop codon (*) is shown and is numbered 1-5376. The translated polypeptide sequence of preproPAPP-A2 is also shown. The signal peptide cleavage site was predicted using SignalP V2.0 to be after the alanine residue encoded by nt. 64-66 ((Nielsen et al., 1997, Protein Eng 10, 1-6), WWW prediction server is located at <http://genome.cbs.dtu.dk/>). The signal peptide of preproPAPP-A2 (nt. 1-66, 22 residues) is shown in bold. The nucleotide sequence of this figure represents nt. 1 to 5376 of SEQ ID NO:1. The protein sequence of this figure is illustrated as SEQ ID NO:2.

15

20

Figure 2 is a schematic drawing of the relationship between PAPP-A (Kristensen et al., 1994, Biochemistry 33, 1592-8), and sequence stretches contained within two genomic clones with homology to the N-terminal end (hom-N, coding portion of accession number AL031734) and the C-terminal end (hom-C, coding portion of accession number AL031290) of PAPP-A, when translated into amino acid sequence. This figure also illustrates the method by which a cDNA sequence with homology to the midregion of PAPP-A was obtained. Hom-N, hom-C, and the midregion together encodes the complete sequence of a novel protein, PAPP-A2, which is a homolog of PAPP-A. The midregion was obtained by PCR using specifically primed (primer RT-N-mid), reversed transcribed human placental mRNA as the template, and primers PR-mid5 and PR-mid3 for the PCR (Table 1). To obtain a cDNA construct encoding the full-length PAPP-A2, cDNA clones corresponding to the genomic clones hom-N and hom-C were also obtained using cDNA synthesized with specifically primed placental mRNA as the template (primers not shown, see Table 1). This required identification of a signal peptide stretch (in hom-N) and a stop codon (at the 3' end of hom-C), as detailed in the main text. All primers used are shown in Table 1. Note: The relative positions of the sequences depicted here are in accordance with the experiments performed, but the figure is not accurately drawn to scale.

25

30

35

Figure 3 shows the amino acid sequence of preproPAPP-A2 (SEQ ID NO:2) aligned with preproPAPP-A. The deduced amino acid sequence of preproPAPP-A2 (PA2) was aligned with the sequence of preproPAPP-A (PA) ((Haaning et al., 1996, Eur J Biochem 237, 159-63), AAC50543) using CLUSTAL W (Thompson et al., 1994, Nucleic Acids Res 22, 4673-80). Because the prepro-portion of PAPP-A did not show significant identity with the corresponding region of PAPP-A2, the alignment was manually adjusted to emphasize difference in length of pro-peptides. Arrows indicate the N-termini of the mature proteins as found earlier for PAPP-A (Kristensen et al., 1994, Biochemistry 33, 1592-8) (Glu-81), and here for PAPP-A2 (Ser-234). Putative signal peptides, strongly predicted using SignalP V2.0 (Nielsen et al., 1997, Protein Eng 10, 1-6) are shown with lower case letters. The pro-portion of PAPP-A2 contains one other candidate initiation codon corresponding to Met-168, but no signal peptide was predicted following this residue using SignalP. The sequence motifs of PAPP-A (Kristensen et al., 1994, Biochemistry 33, 1592-8) are also found in PAPP-A2: The catalytic zinc binding motif and residues of the putative Met-turn are underlined and bolded in both sequences. Lin-notch motifs (LNR1-3) and short consensus repeats (SCR-1-5) are boxed. Cysteine residues are shaded. All cysteines of mature PAPP-A are also found in PAPP-A2. In addition, the secreted form of PAPP-A2 has four cysteine residues (Cys-343, Cys-533, Cys-618, and Cys-1268) with no counter-part in PAPP-A.

45

50

Figure 4 shows PAPP-A2 by Western blotting and Coomassie staining. Medium from transfected 293T cells was Western blotted using monoclonal anti-*c-myc*. Lane 1, cells transfected with empty vector; lane 2, cells transfected with cDNA encoding wild-type PAPP-A2 C-terminally tagged with the *c-myc* peptide (pPA2-mH), non-reduced; lane 3, cells transfected with or cDNA encoding PAPP-A2 with an inactivating E734Q mutation (pPA2-KO-mH), non-reduced; lane 4, as lane 2, but reduced. Recombinant PAPP-A2 was purified by nickel affinity chromatography from serum free medium of cells transfected with pPA2-KO-mH, to eliminate possible autocatalysis (lane 5, reduced).

55

Figure 5 shows the activity of PAPP-A2 against IGFBP-1-6. Medium from 293T cells transfected with empty vector (-), or cDNA encoding PAPP-A2 (pPA2) (+) was incubated with each of the six IGFBPs (BP1-BP6), and the activity was assessed by ligand blotting using radiolabeled IGF-II. Complete cleavage of IGFBP-5 is evident from the absence of a signal in the BP5+ lane. Partial degradation of IGFBP-3 is also evident.

Figure 6 shows proteolytic activity of PAPP-A2 against IGFBP-5. Medium from 293T cells transfected with empty

EP 1 346 061 B1

vector (lane 1), cDNA encoding PAPP-A2 with an inactivating E734Q mutation (pPA2-KO) (lane 2), or cDNA encoding wild-type PAPP-A2 (pPA2) (lanes 3-6) was incubated with C-terminally c-myc tagged rIGFBP-5. Proteolytic activity was assessed by Western blotting using anti-c-myc. 'i' denotes intact rIGFBP-5; 'c' denotes the detectable C-terminal c-myc tagged cleavage product. In the absence of inhibitors, wild-type PAPP-A2 degraded all rIGFBP-5 (lane 3). The PAPP-A2 activity was abolished by 10 mM phenantroline (lane 4) and 5 mM EDTA (lane 5), but not affected by 100 μ M 3,4-DCI (lane 6). Coomassie-stained SDS-PAGE of purified rIGFBP-5 is shown before (lane 7) and after (lane 8) digestion with purified PAPP-A2. A Western blot of the same digest, using anti-c-myc, is also shown (lane 9). Sequence analysis revealed that PAPP-A2 cleaves IGFBP-5 at one site, between Ser-142 and Lys-143.

Figure 7 shows the cDNA sequence of the PAPP-A2 mRNA coding region directly followed by the sequence of the 3'UTR. The sequence of the 3'UTR was obtained as detailed in Example 6.3 The first 5376 nucleotides of this sequence (nt. 1 - 5376) represents the coding sequence as illustrated in Figure 1 and SEQ ID NO:1 (nt. 1 - 5376). Nucleotides 5377 - 8527 of this sequence corresponds to the 3'UTR of the PAPP-A2 mRNA as illustrated in SEQ ID NO:3 (nt. 5377 - 8527).

Figure 8 shows the disulfide structure of the PAPP-A subunit in the PAPP-A/proMBP complex (upper bar). Cysteine containing peptides originating from the PAPP-A/proMBP complex were isolated by degrading PAPP-A/proMBP complex with proteinases and cyanogen bromide followed by standard HPLC. Peptides were identified by amino acid analysis, N-terminal sequence analysis, and by mass spectrometry (Overgaard, M. T., Oxvig, C., unpublished). Disulfide bonds are shown by thin lines. Two cysteine residues form inter-chain disulfide bridges to proMBP, and one forms an inter-chain bridge to PAPP-A causing it to be a dimer (as indicated). Asterisks mark a cysteine residue to which no partner has been found. The cysteine residues present in mature PAPP-A is also present in mature PAPP-A2 (see Figure 3). It is reasonable to assume that the disulfide pairing of PAPP-A2 is the same. Thus, this information is valuable in determination of boundary regions for expression of isolated domains (fragments) of PAPP-A2. The gene structure of PAPP-A is also show (lower bar). Exon/intron boundaries are based on comparison of PAPP-A cDNA (AN X68280) with genomic sequences (ANs AB020878, AL353141, and AL137024). The central bar shows putative domains of PAPP-A based on information of the upper and lower bars.

EXAMPLES

6.1. Identification of a nucleotide sequence encoding PAPP-A2

[0232] Accession numbers (ANs) given in this text refer to sequences deposited in Gen-Bank or other biological sequence databases. ANs are used interchangeable with the protein or nucleotide sequences deposited under the given AN.

[0233] Searching public nucleotide databases for DNA sequences with homology to PAPP-A ((Kristensen et al., 1994, Biochemistry 33, 1592-8), AN CAA48341) when translated into polypeptide sequence revealed two genomic clones with the ANs AL031734 and AL031290. Both originate from the human chromosome 1 (1q24). The search was performed against the "nr" collection of databases using the program tblastn at <http://www.ncbi.nlm.nih.gov/BLAST/> with default settings. In this example, PAPP-A is numbered with the N-terminal Glu as residue 1, as in (Kristensen et al., 1994, Biochemistry 33, 1592-8). In the deposited sequence record (AN X68280) this Glu is residue 5.

[0234] The sequence reported in AL031734 contains 168835 base pairs. Two noncontiguous sequence stretches (nt. 103432-103566, and 140846-141919) of the total sequence together aligned with residues 16-59, and 59-413 of the PAPP-A polypeptide sequence when translated. The sequence reported in AL031290 contains 121780 base pairs. Four noncontiguous sequence stretches (nt. 10209-10358, 11752-11901, 20531-20463, and 60536-60652) of the total sequence together aligned with residues 1313-1362, 1376-1425, 1457-1479, and 1470-1506 of the PAPP-A polypeptide sequence when translated. The sequence stretches between the coding regions of both of the genomic sequences represent noncoding genomic DNA (introns) or coding regions that do not align.

[0235] Based on these findings, we hypothesized the existence of a novel protein, PAPP-A2, with homology to PAPP-A. It was then established the complete coding sequence of the regions of PAPP-A2 that were partially covered by the two genomic sequences reported in AL031734 and AL031290. We denote those contiguous sequences hom-N and hom-C, respectively (Figure 2). But first, we established the existence of a coding cDNA sequence that also showed homology to PAPP-A, and that connected the sequence of hom-N and hom-C (Figure 2). All essential primers used are described in Table 1. The entire cDNA sequence encoding the 1791-residue preproPAPP-A2 is shown in Figure 1. Standard cloning techniques were used, and all DNA constructs were analyzed by sequencing. The methodology used is described below. The name PAPP-A2 is used for the protein encoded by this DNA sequence.

[0236] Cloning of a contiguous coding cDNA stretch corresponding to the midregion between hom-N and hom-C: To obtain the midregion (Figure 2), cDNA was synthesized using human placental mRNA as a template and a primer, RT-

N-mid, derived from AL031290 (Table 1, Figure 2). This cDNA was used as a template in a PCR to obtain a cDNA corresponding to the midregion of the hypothesized PAPP-A2. PCR primers were PR-mid5 and PR-mid3 (Table 1, Figure 2). The coding sequence of the midregion obtained corresponds to residues 665-1572 of Figure 3 (SEQ ID NO:1), a total of 908 amino acids.

TABLE 1. Locations of primers used for reverse transcription or PCR. The primers are listed in the order of their use.

NAME	SOURCE ^a	Nt. NUMBERS ^b	SEQUENCE ^c
RT-N-mid:	AL031290	10262-10281, (4770-4789)	GCTCACACACCACAGGAATG*
PR-mid5:	AL031734	141874-141894, (1947-1967)	GGCTGATGTGCGCAAGACCTG
PR-mid3:	AL031290	10208-10229, (4716-4737)	GCATTGTATCTTCAGGAGCTTG*
PR-N5:	AL031734	102606-102628, (-)	GAAGTTGACTTCTGGTTCTGTAG
PR-N3:		-, (2380-2400)	CCCTGGGAAGCGAGTGAAGCC*
RT-C:	AL031290	62982-63006, (-)	GCATTTCTTATAAGATCCTTCATGC*
PR-C5:	-	-, (4180-4201)	GACAGCTGTCCGTCATTGCTGC
PR-C3:	AL031290	62876-62897, (-)	CTTACTGCCTCTGAGGCAGTGG*

^aAccession numbers of the relevant genomic clones are given. Primers PR-N3 and PR-C5 were located in the sequence connecting hom-N and hom-C, and are therefore not represented in the databases.

^bNucleotide numbers refer to the numbering of the sequences as reported in the file with the relevant accession number. In parentheses are given the corresponding numbers of SEQ ID NO:1 (Figure 1), except for primers PR-N5, RT-C and PR-C3, not within this sequence.

^cSequences are actual primer sequences (orientation 5'-to-3'). Sequences marked with an asterisk are complementary to the database sequences or the sequence given in Figure 1.

[0237] Cloning of a contiguous coding cDNA stretch corresponding to the N-terminal end of PAPP-A2 (hom-N): Manual inspection of the genomic sequence AL031734 revealed that the open reading frame of the sequence stretch corresponding to PAPP-A residues 16-59 continued further in the 5' direction: Nt. 102646-103566 encodes a polypeptide sequence of 307 residues that starts with a methionine residue. Based on this finding, the cDNA used to obtain the midregion (placental mRNA primed with RT-N-mid, as detailed above) was used as a template in a PCR to obtain the contiguous cDNA of hom-N. PCR primers were: PR-N5 and PR-N3 (Table 1, Figure 2).

[0238] Cloning of a contiguous coding cDNA stretch corresponding to the C-terminal end of PAPP-A2 (hom-C): Searching available databases (using the program blastn at <http://www.ncbi.nlm.nih.gov/BLAST/> with default settings) for human EST sequences matching the genomic sequence of AL031290 revealed an EST sequence overlapping with some of the coding regions of AL031290 already defined by the stretch nt. 60536-60652 (cf. above). Nt. 62790-62995 of AL031290 also matched the sequence of the human EST sequence AA368081 originating from placenta. When translated into polypeptide sequence, this EST sequence showed homology to the C-terminal end of PAPP-A. Further, a stop codon was present within the coding sequence corresponding to amino acid 1537 of PAPP-A. That is, PAPP-A2 does not extend C-terminally beyond PAPP-A when the two sequences are aligned. Based on this, cDNA was synthesized using human placental mRNA as a template and a primer originating from AL031290 (Table 1). This cDNA was used as a template in a PCR to obtain the contiguous cDNA of hom-C using PCR primers PR-C5 and PR-C3 (Table 1, Figure 2).

[0239] All PCRs were carried out with *Pfu* polymerase (Stratagene). The three overlapping PAPP-A2 cDNA fragments (hom-N, the novel midregion, and hom-C) were all cloned into the vector pCR-BluntII-TOPO (Invitrogen). Several clones were sequenced in both orientations. The constructs are referred to as p2N, p2Mid, and p2C, respectively. The entire nucleotide sequence encoding PAPP-A2 is shown in Figure 1 (and SEQ ID NO:1).

6.2. Analyses of the nucleotide and amino acid sequence of PAPP-A2

[0240] Of the 1547 residues of mature PAPP-A, 708 residues (45.8%) are identical in preproPAPP-A2. There is no significant degree of identity between the prepro portion of PAPP-A and the remaining (N-terminal) portion of PAPP-A2 (Figure 3). In this example, PAPP-A is numbered according to ((Haaning et al., 1996, Eur J Biochem 237, 159-63), AAC50543).

[0241] The sequence motifs recognized in PAPP-A (Kristensen et al., 1994, *Biochemistry* 33, 1592-8) are also present in PAPP-A2: An elongated zinc binding consensus sequence, three lin-notch repeats (LNR1-3), and five short consensus repeats (SCR1-5) (Figure 3). Further, all 82 cysteine residues of PAPP-A are conserved between the two proteins, and an additional 4 cysteines are present in the PAPP-A2 polypeptide sequence.

6.3. Identification of human EST sequences originating from the PAPP-A2 mRNA

[0242] A cluster of EST sequences matching the genomic sequence of AL031290 were identified around nt 64000-66000 of AL031290, starting approximately 1.2 kb from the end of the PAPP-A2 encoding sequence. The existence of mRNA connecting the coding region of PAPP-A2 and this cluster was verified in a PCR using primers from AL031290 (5'-GGAAAGAGCAGAGTTCACCCAT-3', nt. 64900-64879 of AL031290) and the PAPP-A2 encoding sequence (5'-CCGTCTTAGTCCACTGCATCC-3', nt. 20499-20519 of AL031290, nt 5171-5191 of AF311940), and oligo-dT primed placental cDNA as a template (Overgaard et al., 1999, *Biol Reprod* 61, 1083-9). As expected, the size of the resulting product was 2.2 kb, further demonstrating the existence of a PAPP-A2 mRNA with a 3'UTR of about 3 kb. The distribution among tissues is shown in Table 2.

TABLE 2. Expression of PAPP-A2 mRNA in human tissues evaluated by available EST sequences^a.

Tissue of origin	Number of ESTs found
Human placenta	38
Pregnant uterus	21
Fetal liver/spleen	11
Kidney	5
Retina/Fetal retina	3
Corneal stroma	2
Fetal heart	2
Gessler Wilms tumor	2
Other tissues ^b	14

^a Using the blast algorithm (Altschul et al., 1997, *Nucleic Acids Res* 25, 3389-402), a total of 98 human EST sequences were identified that matched the 3'UTR of the PAPP-A2 mRNA sequence. The distribution among tissues is based on the annotations of individual database entries (not listed).
^b EST sequences originated from pools of tissue, or from tissue represented by only one EST sequence.

6.4. Expression in mammalian cells of recombinant PAPP-A2 and variants of PAPP-A2

[0243] The following plasmid constructs were made:

- pPA2: The cDNA sequence of pre-pro-PAPP-A2 encoding amino acids 1-1791 in expression vector pcDNA3.1+.
- pPA2-KO: As pPA2, but Glu-734 of the active site of PAPP-A2 substituted with a Gln residue (E734Q).
- pPA2-mH: The expression vector pcDNA3.1/*Myc*-His(-)A containing the cDNA sequence of pre-pro-PAPP-A2 encoding amino acids 1-1791, not followed by a stop codon, but rather a *c-myc* and a His tag.
- pPA2-KO-mH: As pPA2-mH, but with the E734Q substitution of pPA2-KO.

[0244] The three overlapping PAPP-A2 cDNA fragments (hom-N, the midregion, and hom-C) were used for the construction of a single contiguous cDNA sequence encoding PAPP-A2. The overlapping fragments were all contained in the vector pCR-BluntII-TOPO (Invitrogen) and referred to as p2N, p2Mid, and p2C, as detailed above (example 6.1). Clones of p2N and p2C were selected that had the proper orientation of the cDNA insert.

[0245] Construction of pPA2: The *NotI*-*Bam**HI* fragment was excised from p2C and cloned into pBluescriptIISK+ (Stratagene) to obtain p2CBlue. The *NotI*-*SpeI* fragment was excised from p2N, and the *SpeI*-*BclI* fragment was excised from p2Mid. Those two fragments were ligated into the *NotI*/*BclI* sites of p2CBlue in one reaction to obtain p2NMidCBlue, containing the entire PAPP-A2 cDNA. The *NotI*-*Apal* fragment of pBluescriptIISK+ was excised and ligated into the *NotI*/*Apal* sites of the mammalian expression vector pcDNA3.1+ (Invitrogen) to obtain a modified version of this vector,

pcDNA-NA. The full length cDNA was then excised from p2NMidCBlue with *NotI* and *XhoI* and cloned into pcDNA-NA to obtain pPA2. All restriction sites used are in the multi cloning sites of the vectors, except for *SpeI* and *BclI*, both located in each of the two overlapping regions of the coding PAPP-A2 sequence stretches of p2N, p2Mid, and p2C (nt. 2365 and nt. 4203, respectively, of Figure 3).

[0246] Construction of pPA2-KO: The construct pPA2-KO is a variant of the pPA2 expression construct in which residue Glu-734 of the active site of PAPP-A2 was substituted with a Gln residue. Thus, the mutant is E734Q. The pPA2-KO construct was made by site directed mutagenesis using the method of overlap extension PCR (Ho et al., 1989, Gene 77, 51-9) with pPA2 as the template. In brief, outer primers were 5'-CGCTCAGGGAAGGACAAGGG-3' (5' end primer, nt. 976-995 of SEQ ID NO:1) and 5'-CTAGAAGGCACAGTCGAGGC-3' (3' end primer, nt. 1040-1021, sequence of vector pcDNA3.1+). Overlapping internal primers were 5'-TGTCCCACTTGATGGATCATGGTGTGGTGTGG-3' (nt. 2210-2178 of SEQ ID NO:1, nt. 2200 not C, but G resulting in E734Q) and 5'-CCATCAAGTGGGACATGTTCTGGGAC-3' (nt. 2196-2221 of SEQ ID NO:1, nt. 2200 not G, but C resulting in E734Q). The resulting mutated fragment was digested with *XbaI* and *XhoI* and swapped into pPA2 to generate pPA2-KO. All PCRs were carried out with *Pfu* DNA polymerase (Stratagene), and all constructs were verified by sequence analysis.

[0247] Construction of pPA2-mH: Two primers (5'-GAGGGCCTGTGGACCCAGGAG-3', nt. 4906-4926 of SEQ ID NO:1, and 5'-GACGTAAAGCTTCTGATTTTCTTCTGCCTTGG-3', nt. 5373-5354 of SEQ ID NO:1, preceded by a *HindIII* site, AAGCTT, and nt. GACGTA to facilitate cleavage of the PCR product) were used in a PCR with pPA2 as the template to generate a nucleotide fragment encoding the C-terminal 156 residues of PAPP-A2 with the stop codon replaced by a *HindIII* site for in-frame ligation to expression vector. In brief, the PCR product was digested with *EcoRI* and *HindIII* and cloned into the *EcoRI/HindIII* sites of the vector pcDNA3.1/*Myc*-His(-)A to generate pPA2C-mH. The *NotI-XbaI* fragment (encoding the N-terminal portion of PAPP-A2), and the *XbaI-EcoRI* fragment (encoding the remaining central portion of PAPP-A2) were excised from pPA2 and ligated in one reaction into the *NotI/EcoRI* sites of pPA2C-mH. The resulting construct, pPA2-mH, encoded PAPP-A2 followed by residues KLGP, the *myc* epitope (EQKLISEEDL), residues NSAVD, and six H-residues (amino acids are given as one letter code). A stop codon follows immediately after the six histidine residues.

[0248] Construction of pPA2-KO-mH: A variant of pPA2-mH was constructed with residue Glu-734 substituted into a Gln residue: The *NotI-KpnI* fragment of pPA2-KO was excised and swapped into the *NotI-KpnI* sites of pPA2-mH, to generate pPA2-KO-mH.

[0249] Expression in mammalian cells: All constructs (pPA2, pPA2-KO, pPA2-mH, and pPA2-KO-mH) as well as empty expression vectors (pcDNA3.1+ and pcDNA3.1/*Myc*-His(-)A) were transiently transfected into mammalian cells for expression of recombinant PAPP-A2 protein. Briefly, human embryonic kidney 293T cells (293tsA1609neo) (DuBridge et al., 1987, Mol Cell Biol 7, 379-87) were maintained in high glucose DMEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, nonessential amino acids, and gentamicin (Life Technologies). Cells were plated onto 6 cm tissue culture dishes, and were transfected 18 h later by calcium phosphate coprecipitation (Pear et al., 1993, Proc Natl Acad Sci U S A 90, 8392-6) using 10 µg of plasmid DNA prepared by QIAprep Spin Kit (Qiagen). After a further 48 h the supernatants were harvested, and replaced by serum-free medium (293 SFM II, Life Technologies) for another 48 h. The serum-free medium was harvested and cleared by centrifugation.

[0250] Analysis by Western blotting of recombinant protein resulting from transfection with the constructs pPA2-mH and pPA2-KO-mH, demonstrated that PAPP-A2 is secreted as a protein of 220 kDa (See Figure 2). Reduction of disulfide bonds did not cause a visible change in band migration. Thus, in contrast to PAPP-A, PAPP-A2 is secreted as a monomer.

6.5. Purification by affinity chromatography of tagged PAPP-A2

[0251] A metal chelate affinity column (2 ml, Pharmacia) was charged with nickel ions and loaded with serum-free medium (50 ml) from cells transiently transfected with pPA2-KO-mH (see example 6.4). After washing in PBS containing 1 M NaCl, bound protein was eluted with 10 mM EDTA in PBS in fractions of 0.5 ml. PAPP-A2 containing fractions were located by SDS-PAGE (Figure 4, lane 5). This protein was not seen from medium of cells transfected with empty vector (mock transfectants) and treated in a parallel manner.

6.6. N-terminal sequence analysis of PAPP-A2

[0252] C-terminally tagged PAPP-A2 purified from medium of cells transfected with construct pPA2-KO-mH (see examples 6.4 and 6.5) was reduced and run on a 10-20% SDS gel, and further blotted onto PVDF membrane (ProBlott, Applied Biosystems). Bands of 4 lanes were excised and subjected to N-terminal sequence analysis on an Applied Biosystems 477A sequencer equipped with an on-line HPLC (Sottrup-Jensen, 1995, Anal Biochem 225, 187-8). The N-terminal sequence observed at a level of approximately 20 pmol was: Ser-Pro-Pro-Glu-Glu-Ser-Asn (SPPEESN), resulting from cleavage before Ser-234 of the PAPP-A2 polypeptide after R(230)VKK.

[0253] This confirms the prediction, that PAPP-A2, like PAPP-A, is synthesized as a prepro protein. The absence of

an arginine residue in the P1 position, indicates that the proprotein processing enzyme responsible for this cleavage is not furin, but likely another proprotein convertase (Nakayama, 1997, Biochem J 327, 625-35). Cleavage of proPAPP-A2 might have been predicted after R(196)QRR, which archetypically marks furin cleavage (Nakayama, 1997, Biochem J 327, 625-35). We cannot exclude that cleavage occurred at this site, and that the observed N-terminus results from further processing.

6.7. Cleavage of insulin-like growth factor binding protein (IGFBP)-5

[0254] Ligand blotting (Conover et al., 1993, J Clin Invest 91, 1129-37) with radiolabeled IGF-II (Bachem) was used to assay for activity against IGFBP-1 (from HepG2 conditioned medium), rIGFBP-2 (GroPep), rIGFBP-3 (gift of D. Powell), rIGFBP-4 (Austral), rIGFBP-5 (gift of D. Address), and rIGFBP-6 (Austral). Of the six binding proteins, IGFBP-5 showed complete cleavage (Figure 5). IGFBP-3 was partially degraded (Figure 5). This cleavage was independent of the presence of IGF. Experiments were carried out with media from cells transfected with pPA2 or empty vector.

[0255] For further analysis, recombinant IGFBP-5 was produced in mammalian cells. In brief, human placental oligo-dT primed cDNA (Overgaard et al., 1999, Biol Reprod 61, 1083-9) was used as a template to amplify cDNA encoding human IGFBP-5 (Accession number M65062). Specific primers containing an *XhoI* site (5'-TCCGCTCGAGATGGTGTT-GCTCACCGCGGT-3') and a *HindIII* site (5'-CGATAAGCTTCTCAACGTTGCTGCTGCTCG-3') were used, and the resulting PCR product was digested and cloned into the *XhoI/HindIII* sites of pcDNA3.1/*Myc*-His(A) (Invitrogen). The construct encoded the full-length proIGFBP-5, immediately followed by residues KLGP, the *myc* epitope (EQKLISEEDL), residues NSAVD, and six H-residues (amino acids are given as one letter code). The construct was verified by sequence analysis. Plasmid DNA for transfection was prepared by QIAprep Spin Kit (Qiagen). Cell culture and expression of recombinant IGFBP-5 was performed as described above in Example 6.4.

[0256] Cleavage analysis was performed by Western blotting (Figure 6). Briefly, recombinant IGFBP-5 as contained in 5 microL cell culture medium was incubated with culture supernatants (10 microL) from cells transfected with pPA2, pPA2-KO, or empty expression expression vectors (see example 6.4). Phosphate buffered saline was added to a final volume of 50 microL. After incubation at 37 degrees Celsius for 12 hours, 15 microL of the reaction mixture was separated by reducing 16% SDS-PAGE, blotted onto a PVDF membrane, and the C-terminal cleavage product was detected with monoclonal anti-*c-myc* (clone 9E19, ATTC) using peroxidase-conjugated secondary antibodies (P260, DAKO), and enhanced chemiluminescence (ECL, Amersham).

6.8. Inhibition of the activity of PAPP-A2

[0257] Various agents were analyzed for their ability to inhibit the proteolytic activity of PAPP-A2 against IGFBP-5. The experimental conditions were essentially as described in Example 6.7, except the agents to be tested were added (Figure 6). Agents found to have no effect on the proteolytic activity of PAPP-A2 further included PMSF and aprotinin.

6.9. Identification of the cleavage site in IGFBP-5

[0258] For cleavage site determination, purified rIGFBP-5 (Fig. 6, lane 7) was digested with purified PAPP-A2 and analyzed by SDS-PAGE (Fig. 6, lane 8). Edman degradation of blotted material showed that both distinct, visible degradation products (fig. 6, lane 8) contained the N-terminal sequence K(144)FVGGA (IGFBP-5 is numbered with the N-terminal Leu of the mature protein as residue 1). The two bands both represent intact C-terminal cleavage fragments, because they also contain the C-terminal *c-myc* tag (Fig. 6, lane 9); they are likely to be differently glycosylated, in accordance with the heterogeneity of purified rIGFBP-5 (Figure 6, lane 7). Both bands contained a second sequence at lower level (45%), L(1)GXFVH, corresponding to the N-terminal sequence of IGFBP-5. The absence of Ser, expected in the third cycle, was taken as evidence for carbohydrate substitution of Ser-3. O-linked glycan on the N-terminal cleavage fragment is likely to cause it to smear around the two distinct, C-terminal fragments. Sequence analysis on the reaction mixture (> 100 pmol) without SDS-PAGE separation showed only the same two IGFBP-5 sequences in equimolar amounts. Thus, PAPP-A2 cleaves IGFBP-5 at one site, between Ser-143 and Lys-144.

6.10. Tissues where PAPP-A2 may cause proteolysis of IGFBP-5

[0259] Proteolytic activity against IGFBP-5 has been widely reported from several sources, e.g. pregnancy serum (Claussen et al., 1994, Endocrinology 134, 1964-6), seminal plasma (Lee et al., 1994, J Clin Endocrinol Metab 79, 1367-72), culture media from smooth muscle cells (Imai et al., 1997, J Clin Invest 100, 2596-605), granulosa cells (Resnick et al., 1998, Endocrinology 139, 1249-57), osteosarcoma cells (Conover and Kiefer, 1993, J Clin Endocrinol Metab 76, 1153-9), and also from osteoblasts (Thraill et al., 1995, Endocrinology 136, 3527-33), and fibroblasts (Busby et al., 2000, J Biol Chem). In general, the proteinase responsible for cleavage of IGFBP-5 has remained unidentified.

[0260] The recent identification of PAPP-A as the IGFBP-4 proteinase in fibroblasts and osteoblasts (Lawrence et al., 1999, Proc Natl Acad Sci U S A 96, 3149-53), ovarian follicular fluid (Conover et al., 1999, J Clin Endocrinol Metab 84, 4742-5), pregnancy serum (Overgaard et al., 2000, J Biol Chem), and vascular smooth muscle cells (Bayes-Genis, A., Schwartz, R. S., Ashai, K., Lewis, D. A., Overgaard, M. T., Christiansen, M., Oxvig, C., Holmes, D. R., Jr., and Conover, C. A. Arterioscler. Thromb. Vasc. Biol., in press) firmly establishes PAPP-A and IGFBP-4 as an important functional pair in several systems. No other substrate as has been found for PAPP-A, and no other proteinase has been shown to cleave IGFBP-4 physiologically. It is therefore likely that the pair of PAPP-A2 and IGFBP-5 plays an analogous role in a number of the tissues mentioned above and/or elsewhere. Interestingly, incubating IGFBP-5 with smooth muscle cells conditioned medium resulted in cleavage between Ser-143 and Lys-144 (Imai et al., 1997, J Clin Invest 100, 2596-605), the same cleavage site as found here with PAPP-A2. This immediately suggests PAPP-A2 as an obvious candidate IGFBP-5 proteinase for this tissue.

Cited references

[0261]

Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 25, 3389-402.

Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1989). *Current Protocols in Molecular Biology* (New York City, NY: John Wiley & Sons).

Barker, R. L., Gleich, G. J., and Pease, L. R. (1988). Acidic precursor revealed in human eosinophil granule major basic protein cDNA [published erratum appears in *J Exp Med* 1989 Sep 1;170(3):1057]. *J Exp Med* 168, 1493-8.

Bayes-Genis, A., Schwartz, R. S., Ashai, K., A., L. D., Overgaard, M. T., Christiansen, M., Oxvig, C., Holmes Jr, D. R., and Conover, C. A. (2000). Insulin-like growth factor binding protein-4 protease produced by arterial smooth muscle cells in vitro is increased in the coronary artery following angioplasty. *Arterioscler Thromb Vasc Biol*, in press.

Biagiotti, R., Cariati, E., Brizzi, L., Cappelli, G., and D'Agata, A. (1998). Maternal serum screening for trisomy 18 in the first trimester of pregnancy. *Prenat Diagn* 18, 907-13.

Bischof, P. (1979). Purification and characterization of pregnancy associated plasma protein A (PAPP-A). *Arch Gynecol* 227, 315-26.

Bitter, G. A., Egan, K. M., Koski, R. A., Jones, M. O., Elliott, S. G., and Giffin, J. C. (1987). Expression and secretion vectors for yeast. *Methods Enzymol* 153, 516-44.

Bode, W., Gomis-Ruth, F. X., and Stockler, W. (1993). Astacins, serralsins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. *FEBS Lett* 331, 134-40.

Bonno, M., Oxvig, C., Kephart, G. M., Wagner, J. M., Kristensen, T., Sottrup-Jensen, L., and Gleich, G. J. (1994). Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. *Lab Invest* 71, 560-6.

Brambati, B., Macintosh, M. C., Teisner, B., Maguiness, S., Shrimanker, K., Lanzani, A., Bonacchi, I., Tului, L., Chard, T., and Grudzinskas, J. G. (1993). Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. *Br J Obstet Gynaecol* 100, 324-6.

Brogliè, R., Coruzzi, G., Fraley, R. T., Rogers, S. G., Horsch, R. B., Niedermeyer, J. G., Fink, C. L., and Chua, N. H. (1984). Light-regulated expression of a pea ribulose-1,5-bisphosphate carboxylase small subunit gene in transformed plant cells. *Science* 224, 838-43.

Busby, W. H., Jr., Nam, T. J., Moralez, A., Smith, C., Jennings, M., and Clemmons, D. R. (2000). The Complement Component C1 s is the Protease That Accounts for Cleavage of Insulin-like Growth Factor Binding Protein-5 in Fibroblast Medium. *J Biol Chem*.

- Christiansen, M., Oxvig, C., Wagner, J. M., Qin, Q. P., Nguyen, T. H., Overgaard, M. T., Larsen, S. O., Sottrup-Jensen, L., Gleich, G. J., and Norgaard-Pedersen, B. (1999). The proform of eosinophil major basic protein: a new maternal serum marker for Down syndrome. *Prenat Diagn* 19, 905-10.
- 5 Christiansen, M., Jaliashvili, I., Overgaard, M.T., Ensinger, C., Oxvig, C. (2000) Quantitation and characterization of pregnancy-associated complexes between angiotensinogen and the proform of eosinophil major basic protein in serum and amniotic fluid. *Clin. Chem.* 46, 1099-1105
- 10 Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. (1991). Making antibody fragments using phage display libraries. *Nature* 352, 624-8.
- Claussen, M., Zapf, J., and Braulke, T. (1994). Proteolysis of insulin-like growth factor binding protein-5 by pregnancy serum and amniotic fluid. *Endocrinology* 134, 1964-6.
- 15 Conover, C. A., and Kiefer, M. C. (1993). Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. *J Clin Endocrinol Metab* 76, 1153-9.
- Conover, C. A., Kiefer, M. C., and Zapf, J. (1993). Posttranslational regulation of insulin-like growth factor binding protein-4 in normal and transformed human fibroblasts. Insulin-like growth factor dependence and biological studies. *J Clin Invest* 91, 1129-37.
- 20 Conover, C. A., Oxvig, C., Overgaard, M. T., Christiansen, M., and Giudice, L. C. (1999). Evidence that the insulin-like growth factor binding protein-4 protease in human ovarian follicular fluid is pregnancy associated plasma protein-A [In Process Citation]. *J Clin Endocrinol Metab* 84, 4742-5.
- 25 Crowther, J. R. (1995). ELISA. Theory and Practice, Methods in Molecular Biology. vol 42 (Totowa, NJ: Humana Press).
- DuBridg, R. B., Tang, P., Hsia, H. C., Leong, P. M., Miller, J. H., and Calos, M. P. (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol Cell Biol* 7, 379-87.
- 30 Folkersen, J., Grudzinskas, J. G., Hindersson, P., Teisner, B., and Westergaard, J. G. (1981). Pregnancy-associated plasma protein A: circulating levels during normal pregnancy. *Am J Obstet Gynecol* 139, 910-4.
- 35 Fowlkes, J. L. (1997). Insulinlike growth factor-binding protein proteolysis. An emerging paradigm in insulinlike growth factor physiology. *Trends Endocrinol Metab* 8, 299-306.
- Gmunder, H., and Kohli, J. (1989). Cauliflower mosaic virus promoters direct efficient expression of a bacterial G418 resistance gene in *Schizosaccharomyces pombe*. *Mol Gen Genet* 220, 95-101.
- 40 Haddow, J. E., Palomaki, G. E., Knight, G. J., Williams, J., Miller, W. A., and John-son, A. (1998). Screening of maternal serum for fetal Down's syndrome in the first trimester. *N Engl J Med* 338, 955-61.
- 45 Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989). Site-directed mutagenesis by overlap extension using the polymerase chain reaction [see comments]. *Gene* 77, 51-9.
- Hwa, V., Oh, Y., and Rosenfeld, R. G. (1999). The insulin-like growth factor-binding protein (IGFBP) superfamily. *Endocr Rev* 20, 761-87.
- 50 Haaning, J., Oxvig, C., Overgaard, M. T., Ebbesen, P., Kristensen, T., and Sottrup-Jensen, L. (1996). Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A. Evidence for expression in the brain and induction by cAMP. *Eur J Biochem* 237, 159-63.
- 55 Imai, Y., Busby, W. H., Jr., Smith, C. E., Clarke, J. B., Garmong, A. J., Horwitz, G. D., Rees, C., and Clemmons, D. R. (1997). Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. *J Clin Invest* 100, 2596-605.
- Kristensen, T., Oxvig, C., Sand, O., Moller, N. P., and Sottrup-Jensen, L. (1994). Amino acid sequence of human

pregnancy-associated plasma protein-A derived from cloned cDNA. *Biochemistry* 33, 1592-8.

Lawrence, J. B., Oxvig, C., Overgaard, M. T., Sottrup-Jensen, L., Gleich, G. J., Hays, L. G., Yates, J. R., 3rd, and Conover, C. A. (1999). The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. *Proc Natl Acad Sci U S A* 96, 3149-53.

Lee, K. O., Oh, Y., Giudice, L. C., Cohen, P., Peehl, D. M., and Rosenfeld, R. G. (1994). Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients. *J Clin Endocrinol Metab* 79, 1367-72.

Lin, T. M., Galbert, S. P., Kiefer, D., Spellacy, W. N., and Gall, S. (1974). Characterization of four human pregnancy-associated plasma proteins. *Am J Obstet Gynecol* 118, 223-36.

Logan, J., and Shenk, T. (1984). Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. *Proc Natl Acad Sci U S A* 81, 3655-9.

Mackett, M., Smith, G. L., and Moss, B. (1982). Vaccinia virus: a selectable eukaryotic cloning and expression vector. *Proc Natl Acad Sci U S A* 79, 7415-9.

Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., and Winter, G. (1991). By-passing immunization. Human antibodies from V-gene libraries displayed on phage. *J Mol Biol* 222, 581-97.

Matthews, D. J., and Wells, J. A. (1993). Substrate phage: selection of protease substrates by monovalent phage display. *Science* 260, 1113-7.

McGrogan, M., Simonsen, C., Scott, R., Griffith, J., Ellis, N., Kennedy, J., Campanelli, D., Nathan, C., and Gabay, J. (1988). Isolation of a complementary DNA clone encoding a precursor to human eosinophil major basic protein. *J Exp Med* 168, 2295-308.

Meldal, M. (1998). Intramolecular fluorescence-quenched substrate libraries. *Methods Mol Biol* 87, 65-74.

Meldal, M. (1998). Introduction to combinatorial solid-phase assays for enzyme activity and inhibition. *Methods Mol Biol* 87, 51-7.

Meldal, M. (1998). The solid-phase enzyme inhibitor library assay. *Methods Mol Biol* 87, 75-82.

Nakayama, K. (1997). Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. *Biochem J* 327, 625-35.

Nielsen, H., Engelbrecht, J., Brunak, S., and von Heijne, G. (1997). Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Protein Eng* 10, 1-6.

Overgaard, M. T., Haaning, J., Boldt, H. B., Olsen, I. M., Laursen, L., Christiansen, M., Gleich, G. J., Sottrup-Jensen, L., (Conover, C. A., and Oxvig, C. (2000). Expression of Recombinant Human Pregnancy-Associated Plasma Protein-A and Identification of the Proform of Eosinophil Major Basic Protein as its Physiological Inhibitor. *J Biol Chem*.

Overgaard, M. T., Oxvig, C., Christiansen, M., Lawrence, J. B., Conover, C. A., Gleich, G. J., Sottrup-Jensen, L., and Haaning, J. (1999). Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonreproductive tissues. *Biol Reprod* 61, 1083-9.

Oxvig, C., Haaning, J., Hojrup, P., and Sottrup-Jensen, L. (1994). Location and nature of carbohydrate groups in proform of human major basic protein isolated from pregnancy serum. *Biochem Mol Biol Int* 33, 329-36.

Oxvig, C., Haaning, J., Kristensen, L., Wagner, J. M., Rubin, I., Stigbrand, T., Gleich, G. J., and Sottrup-Jensen, L. (1995). Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma. *J Biol Chem* 270, 13645-51.

- Oxvig, C., Sand, O., Kristensen, T., Gleich, G. J., and Sottrup-Jensen, L. (1993). Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. *J Biol Chem* 268, 12243-6.
- 5 Oxvig, C., Sand, O., Kristensen, T., Kristensen, L., and Sottrup-Jensen, L. (1994). Isolation and characterization of circulating complex between human pregnancy-associated plasma protein-A and proform of eosinophil major basic protein. *Biochim Biophys Acta* 1201, 415-23.
- 10 Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. *Proc Natl Acad Sci U S A* 90, 8392-6.
- Peters, J. H., and Baumgarten, H. (1992). *Monoclonal Antibodies* (Offensheim, Germany: Springer-Verlag).
- 15 Rajaram, S., Baylink, D. J., and Mohan, S. (1997). Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. *Endocr Rev* 18, 801-31.
- Resnick, C. E., Fielder, P. J., Rosenfeld, R. G., and Adashi, E. Y. (1998). Characterization and hormonal regulation of a rat ovarian insulin-like growth factor binding protein-5 endopeptidase: an FSH-inducible granulosa cell-derived metalloprotease. *Endocrinology* 139, 1249-57.
- 20 Rosenfeld, S. A. (1999). Use of *Pichia pastoris* for expression of recombinant proteins. *Methods Enzymol* 306, 154-69.
- Ruther, U., and Muller-Hill, B. (1983). Easy identification of cDNA clones. *Embo J* 2, 1791-4.
- 25 Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). *Molecular Cloning. A Laboratory Manual* (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).
- Scopes, R. K. (1987). *Protein Purification. Principles and Practice.* (Harrisonburg, VA: Springer-Verlag).
- 30 Sinosich, M. J. (1990). Molecular characterization of pregnancy-associated plasma protein-A by electrophoresis. *Electrophoresis* 11, 70-8.
- Smith, G. E., Summers, M. D., and Fraser, M. J. (1983). Production of human beta interferon in insect cells infected with a baculovirus expression vector. *Mol Cell Biol* 3, 2156-65.
- 35 Sottrup-Jensen, L. (1993). Determination of halfcystine in proteins as cysteine from reducing hydrolyzates. *Biochem Mol Biol Int* 30, 789-94.
- Sottrup-Jensen, L. (1995). A low-pH reverse-phase high-performance liquid chromatography system for analysis of the phenylthiohydantoins of S-carboxymethylcysteine and S-carboxyamidomethylcysteine. *Anal Biochem* 225, 187-8.
- 40 Spencer, K., Ong, C., Skentou, H., A, W. L., and K, H. N. (2000). Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. *Prenat Diagn* 20, 411-6.
- 45 Stocker, W., Grams, F., Baumann, U., Reinemer, P., Gomis-Ruth, F. X., McKay, D. B., and Bode, W. (1995). The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. *Protein Sci* 4, 823-40.
- 50 Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 22, 4673-80.
- 55 Thrailkill, K. M., Quarles, L. D., Nagase, H., Suzuki, K., Serra, D. M., and Fowlkes, J. L. (1995). Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. *Endocrinology* 136, 3527-33.
- Wald, N., Stone, R., Cuckle, H. S., Grudzinskas, J. G., Barkai, G., Brambati, B., Teisner, B., and Fuhrmann, W.

EP 1 346 061 B1

(1992). First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome [see comments]. *Bmj* 305, 28.

5 Wald; N. J., Watt, H. C., and Hackshaw, A. K. (1999). Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters [see comments]. *N Engl J Med* 341, 461-7.

Walsh, P. S., Erlich, H. A., and Higuchi, R. (1992). Preferential PCR amplification of alleles: mechanisms and solutions. *PCR Methods Appl* 1, 241-50.

10 Westergaard, J. G., Chemnitz, J., Teisner, B., Poulsen, H. K., Ipsen, L., Beck, B., and Grudzinkas, J. G. (1983). Pregnancy-associated plasma protein A: a possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndrome. *Prenat Diagn* 3, 225-32.

SEQUENCE LISTING

15

[0262]

<110> Como Biotech

20

<120> Pregnancy-Associated Plasma Protein-A2 (PAPP-A2)

<130> P 495 DK00

<140>

25

<141>

<160> 2

<170> PatentIn Ver. 2.1

30

<210> 1

<211> 8527

<212> DNA

<213> Homo sapiens

35

<220>

<221> CDS

<222> (1)..(5376)

<223> prepro-PAPP-A2 coding sequence

40

<220>

<221> 3'UTR

<222> (5377)..(8527)

45

<220>

<221> mat_peptide

<222> (700)..(5376)

<220>

50

<221> sig_peptide

<222> (1)..(66)

<220>

<221> misc_feature

55

<222> (1)..(699)

<223> prepro part of PAPP-A2

<220>

EP 1 346 061 B1

<221> misc_feature

<222> (67)..(699)

<223> pro part of PAPP-A2

5 <400> 1

atg atg tgc tta aag atc cta aga ata agc ctg gcg att ttg gct ggg 48
 Met Met Cys Leu Lys Ile Leu Arg Ile Ser Leu Ala Ile Leu Ala Gly
 -230 -225 -220

10

tgg gca ctc tgt tct gcc aac tct gag ctg ggc tgg aca cgc aag aaa 96
 Trp Ala Leu Cys Ser Ala Asn Ser Glu Leu Gly Trp Thr Arg Lys Lys
 -215 -210 -205

15

tcc ttg gtt gag agg gaa cac ctg aat cag gtg ctg ttg gaa gga gaa 144
 Ser Leu Val Glu Arg Glu His Leu Asn Gln Val Leu Leu Glu Gly Glu
 -200 -195 -190

20

25

30

35

40

45

50

55

EP 1 346 061 B1

cgt tgt tgg ctg ggg gcc aag gtt cga aga ccc aga gct tct cca cag 192
 Arg Cys Trp Leu Gly Ala Lys Val Arg Arg Pro Arg Ala Ser Pro Gln
 -185 -180 -175 -170

5 cat cac ctc ttt gga gtc tac ccc agc agg gct ggg aac tac cta agg 240
 His His Leu Phe Gly Val Tyr Pro Ser Arg Ala Gly Asn Tyr Leu Arg
 -165 -160 -155

10 ccc tac ccc gtg ggg gag caa gaa atc cat cat aca gga cgc agc aaa 288
 Pro Tyr Pro Val Gly Glu Gln Glu Ile His His Thr Gly Arg Ser Lys
 -150 -145 -140

15 cca gac act gaa gga aat gct gtg agc ctt gtt ccc cca gac ctg act 336
 Pro Asp Thr Glu Gly Asn Ala Val Ser Leu Val Pro Pro Asp Leu Thr
 -135 -130 -125

20 gaa aat cca gca gga ctg agg ggt gca gtt gaa gag ccg gct gcc cca 384
 Glu Asn Pro Ala Gly Leu Arg Gly Ala Val Glu Glu Pro Ala Ala Pro
 -120 -115 -110

25 tgg gta ggg gat agt cct att ggg caa tct gag ctg ctg gga gat gat 432
 Trp Val Gly Asp Ser Pro Ile Gly Gln Ser Glu Leu Leu Gly Asp Asp
 -105 -100 -95 -90

30 gac gct tat ctc ggc aat caa aga tcc aag gag tct cta ggt gag gcc 480
 Asp Ala Tyr Leu Gly Asn Gln Arg Ser Lys Glu Ser Leu Gly Glu Ala
 -85 -80 -75

35 ggg att cag aaa ggc tca gcc atg gct gcc act act acc acc gcc att 528
 Gly Ile Gln Lys Gly Ser Ala Met Ala Ala Thr Thr Thr Thr Ala Ile
 -70 -65 -60

40 ttc aca acc ctg aac gaa ccc aaa cca gag acc caa agg agg ggc tgg 576
 Phe Thr Thr Leu Asn Glu Pro Lys Pro Glu Thr Gln Arg Arg Gly Trp
 -55 -50 -45

45 gcc aag tcc agg cag cgt cgc caa gtg tgg aag agg cgg gcg gaa gat 624
 Ala Lys Ser Arg Gln Arg Arg Gln Val Trp Lys Arg Arg Ala Glu Asp
 -40 -35 -30

50 ggg cag gga gac tcc ggt atc tct tca cat ttc caa cct tgg ccc aag 672
 Gly Gln Gly Asp Ser Gly Ile Ser Ser His Phe Gln Pro Trp Pro Lys
 -25 -20 -15 -10

55 cat tcc ctt aaa cac agg gtc aaa aag agt cca ccg gag gaa agc aac 720
 His Ser Leu Lys His Arg Val Lys Lys Ser Pro Pro Glu Glu Ser Asn
 -5 -1 1 5

60 caa aat ggt gga gag ggc tcc tac cga gaa gca gag acc ttt aac tcc 768
 Gln Asn Gly Gly Glu Gly Ser Tyr Arg Glu Ala Glu Thr Phe Asn Ser
 10 15 20

65 caa gta gga ctg ccc atc tta tac ttc tct ggg agg cgg gag cgg ctg 816
 Gln Val Gly Leu Pro Ile Leu Tyr Phe Ser Gly Arg Arg Glu Arg Leu
 25 30 35

70 ctg ctg cgt cca gaa gtg ctg gct gag att ccc cgg gag gcg ttc aca 864
 Leu Leu Arg Pro Glu Val Leu Ala Glu Ile Pro Arg Glu Ala Phe Thr

EP 1 346 061 B1

	40		45		50		55	
	gtg gaa gcc tgg gtt aaa ccg gag gga gga cag aac aac cca gcc atc							912
5	Val Glu Ala Trp Val Lys Pro Glu Gly Gly Gln Asn Asn Pro Ala Ile		60		65		70	
	atc gca ggt gtg ttt gat aac tgc tcc cac act gtc agt gac aaa ggc							960
10	Ile Ala Gly Val Phe Asp Asn Cys Ser His Thr Val Ser Asp Lys Gly		75		80		85	
	tgg gcc ctg ggg atc cgc tca ggg aag gac aag gga aag cgg gat gct							1008
15	Trp Ala Leu Gly Ile Arg Ser Gly Lys Asp Lys Gly Lys Arg Asp Ala		90		95		100	
	cgc ttc ttc ttc tcc ctc tgc acc gac cgc gtg aag aaa gcc acc atc							1056
20	Arg Phe Phe Phe Ser Leu Cys Thr Asp Arg Val Lys Lys Ala Thr Ile		105		110		115	
	ttg att agc cac agt cgc tac caa cca ggc aca tgg acc cat gtg gca							1104
25	Leu Ile Ser His Ser Arg Tyr Gln Pro Gly Thr Trp Thr His Val Ala		120		125		130	135
	gcc act tac gat gga cgg cac atg gcc ctg tat gtg gat ggc act cag							1152
30	Ala Thr Tyr Asp Gly Arg His Met Ala Leu Tyr Val Asp Gly Thr Gln		140		145		150	
	gtg gct agc agt cta gac cag tct ggt ccc ctg aac agc ccc ttc atg							1200
35	Val Ala Ser Ser Leu Asp Gln Ser Gly Pro Leu Asn Ser Pro Phe Met		155		160		165	
	gca tct tgc cgc tct ttg ctc ctg ggg gga gac agc tct gag gat ggg							1248
40	Ala Ser Cys Arg Ser Leu Leu Leu Gly Gly Asp Ser Ser Glu Asp Gly		170		175		180	
	cac tat ttc cgt gga cac ctg ggc aca ctg gtt ttc tgg tcg acc gcc							1296
45	His Tyr Phe Arg Gly His Leu Gly Thr Leu Val Phe Trp Ser Thr Ala		185		190		195	
	ctg cca caa agc cat ttt cag cac agt tct cag cat tca agt ggg gag							1344
50	Leu Pro Gln Ser His Phe Gln His Ser Ser Gln His Ser Ser Gly Glu		200		205		210	215
	gag gaa gcg act gac ttg gtc ctg aca gcg agc ttt gag cct gtg aac							1392
55	Glu Glu Ala Thr Asp Leu Val Leu Thr Ala Ser Phe Glu Pro Val Asn		220		225		230	
	aca gag tgg gtt ccc ttt aga gat gag aag tac cca cga ctt gag gtt							1440
60	Thr Glu Trp Val Pro Phe Arg Asp Glu Lys Tyr Pro Arg Leu Glu Val		235		240		245	
	ctc cag ggc ttt gag cca gag cct gag att ctg tcg cct ttg cag ccc							1488
65	Leu Gln Gly Phe Glu Pro Glu Pro Glu Ile Leu Ser Pro Leu Gln Pro		250		255		260	
	cca ctc tgt ggg caa aca gtc tgt gac aat gtg gaa ttg atc tcc cag							1536
70	Pro Leu Cys Gly Gln Thr Val Cys Asp Asn Val Glu Leu Ile Ser Gln		265		270		275	
	tac aat gga tac tgg ccc ctt cgg gga gag aag gtg ata cgc tac cag							1584

EP 1 346 061 B1

	Tyr	Asn	Gly	Tyr	Trp	Pro	Leu	Arg	Gly	Glu	Lys	Val	Ile	Arg	Tyr	Gln	
	280					285					290					295	
5	gtg	gtg	aac	atc	tgt	gat	gat	gag	ggc	cta	aac	ccc	att	gtg	agt	gag	1632
	Val	Val	Asn	Ile	Cys	Asp	Asp	Glu	Gly	Leu	Asn	Pro	Ile	Val	Ser	Glu	
					300					305					310		
10	gag	cag	att	cgt	ctg	cag	cac	gag	gca	ctg	aat	gag	gcc	ttc	agc	cgc	1680
	Glu	Gln	Ile	Arg	Leu	Gln	His	Glu	Ala	Leu	Asn	Glu	Ala	Phe	Ser	Arg	
				315					320					325			
15	tac	aac	atc	agc	tgg	cag	ctg	agc	gtc	cac	cag	gtc	cac	aat	tcc	acc	1728
	Tyr	Asn	Ile	Ser	Trp	Gln	Leu	Ser	Val	His	Gln	Val	His	Asn	Ser	Thr	
				330				335					340				
20	ctg	cga	cac	cgg	gtt	gtg	ctt	gtg	aac	tgt	gag	ccc	agc	aag	att	ggc	1776
	Leu	Arg	His	Arg	Val	Val	Leu	Val	Asn	Cys	Glu	Pro	Ser	Lys	Ile	Gly	
		345					350					355					
25	aat	gac	cat	tgt	gac	ccc	gag	tgt	gag	cac	cca	ctc	aca	ggc	tat	gat	1824
	Asn	Asp	His	Cys	Asp	Pro	Glu	Cys	Glu	His	Pro	Leu	Thr	Gly	Tyr	Asp	
	360					365					370					375	
30	ggg	ggt	gac	tgc	cgc	ctg	cag	ggc	cgc	tgc	tac	tcc	tgg	aac	cgc	agg	1872
	Gly	Gly	Asp	Cys	Arg	Leu	Gln	Gly	Arg	Cys	Tyr	Ser	Trp	Asn	Arg	Arg	
				380					385						390		
35	gat	ggg	ctc	tgt	cac	gtg	gag	tgt	aac	aac	atg	ctg	aac	gac	ttt	gac	1920
	Asp	Gly	Leu	Cys	His	Val	Glu	Cys	Asn	Asn	Met	Leu	Asn	Asp	Phe	Asp	
				395				400						405			
40	gac	gga	gac	tgc	tgc	gac	ccc	cag	gtg	gct	gat	gtg	cgc	aag	acc	tgc	1968
	Asp	Gly	Asp	Cys	Cys	Asp	Pro	Gln	Val	Ala	Asp	Val	Arg	Lys	Thr	Cys	
			410					415					420				
45	ttt	gac	cct	gac	tca	ccc	aag	agg	gca	tac	atg	agt	gtg	aag	gag	ctg	2016
	Phe	Asp	Pro	Asp	Ser	Pro	Lys	Arg	Ala	Tyr	Met	Ser	Val	Lys	Glu	Leu	
		425					430					435					
50	aag	gag	gcc	ctg	cag	ctg	aac	agt	act	cac	ttc	ctc	aac	atc	tac	ttt	2064
	Lys	Glu	Ala	Leu	Gln	Leu	Asn	Ser	Thr	His	Phe	Leu	Asn	Ile	Tyr	Phe	
	440					445					450					455	
55	gcc	agc	tca	gtg	cgg	gaa	gac	ctt	gca	ggt	gct	gcc	acc	tgg	cct	tgg	2112
	Ala	Ser	Ser	Val	Arg	Glu	Asp	Leu	Ala	Gly	Ala	Ala	Thr	Trp	Pro	Trp	
				460					465						470		
60	gac	aag	gac	gct	gtc	act	cac	ctg	ggt	ggc	att	gtc	ctc	agc	cca	gca	2160
	Asp	Lys	Asp	Ala	Val	Thr	His	Leu	Gly	Gly	Ile	Val	Leu	Ser	Pro	Ala	
				475					480					485			
65	tat	tat	ggg	atg	cct	ggc	cac	acc	gac	acc	atg	atc	cat	gaa	gtg	gga	2208
	Tyr	Tyr	Gly	Met	Pro	Gly	His	Thr	Asp	Thr	Met	Ile	His	Glu	Val	Gly	
			490					495					500				
70	cat	gtt	ctg	gga	ctc	tac	cat	gtc	ttt	aaa	gga	gtc	agt	gaa	aga	gaa	2256
	His	Val	Leu	Gly	Leu	Tyr	His	Val	Phe	Lys	Gly	Val	Ser	Glu	Arg	Glu	
			505				510					515					

EP 1 346 061 B1

	tcc tgc aat gac ccc tgc aag gag aca gtg cca tcc atg gaa acg gga	2304
	Ser Cys Asn Asp Pro Cys Lys Glu Thr Val Pro Ser Met Glu Thr Gly	
	520 525 530 535	
5	gac ctc tgt gcc gac acc gcc ccc act ccc aag agt gag ctg tgc cgg	2352
	Asp Leu Cys Ala Asp Thr Ala Pro Thr Pro Lys Ser Glu Leu Cys Arg	
	540 545 550	
10	gaa cca gag ccc act agt gac acc tgt ggc ttc act cgc ttc cca ggg	2400
	Glu Pro Glu Pro Thr Ser Asp Thr Cys Gly Phe Thr Arg Phe Pro Gly	
	555 560 565	
15	gct ccg ttc acc aac tac atg agc tac acg gat gat aac tgc act gac	2448
	Ala Pro Phe Thr Asn Tyr Met Ser Tyr Thr Asp Asp Asn Cys Thr Asp	
	570 575 580	
20	aac ttc act cct aac caa gtg gcc cga atg cat tgc tat ttg gac cta	2496
	Asn Phe Thr Pro Asn Gln Val Ala Arg Met His Cys Tyr Leu Asp Leu	
	585 590 595	
25	gtc tat cag cag tgg act gaa agc aga aag ccc acc ccc atc ccc att	2544
	Val Tyr Gln Gln Trp Thr Glu Ser Arg Lys Pro Thr Pro Ile Pro Ile	
	600 605 610 615	
30	cca cct atg gtc atc gga cag acc aac aag tcc ctc act atc cac tgg	2592
	Pro Pro Met Val Ile Gly Gln Thr Asn Lys Ser Leu Thr Ile His Trp	
	620 625 630	
35	ctg cct cct att agt gga gtt gta tat gac agg gcc tca ggc agc ttg	2640
	Leu Pro Pro Ile Ser Gly Val Val Tyr Asp Arg Ala Ser Gly Ser Leu	
	635 640 645	
40	tgt ggc gct tgc act gaa gat ggg acc ttt cgt cag tat gtg cac aca	2688
	Cys Gly Ala Cys Thr Glu Asp Gly Thr Phe Arg Gln Tyr Val His Thr	
	650 655 660	
45	gct tcc tcc cgg cgg gtg tgt gac tcc tca ggt tat tgg acc cca gag	2736
	Ala Ser Ser Arg Arg Val Cys Asp Ser Ser Gly Tyr Trp Thr Pro Glu	
	665 670 675	
50	gag gct gtg ggg cct cct gat gtg gat cag ccc tgc gag cca agc tta	2784
	Glu Ala Val Gly Pro Pro Asp Val Asp Gln Pro Cys Glu Pro Ser Leu	
	680 685 690 695	
55	cag gcc tgg agc cct gag gtc cac ctg tac cac atg aac atg acg gtc	2832
	Gln Ala Trp Ser Pro Glu Val His Leu Tyr His Met Asn Met Thr Val	
	700 705 710	
60	ccc tgc ccc aca gaa ggc tgt agc ttg gag ctg ctc ttc caa cac ccg	2880
	Pro Cys Pro Thr Glu Gly Cys Ser Leu Glu Leu Leu Phe Gln His Pro	
	715 720 725	
65	gtc caa gcc gac acc ctc acc ctg tgg gtc act tcc ttc ttc atg gag	2928
	Val Gln Ala Asp Thr Leu Thr Leu Trp Val Thr Ser Phe Phe Met Glu	
	730 735 740	
70	tcc tcg cag gtc ctc ttt gac aca gag atc ttg ctg gaa aac aag gag	2976
	Ser Ser Gln Val Leu Phe Asp Thr Glu Ile Leu Leu Glu Asn Lys Glu	
	745 750 755	

EP 1 346 061 B1

tca gtg cac ctg ggc ccc tta gac act ttc tgt gac atc cca ctc acc 3024
 Ser Val His Leu Gly Pro Leu Asp Thr Phe Cys Asp Ile Pro Leu Thr
 760 765 770 775

5
 atc aaa ctg cac gtg gat ggg aag gtg tcg ggg gtg aaa gtc tac acc 3072
 Ile Lys Leu His Val Asp Gly Lys Val Ser Gly Val Lys Val Tyr Thr
 780 785 790

10
 ttt gat gag agg ata gag att gat gca gca ctc ctg act tct cag ccc 3120
 Phe Asp Glu Arg Ile Glu Ile Asp Ala Ala Leu Leu Thr Ser Gln Pro
 795 800 805

15
 cac agt ccc ttg tgc tct ggc tgc agg cct gtg agg tac cag gtt ctc 3168
 His Ser Pro Leu Cys Ser Gly Cys Arg Pro Val Arg Tyr Gln Val Leu
 810 815 820

20
 cgc gat ccc cca ttt gcc agt ggt ttg ccc gtg gtg gtg aca cat tct 3216
 Arg Asp Pro Pro Phe Ala Ser Gly Leu Pro Val Val Val Thr His Ser
 825 830 835

25
 cac agg aag ttc acg gac gtg gag gtc aca cct gga cag atg tat cag 3264
 His Arg Lys Phe Thr Asp Val Glu Val Thr Pro Gly Gln Met Tyr Gln
 840 845 850 855

30
 tac caa gtt cta gct gaa gct gga gga gaa ctg gga gaa gct tcg cct 3312
 Tyr Gln Val Leu Ala Glu Ala Gly Gly Glu Leu Gly Glu Ala Ser Pro
 860 865 870

35
 cct ctg aac cac att cat gga gct cct tat tgt gga gat ggg aag gtg 3360
 Pro Leu Asn His Ile His Gly Ala Pro Tyr Cys Gly Asp Gly Lys Val
 875 880 885

40
 tca gag aga ctg gga gaa gag tgt gat gat gga gac ctt gtg agc gga 3408
 Ser Glu Arg Leu Gly Glu Glu Cys Asp Asp Gly Asp Leu Val Ser Gly
 890 895 900

45
 gat ggc tgc tcc aag gtg tgt gag ctg gag gaa ggt ttc aac tgt gta 3456
 Asp Gly Cys Ser Lys Val Cys Glu Leu Glu Glu Gly Phe Asn Cys Val
 905 910 915

50
 gga gag cca agc ctt tgc tac atg tat gag gga gat ggc ata tgt gaa 3504
 Gly Glu Pro Ser Leu Cys Tyr Met Tyr Glu Gly Asp Gly Ile Cys Glu
 920 925 930 935

55
 cct ttt gag aga aaa acc agc att gta gac tgt ggc atc tac act ccc 3552
 Pro Phe Glu Arg Lys Thr Ser Ile Val Asp Cys Gly Ile Tyr Thr Pro
 940 945 950

60
 aaa gga tac ttg gat caa tgg gct acc cgg gct tac tcc tct cat gaa 3600
 Lys Gly Tyr Leu Asp Gln Trp Ala Thr Arg Ala Tyr Ser Ser His Glu
 955 960 965

65
 gac aag aag aag tgt cct gtt tcc ttg gta act gga gaa cct cat tcc 3648
 Asp Lys Lys Lys Cys Pro Val Ser Leu Val Thr Gly Glu Pro His Ser
 970 975 980

70
 cta att tgc aca tca tac cat cca gat tta ccc aac cac cgt ccc cta 3696
 Leu Ile Cys Thr Ser Tyr His Pro Asp Leu Pro Asn His Arg Pro Leu

EP 1 346 061 B1

	985		990		995												
	act	ggc	tgg	ttt	ccc	tgt	gtt	gcc	agt	gaa	aat	gaa	act	cag	gat	gac	3744
5	Thr	Gly	Trp	Phe	Pro	Cys	Val	Ala	Ser	Glu	Asn	Glu	Thr	Gln	Asp	Asp	
	1000					1005					1010				1015		
	agg	agt	gaa	cag	cca	gaa	ggt	agc	ctg	aag	aaa	gag	gat	gag	ggt	tgg	3792
	Arg	Ser	Glu	Gln	Pro	Glu	Gly	Ser	Leu	Lys	Lys	Glu	Asp	Glu	Val	Trp	
10					1020					1025					1030		
	ctc	aaa	gtg	tgt	ttc	aat	aga	cca	gga	gag	gcc	aga	gca	att	ttt	att	3840
	Leu	Lys	Val	Cys	Phe	Asn	Arg	Pro	Gly	Glu	Ala	Arg	Ala	Ile	Phe	Ile	
				1035					1040						1045		
	ttt	ttg	aca	act	gat	ggc	cta	gtt	ccc	gga	gag	cat	cag	cag	ccg	aca	3888
15	Phe	Leu	Thr	Thr	Asp	Gly	Leu	Val	Pro	Gly	Glu	His	Gln	Gln	Pro	Thr	
			1050					1055						1060			
	gtg	act	ctc	tac	ctg	acc	gat	gtc	cgt	gga	agc	aac	cac	tct	ctt	gga	3936
20	Val	Thr	Leu	Tyr	Leu	Thr	Asp	Val	Arg	Gly	Ser	Asn	His	Ser	Leu	Gly	
			1065				1070					1075					
	acc	tat	gga	ctg	tca	tgc	cag	cat	aat	cca	ctg	att	atc	aat	gtg	acc	3984
	Thr	Tyr	Gly	Leu	Ser	Cys	Gln	His	Asn	Pro	Leu	Ile	Ile	Asn	Val	Thr	
25			1080			1085					1090				1095		
	cat	cac	cag	aat	gtc	ctt	ttc	cac	cat	acc	acc	tca	gtg	ctg	ctg	aat	4032
	His	His	Gln	Asn	Val	Leu	Phe	His	His	Thr	Thr	Ser	Val	Leu	Leu	Asn	
				1100						1105					1110		
	ttc	tca	tcc	cca	cgg	gtc	ggc	atc	tca	gct	gtg	gct	cta	agg	aca	tcc	4080
30	Phe	Ser	Ser	Pro	Arg	Val	Gly	Ile	Ser	Ala	Val	Ala	Leu	Arg	Thr	Ser	
				1115					1120						1125		
	tcc	cgc	att	ggt	ctt	tcg	gct	ccc	agt	aac	tgc	atc	tca	gag	gac	gag	4128
35	Ser	Arg	Ile	Gly	Leu	Ser	Ala	Pro	Ser	Asn	Cys	Ile	Ser	Glu	Asp	Glu	
			1130					1135						1140			
	ggg	cag	aat	cat	cag	gga	cag	agc	tgt	atc	cat	cgg	ccc	tgt	ggg	aag	4176
	Gly	Gln	Asn	His	Gln	Gly	Gln	Ser	Cys	Ile	His	Arg	Pro	Cys	Gly	Lys	
40			1145				1150					1155					
	cag	gac	agc	tgt	ccg	tca	ttg	ctg	ctt	gat	cat	gct	gat	gtg	gtg	aac	4224
	Gln	Asp	Ser	Cys	Pro	Ser	Leu	Leu	Leu	Asp	His	Ala	Asp	Val	Val	Asn	
				1160			1165				1170				1175		
	tgt	acc	tct	ata	ggc	cca	ggt	ctc	atg	aag	tgt	gct	atc	act	tgt	caa	4272
45	Cys	Thr	Ser	Ile	Gly	Pro	Gly	Leu	Met	Lys	Cys	Ala	Ile	Thr	Cys	Gln	
				1180						1185					1190		
	agg	gga	ttt	gcc	ctt	cag	gcc	agc	agt	ggg	cag	tac	atc	agg	ccc	atg	4320
50	Arg	Gly	Phe	Ala	Leu	Gln	Ala	Ser	Ser	Gly	Gln	Tyr	Ile	Arg	Pro	Met	
				1195					1200						1205		
	cag	aag	gaa	att	ctg	ctc	aca	tgt	tct	tct	ggg	cac	tgg	gac	cag	aat	4368
	Gln	Lys	Glu	Ile	Leu	Leu	Thr	Cys	Ser	Ser	Gly	His	Trp	Asp	Gln	Asn	
55			1210				1215						1220				
	gtg	agc	tgc	ctt	ccc	gtg	gac	tgc	ggt	ggt	ccc	gac	ccg	tct	ttg	gtg	4416

EP 1 346 061 B1

	Val	Ser	Cys	Leu	Pro	Val	Asp	Cys	Gly	Val	Pro	Asp	Pro	Ser	Leu	Val	
	1225						1230					1235					
5	aac	tat	gca	aac	ttc	tcc	tgc	tca	gag	gga	acc	aaa	ttt	ctg	aaa	cgc	4464
	Asn	Tyr	Ala	Asn	Phe	Ser	Cys	Ser	Glu	Gly	Thr	Lys	Phe	Leu	Lys	Arg	
	1240				1245				1250						1255		
10	tgc	tca	atc	tct	tgt	gtc	cca	cca	gcc	aag	ctg	caa	gga	ctg	agc	cca	4512
	Cys	Ser	Ile	Ser	Cys	Val	Pro	Pro	Ala	Lys	Leu	Gln	Gly	Leu	Ser	Pro	
				1260					1265					1270			
15	tgg	ctg	aca	tgt	ctt	gaa	gat	ggt	ctc	tgg	tct	ctc	cct	gaa	gtc	tac	4560
	Trp	Leu	Thr	Cys	Leu	Glu	Asp	Gly	Leu	Trp	Ser	Leu	Pro	Glu	Val	Tyr	
			1275					1280					1285				
20	tgc	aag	ttg	gag	tgt	gat	gct	ccc	cct	att	att	ctg	aat	gcc	aac	ttg	4608
	Cys	Lys	Leu	Glu	Cys	Asp	Ala	Pro	Pro	Ile	Ile	Leu	Asn	Ala	Asn	Leu	
		1290					1295					1300					
25	ctc	ctg	cct	cac	tgc	ctc	cag	gac	aac	cac	gac	gtg	ggc	acc	atc	tgc	4656
	Leu	Leu	Pro	His	Cys	Leu	Gln	Asp	Asn	His	Asp	Val	Gly	Thr	Ile	Cys	
	1305					1310					1315						
30	aaa	tat	gaa	tgc	aaa	cca	ggg	tac	tat	gtg	gca	gaa	agt	gca	gag	ggt	4704
	Lys	Tyr	Glu	Cys	Lys	Pro	Gly	Tyr	Tyr	Val	Ala	Glu	Ser	Ala	Glu	Gly	
	1320				1325				1330						1335		
35	aaa	gtc	agg	aac	aag	ctc	ctg	aag	ata	caa	tgc	ctg	gaa	ggt	gga	atc	4752
	Lys	Val	Arg	Asn	Lys	Leu	Leu	Lys	Ile	Gln	Cys	Leu	Glu	Gly	Gly	Ile	
				1340				1345					1350				
40	tgg	gag	caa	ggc	agc	tgc	att	cct	gtg	gtg	tgt	gag	cca	ccc	cct	cct	4800
	Trp	Glu	Gln	Gly	Ser	Cys	Ile	Pro	Val	Val	Cys	Glu	Pro	Pro	Pro	Pro	
			1355				1360					1365					
45	gtg	ttt	gaa	ggc	atg	tat	gaa	tgt	acc	aat	ggc	ttc	agc	ctg	gac	agc	4848
	Val	Phe	Glu	Gly	Met	Tyr	Glu	Cys	Thr	Asn	Gly	Phe	Ser	Leu	Asp	Ser	
		1370				1375					1380						
50	cag	tgt	gtg	ctc	aac	tgt	aac	cag	gaa	cgt	gaa	aag	ctt	ccc	atc	ctc	4896
	Gln	Cys	Val	Leu	Asn	Cys	Asn	Gln	Glu	Arg	Glu	Lys	Leu	Pro	Ile	Leu	
	1385				1390				1395								
55	tgc	act	aaa	gag	ggc	ctg	tgg	acc	cag	gag	ttt	aag	ttg	tgt	gag	aat	4944
	Cys	Thr	Lys	Glu	Gly	Leu	Trp	Thr	Gln	Glu	Phe	Lys	Leu	Cys	Glu	Asn	
	1400				1405				1410				1415				
60	ctg	caa	gga	gaa	tgc	cca	cca	ccc	ccc	tca	gag	ctg	aat	tct	gtg	gag	4992
	Leu	Gln	Gly	Glu	Cys	Pro	Pro	Pro	Pro	Ser	Glu	Leu	Asn	Ser	Val	Glu	
				1420				1425				1430					
65	tac	aaa	tgt	gaa	caa	gga	tat	ggg	att	ggt	gca	gtg	tgt	tcc	cca	ttg	5040
	Tyr	Lys	Cys	Glu	Gln	Gly	Tyr	Gly	Ile	Gly	Ala	Val	Cys	Ser	Pro	Leu	
			1435			1440					1445						
70	tgt	gta	atc	ccc	ccc	agt	gac	ccc	gtg	atg	cta	cct	gag	aat	atc	act	5088
	Cys	Val	Ile	Pro	Pro	Ser	Asp	Pro	Val	Met	Leu	Pro	Glu	Asn	Ile	Thr	
		1450				1455					1460						

EP 1 346 061 B1

gct gac act ctg gag cac tgg atg gaa cct gtc aaa gtc cag agc att 5136
 Ala Asp Thr Leu Glu His Trp Met Glu Pro Val Lys Val Gln Ser Ile
 1465 1470 1475
 5
 gtg tgc act ggc cgg cgt caa tgg cac cca gac ccc gtc tta gtc cac 5184
 Val Cys Thr Gly Arg Arg Gln Trp His Pro Asp Pro Val Leu Val His
 1480 1485 1490 1495
 10
 tgc atc cag tca tgt gag ccc ttc caa gca gat ggt tgg tgt gac act 5232
 Cys Ile Gln Ser Cys Glu Pro Phe Gln Ala Asp Gly Trp Cys Asp Thr
 1500 1505 1510
 15
 atc aac aac cga gcc tac tgc cac tat gac ggg gga gac tgc tgc tct 5280
 Ile Asn Asn Arg Ala Tyr Cys His Tyr Asp Gly Gly Asp Cys Cys Ser
 1515 1520 1525
 20
 tcc aca ctc tcc tcc aag aag gtc att cca ttt gct gct gac tgt gac 5328
 Ser Thr Leu Ser Ser Lys Lys Val Ile Pro Phe Ala Ala Asp Cys Asp
 1530 1535 1540
 25
 ctg gat gag tgc acc tgc cgg gac ccc aag gca gaa gaa aat cag taa 5376
 Leu Asp Glu Cys Thr Cys Arg Asp Pro Lys Ala Glu Glu Asn Gln
 1545 1550 1555
 30
 ctgtgggaac aagcccctcc ctccactgcc tcagaggcag taagaaagag aggccgaccc 5436
 aggaggaaac aaaggtgaa tgaagaagaa caatcatgaa atggaagaag gaggaagagc 5496
 atgaaggatc ttataagaaa tgcaagagga tattgatagg tgtgaactag ttcatcaagt 5556
 35
 agcccaagta ggagagaatc ataggcaaaa gtttctttaa agtggcagtt gattaacatg 5616
 gaaggggaaa tatgatagat atataaggac cctcctccct cacttatatt ctattaaatc 5676
 ctatcctcaa ctcttgccct gctctccgct ccaccccctg ccaactactc agtcccaccc 5736
 aacttgtaaa ccaataccaa aatactagag gagaagttgg cagggatact gttaataccc 5796
 attttgaatg gattgccatc ttccagagct tgtctgctct caactggctc tttttctttt 5856
 40
 tgtgtagttt cccttaaata atgaagttag ttattaattc tttataagta tttaaacata 5916
 attatataaa tatattatat atattatatt ttttgctggt tactaagcta aaaattattc 5976
 attgttccac acatgctgct gtgaagttca cattcaagat gaatgttgag actttgagga 6036
 45
 cagaaaggca acttattttc ccatctttct atggatgagg attggcaggt tgaatgggaa 6096
 gtacagaagg agagagagta attagatgga attctggatg ctagcatgta aagctaatca 6156
 tctttttttt tatgacctgg gagctgggccc cattttatga ccaaggagat ggggagttgg 6216
 50
 aatggtggta ctaagaggca taggaagttg agtgtgaata ccattggtga tgggtccagg 6276
 agaactagac tatggttctt gaatatctgt ccacaaagaa tataactaact tttgtcaact 6336
 55
 tctcagaact cccaactgga gtcggtgaga cctaggattt tctgcacttc cacacatgcc 6396
 tgttccaagt gtggctgtca gccagtcaac aagtttgtac tatggcccat tctctgatca 6456

EP 1 346 061 B1

ccaggattac aggaactcac acactcctca tacttggcct gtagtcctac ttcttgtag 6516
 aagtctccaa gtctggccag tcacatgacc aagtgttgat tttctggag gaaaaatttt 6576
 5 atggaaatga tataggggaa aggtgggagg agatgaaaga acaggcaaga gctgtcaggg 6636
 ttaaattccag gcccgggcat gagaatggaa gtgatcaggg agactcggtc cttgttccaa 6696
 10 gtctccaaag aagaccaaag tgggtccctt gagcaatgaa gaatctgaga taaattctct 6756
 tcaagtatca tgtacaaaat ctgtgagcca gagatthtga cttgagcaag ccatggaaat 6816
 gcatggagca aggggtgacac tctgtgggga gacagaagaa tttcaactat ttaatgtcca 6876
 15 ttttgttgtt tttacccttt cttatccaat agatggaatg cacatgaaat gaccatatta 6936
 agcctctctc tatttacatc ccaggctcac tgggatgtga tctactgcag ttacattttc 6996
 ttgtaacggg ttctggatta gaccctaggg aaagtgagta aggagccagt ttctgtttaa 7056
 20 cattctagtt ttactcattt taggaaggct gtgagtgagg cttgtctcct ttaaagtttc 7116
 ttctccaatg gaaaccaaga acagacaaaa tttagagctc agctgtggtc tcttctcatc 7176
 25 ttctgctctt ttgctttgac cacagthttt ctactcttcc catcaacact agagcaatgg 7236
 ctgtgcaaat aggaatagga aatactacca caatgataga aatattatcc acactatcac 7296
 gtagggaaga acaatatact gaaagagaat aaaacacgaa taaggatgatg taccacatt 7356
 30 aatctgtggg tttgtggaat gagggttgca aagttattgg gaaaaggaaa gagcagagtt 7416
 caccattca aaaaaaacct tttgtctact aatctctagt gtaaagaaaa tgtagttcag 7476
 35 ataccattca ttgtcttggg tcatgcttag tgcccccaag aagacaaaca tatttattct 7536
 tgggattctg ataggcttca atatgcaaag gacaatggaa aagtttagac actctatttt 7596
 caaaatttta taaacttgtt ttattgggga aatgtccaa attgctagac acattctaag 7656
 40 ttctgccttg gagaatccta ctttgtctga gattgaggca gaggaattgt tctctgggc 7716
 attactcagc tcaggaacat ggagcctgtg gttcatgcca gtgtgtgtct tcatgcagtc 7776
 tctccacaag agcaacagta agaacatttc tgttttaaat ttcattttaa aatattttat 7836
 45 tatctgcaat tcaccactgc tctgggaaag caaaaggaaa gttcctgttg tgtgtgaaga 7896
 gcctcttagg ctataaggct tcccagccat agtcagctat agctattcag agacagcagg 7956
 50 ttcttccagt ctttgttctt gggacctgat gttttgagca actcaggtca ctgataaagt 8016
 ggaaggacta agacactgtg gtcacagatc ccagcaacat caactcacac tcaatccatg 8076
 tgggtgtcca cattctgcta ctcttatcca cccatgtggt cattgagagc ctttctcaga 8136
 55 gactcttctg tgtgtttgat tgtgccagc tggcccaggg ctagctggct ctaacaacta 8196

EP 1 346 061 B1

gcatgacagc ctccaatcag aaaggcaggt aaggggacag ggtgaggaga atgggcagat 8256
actgacagaa attaaagtaa agggattgtg aaagtaaaga gctcttctg attctcatct 8316
5 tctctttttt ctattacaag gcattgaact tggcacttcc tgtattcttt gtgatcacta 8376
ttgagtgcac tagttaacac ccaaggggat ggcttgattg ggaatgtagt gaaaggagct 8436
10 gatctactgt attgtaatgt aaaacagcta cagccagtta ttttgtaaga ttataagttg 8496
ttcattaataa aatcagcaca caaaatatga a 8527

15 <210> 2
<211> 1791
<212> PRT
<213> Homo sapiens

20 <400> 2

25

30

35

40

45

50

55

EP 1 346 061 B1

Met Met Cys Leu Lys Ile Leu Arg Ile Ser Leu Ala Ile Leu Ala Gly
 1 5 10 15
 Trp Ala Leu Cys Ser Ala Asn Ser Glu Leu Gly Trp Thr Arg Lys Lys
 20 25 30
 5 Ser Leu Val Glu Arg Glu His Leu Asn Gln Val Leu Leu Glu Gly Glu
 35 40 45
 Arg Cys Trp Leu Gly Ala Lys Val Arg Arg Pro Arg Ala Ser Pro Gln
 50 55 60
 10 His His Leu Phe Gly Val Tyr Pro Ser Arg Ala Gly Asn Tyr Leu Arg
 65 70 75 80
 Pro Tyr Pro Val Gly Glu Gln Glu Ile His His Thr Gly Arg Ser Lys
 85 90 95
 Pro Asp Thr Glu Gly Asn Ala Val Ser Leu Val Pro Pro Asp Leu Thr
 100 105 110
 15 Glu Asn Pro Ala Gly Leu Arg Gly Ala Val Glu Glu Pro Ala Ala Pro
 115 120 125
 Trp Val Gly Asp Ser Pro Ile Gly Gln Ser Glu Leu Leu Gly Asp Asp
 130 135 140
 Asp Ala Tyr Leu Gly Asn Gln Arg Ser Lys Glu Ser Leu Gly Glu Ala
 145 150 155 160
 20 Gly Ile Gln Lys Gly Ser Ala Met Ala Ala Thr Thr Thr Thr Ala Ile
 165 170 175
 Phe Thr Thr Leu Asn Glu Pro Lys Pro Glu Thr Gln Arg Arg Gly Trp
 180 185 190
 25 Ala Lys Ser Arg Gln Arg Arg Gln Val Trp Lys Arg Arg Ala Glu Asp
 195 200 205
 Gly Gln Gly Asp Ser Gly Ile Ser Ser His Phe Gln Pro Trp Pro Lys
 210 215 220
 His Ser Leu Lys His Arg Val Lys Lys Ser Pro Pro Glu Glu Ser Asn
 225 230 235 240
 30 Gln Asn Gly Gly Glu Gly Ser Tyr Arg Glu Ala Glu Thr Phe Asn Ser
 245 250 255
 Gln Val Gly Leu Pro Ile Leu Tyr Phe Ser Gly Arg Arg Glu Arg Leu
 260 265 270
 35 Leu Leu Arg Pro Glu Val Leu Ala Glu Ile Pro Arg Glu Ala Phe Thr
 275 280 285
 Val Glu Ala Trp Val Lys Pro Glu Gly Gly Gln Asn Asn Pro Ala Ile
 290 295 300
 Ile Ala Gly Val Phe Asp Asn Cys Ser His Thr Val Ser Asp Lys Gly
 305 310 315 320

40

45

50

55

EP 1 346 061 B1

Trp Ala Leu Gly Ile Arg Ser Gly Lys Asp Lys Gly Lys Arg Asp Ala
 325 330 335
 Arg Phe Phe Phe Ser Leu Cys Thr Asp Arg Val Lys Lys Ala Thr Ile
 340 345 350
 5 Leu Ile Ser His Ser Arg Tyr Gln Pro Gly Thr Trp Thr His Val Ala
 355 360 365
 Ala Thr Tyr Asp Gly Arg His Met Ala Leu Tyr Val Asp Gly Thr Gln
 370 375 380
 10 Val Ala Ser Ser Leu Asp Gln Ser Gly Pro Leu Asn Ser Pro Phe Met
 385 390 395 400
 Ala Ser Cys Arg Ser Leu Leu Leu Gly Gly Asp Ser Ser Glu Asp Gly
 405 410 415
 His Tyr Phe Arg Gly His Leu Gly Thr Leu Val Phe Trp Ser Thr Ala
 420 425 430
 15 Leu Pro Gln Ser His Phe Gln His Ser Ser Gln His Ser Ser Gly Glu
 435 440 445
 Glu Glu Ala Thr Asp Leu Val Leu Thr Ala Ser Phe Glu Pro Val Asn
 450 455 460
 Thr Glu Trp Val Pro Phe Arg Asp Glu Lys Tyr Pro Arg Leu Glu Val
 465 470 475 480
 20 Leu Gln Gly Phe Glu Pro Glu Pro Glu Ile Leu Ser Pro Leu Gln Pro
 485 490 495
 Pro Leu Cys Gly Gln Thr Val Cys Asp Asn Val Glu Leu Ile Ser Gln
 500 505 510
 Tyr Asn Gly Tyr Trp Pro Leu Arg Gly Glu Lys Val Ile Arg Tyr Gln
 515 520 525
 25 Val Val Asn Ile Cys Asp Asp Glu Gly Leu Asn Pro Ile Val Ser Glu
 530 535 540
 Glu Gln Ile Arg Leu Gln His Glu Ala Leu Asn Glu Ala Phe Ser Arg
 545 550 555 560
 30 Tyr Asn Ile Ser Trp Gln Leu Ser Val His Gln Val His Asn Ser Thr
 565 570 575
 Leu Arg His Arg Val Val Leu Val Asn Cys Glu Pro Ser Lys Ile Gly
 580 585 590
 Asn Asp His Cys Asp Pro Glu Cys Glu His Pro Leu Thr Gly Tyr Asp
 595 600 605
 35 Gly Gly Asp Cys Arg Leu Gln Gly Arg Cys Tyr Ser Trp Asn Arg Arg
 610 615 620
 Asp Gly Leu Cys His Val Glu Cys Asn Asn Met Leu Asn Asp Phe Asp
 625 630 635 640
 Asp Gly Asp Cys Cys Asp Pro Gln Val Ala Asp Val Arg Lys Thr Cys
 645 650 655
 40 Phe Asp Pro Asp Ser Pro Lys Arg Ala Tyr Met Ser Val Lys Glu Leu
 660 665 670
 Lys Glu Ala Leu Gln Leu Asn Ser Thr His Phe Leu Asn Ile Tyr Phe
 675 680 685
 45 Ala Ser Ser Val Arg Glu Asp Leu Ala Gly Ala Ala Thr Trp Pro Trp
 690 695 700
 Asp Lys Asp Ala Val Thr His Leu Gly Gly Ile Val Leu Ser Pro Ala
 705 710 715 720
 Tyr Tyr Gly Met Pro Gly His Thr Asp Thr Met Ile His Glu Val Gly
 725 730 735
 50 His Val Leu Gly Leu Tyr His Val Phe Lys Gly Val Ser Glu Arg Glu
 740 745 750
 Ser Cys Asn Asp Pro Cys Lys Glu Thr Val Pro Ser Met Glu Thr Gly
 755 760 765
 Asp Leu Cys Ala Asp Thr Ala Pro Thr Pro Lys Ser Glu Leu Cys Arg
 770 775 780
 55 Glu Pro Glu Pro Thr Ser Asp Thr Cys Gly Phe Thr Arg Phe Pro Gly

EP 1 346 061 B1

	785				790					795				800		
	Ala	Pro	Phe	Thr	Asn	Tyr	Met	Ser	Tyr	Thr	Asp	Asp	Asn	Cys	Thr	Asp
					805					810				815		
5	Asn	Phe	Thr	Pro	Asn	Gln	Val	Ala	Arg	Met	His	Cys	Tyr	Leu	Asp	Leu
				820					825					830		
	Val	Tyr	Gln	Gln	Trp	Thr	Glu	Ser	Arg	Lys	Pro	Thr	Pro	Ile	Pro	Ile
			835					840					845			
10	Pro	Pro	Met	Val	Ile	Gly	Gln	Thr	Asn	Lys	Ser	Leu	Thr	Ile	His	Trp
		850				855						860				
	Leu	Pro	Pro	Ile	Ser	Gly	Val	Val	Tyr	Asp	Arg	Ala	Ser	Gly	Ser	Leu
	865					870					875					880
	Cys	Gly	Ala	Cys	Thr	Glu	Asp	Gly	Thr	Phe	Arg	Gln	Tyr	Val	His	Thr
					885					890					895	
15	Ala	Ser	Ser	Arg	Arg	Val	Cys	Asp	Ser	Ser	Gly	Tyr	Trp	Thr	Pro	Glu
				900					905					910		
	Glu	Ala	Val	Gly	Pro	Pro	Asp	Val	Asp	Gln	Pro	Cys	Glu	Pro	Ser	Leu
			915					920					925			
	Gln	Ala	Trp	Ser	Pro	Glu	Val	His	Leu	Tyr	His	Met	Asn	Met	Thr	Val
		930				935						940				
20	Pro	Cys	Pro	Thr	Glu	Gly	Cys	Ser	Leu	Glu	Leu	Leu	Phe	Gln	His	Pro
	945					950						955				960
	Val	Gln	Ala	Asp	Thr	Leu	Thr	Leu	Trp	Val	Thr	Ser	Phe	Phe	Met	Glu
					965					970					975	
	Ser	Ser	Gln	Val	Leu	Phe	Asp	Thr	Glu	Ile	Leu	Leu	Glu	Asn	Lys	Glu
25				980					985					990		
	Ser	Val	His	Leu	Gly	Pro	Leu	Asp	Thr	Phe	Cys	Asp	Ile	Pro	Leu	Thr
				995			1000					1005				
	Ile	Lys	Leu	His	Val	Asp	Gly	Lys	Val	Ser	Gly	Val	Lys	Val	Tyr	Thr
	1010					1015					1020					
30	Phe	Asp	Glu	Arg	Ile	Glu	Ile	Asp	Ala	Ala	Leu	Leu	Thr	Ser	Gln	Pro
	1025				1030						1035					1040
	His	Ser	Pro	Leu	Cys	Ser	Gly	Cys	Arg	Pro	Val	Arg	Tyr	Gln	Val	Leu
					1045				1050						1055	
	Arg	Asp	Pro	Pro	Phe	Ala	Ser	Gly	Leu	Pro	Val	Val	Val	Thr	His	Ser
				1060					1065					1070		
35	His	Arg	Lys	Phe	Thr	Asp	Val	Glu	Val	Thr	Pro	Gly	Gln	Met	Tyr	Gln
				1075				1080					1085			
	Tyr	Gln	Val	Leu	Ala	Glu	Ala	Gly	Gly	Glu	Leu	Gly	Glu	Ala	Ser	Pro
	1090					1095						1100				
	Pro	Leu	Asn	His	Ile	His	Gly	Ala	Pro	Tyr	Cys	Gly	Asp	Gly	Lys	Val
40	1105				1110						1115					1120
	Ser	Glu	Arg	Leu	Gly	Glu	Glu	Cys	Asp	Asp	Gly	Asp	Leu	Val	Ser	Gly
				1125						1130					1135	
	Asp	Gly	Cys	Ser	Lys	Val	Cys	Glu	Leu	Glu	Glu	Gly	Phe	Asn	Cys	Val
				1140				1145					1150			
45	Gly	Glu	Pro	Ser	Leu	Cys	Tyr	Met	Tyr	Glu	Gly	Asp	Gly	Ile	Cys	Glu
			1155					1160					1165			
	Pro	Phe	Glu	Arg	Lys	Thr	Ser	Ile	Val	Asp	Cys	Gly	Ile	Tyr	Thr	Pro
	1170					1175						1180				
	Lys	Gly	Tyr	Leu	Asp	Gln	Trp	Ala	Thr	Arg	Ala	Tyr	Ser	Ser	His	Glu
	1185				1190					1195						1200
50	Asp	Lys	Lys	Lys	Cys	Pro	Val	Ser	Leu	Val	Thr	Gly	Glu	Pro	His	Ser
				1205						1210					1215	
	Leu	Ile	Cys	Thr	Ser	Tyr	His	Pro	Asp	Leu	Pro	Asn	His	Arg	Pro	Leu
				1220					1225					1230		
	Thr	Gly	Trp	Phe	Pro	Cys	Val	Ala	Ser	Glu	Asn	Glu	Thr	Gln	Asp	Asp
			1235				1240					1245				
55	Arg	Ser	Glu	Gln	Pro	Glu	Gly	Ser	Leu	Lys	Lys	Glu	Asp	Glu	Val	Trp
	1250						1255					1260				

EP 1 346 061 B1

Leu Lys Val Cys Phe Asn Arg Pro Gly Glu Ala Arg Ala Ile Phe Ile
 1265 1270 1275 1280
 Phe Leu Thr Thr Asp Gly Leu Val Pro Gly Glu His Gln Gln Pro Thr
 1285 1290 1295
 5 Val Thr Leu Tyr Leu Thr Asp Val Arg Gly Ser Asn His Ser Leu Gly
 1300 1305 1310
 Thr Tyr Gly Leu Ser Cys Gln His Asn Pro Leu Ile Ile Asn Val Thr
 1315 1320 1325
 10 His His Gln Asn Val Leu Phe His His Thr Thr Ser Val Leu Leu Asn
 1330 1335 1340
 Phe Ser Ser Pro Arg Val Gly Ile Ser Ala Val Ala Leu Arg Thr Ser
 1345 1350 1355 1360
 Ser Arg Ile Gly Leu Ser Ala Pro Ser Asn Cys Ile Ser Glu Asp Glu
 1365 1370 1375
 15 Gly Gln Asn His Gln Gly Gln Ser Cys Ile His Arg Pro Cys Gly Lys
 1380 1385 1390
 Gln Asp Ser Cys Pro Ser Leu Leu Leu Asp His Ala Asp Val Val Asn
 1395 1400 1405
 Cys Thr Ser Ile Gly Pro Gly Leu Met Lys Cys Ala Ile Thr Cys Gln
 1410 1415 1420
 20 Arg Gly Phe Ala Leu Gln Ala Ser Ser Gly Gln Tyr Ile Arg Pro Met
 1425 1430 1435 1440
 Gln Lys Glu Ile Leu Leu Thr Cys Ser Ser Gly His Trp Asp Gln Asn
 1445 1450 1455
 25 Val Ser Cys Leu Pro Val Asp Cys Gly Val Pro Asp Pro Ser Leu Val
 1460 1465 1470
 Asn Tyr Ala Asn Phe Ser Cys Ser Glu Gly Thr Lys Phe Leu Lys Arg
 1475 1480 1485
 Cys Ser Ile Ser Cys Val Pro Pro Ala Lys Leu Gln Gly Leu Ser Pro
 1490 1495 1500
 30 Trp Leu Thr Cys Leu Glu Asp Gly Leu Trp Ser Leu Pro Glu Val Tyr
 1505 1510 1515 1520
 Cys Lys Leu Glu Cys Asp Ala Pro Pro Ile Ile Leu Asn Ala Asn Leu
 1525 1530 1535
 Leu Leu Pro His Cys Leu Gln Asp Asn His Asp Val Gly Thr Ile Cys
 1540 1545 1550
 35 Lys Tyr Glu Cys Lys Pro Gly Tyr Tyr Val Ala Glu Ser Ala Glu Gly
 1555 1560 1565
 Lys Val Arg Asn Lys Leu Leu Lys Ile Gln Cys Leu Glu Gly Gly Ile
 1570 1575 1580
 40 Trp Glu Gln Gly Ser Cys Ile Pro Val Val Cys Glu Pro Pro Pro Pro
 1585 1590 1595 1600
 Val Phe Glu Gly Met Tyr Glu Cys Thr Asn Gly Phe Ser Leu Asp Ser
 1605 1610 1615
 Gln Cys Val Leu Asn Cys Asn Gln Glu Arg Glu Lys Leu Pro Ile Leu
 1620 1625 1630
 45 Cys Thr Lys Glu Gly Leu Trp Thr Gln Glu Phe Lys Leu Cys Glu Asn
 1635 1640 1645
 Leu Gln Gly Glu Cys Pro Pro Pro Ser Glu Leu Asn Ser Val Glu
 1650 1655 1660
 Tyr Lys Cys Glu Gln Gly Tyr Gly Ile Gly Ala Val Cys Ser Pro Leu
 1665 1670 1675 1680
 50 Cys Val Ile Pro Pro Ser Asp Pro Val Met Leu Pro Glu Asn Ile Thr
 1685 1690 1695
 Ala Asp Thr Leu Glu His Trp Met Glu Pro Val Lys Val Gln Ser Ile
 1700 1705 1710
 55 Val Cys Thr Gly Arg Arg Gln Trp His Pro Asp Pro Val Leu Val His
 1715 1720 1725
 Cys Ile Gln Ser Cys Glu Pro Phe Gln Ala Asp Gly Trp Cys Asp Thr

EP 1 346 061 B1

10. The polypeptide of claim 1, wherein said fragment of (c) contains less than 250 amino acid residues.
11. The polypeptide of claim 1, wherein said fragment of (c) contains less than 50 amino acid residues.
- 5 12. The polypeptide according to any of claims 1 to 11 fused to a polypeptide tag for detection or purification.
13. The polypeptide according to claim 12, wherein the tag is a c-myc tag.
14. The polypeptide according to claim 12, wherein the tag is a histidine tag.
- 10 15. A purified polynucleotide encoding the polypeptide according to any of claims 1 to 14, or the complementary strand of said polynucleotide.
16. The polynucleotide according to claim 15 comprising nucleotides 1 to 5376 of SEQ ID NO:1, corresponding to the coding sequence of PAPP-A2, as deposited with DSMZ under accession number DSM 13783.
- 15 17. The polynucleotide according to claim 15 encoding a polypeptide comprising amino acid residues 234 to 1791 of SEQ ID NO:2.
- 20 18. A recombinant DNA molecule in the form of an expression vector comprising an expression signal operably linked to the polynucleotide according to any of claims 15 to 17.
19. A host organism transfected or transformed with the polynucleotide according to any of claims 15 to 17, or the recombinant DNA molecule according to claim 18 wherein the host organism is not a human being.
- 25 20. A composition comprising the polypeptide according to any of claims 1 to 14 in combination with a physiologically acceptable carrier.
21. A pharmaceutical composition comprising the polypeptide according to any of claims 1 to 14 in combination with a pharmaceutically acceptable carrier.
- 30 22. A method for producing an antibody specific against the polypeptide according to any of claims 1 to 14, said method comprising the steps of
- 35 i) providing a host organism, wherein the host organism is not a human being,
ii) immunizing the host organism with a polypeptide according to any of claims 1 to 14, and
iii) obtaining said antibody.
23. A method for producing the polypeptide according to any of claims 1 to 14, said method comprising the steps of
- 40 i) providing a suitable host organism, wherein the host organism is not a human being,
ii) transfecting or transforming the host organism provided in step i) with the polynucleotide according to any of claims 15-17, or the vector according to claim 18,
iii) culturing the host organism obtained in step ii) under conditions suitable for expression of the polypeptide encoded by the polynucleotide or the vector.
- 45 24. The method of claim 23 comprising the further step of isolating the polypeptide from the host organism.
25. The method of claim 23, wherein said host organism is a mammalian cell.
- 50 26. A method for inhibiting and/or reducing expression of a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2 in a cell by means of anti-sense technology, said method comprising the steps of
- 55 i) providing the complementary strand of the polynucleotide according to any of claims 15-17,
ii) transfecting or transforming a cell capable of expressing a PAPP-A2 encoding polynucleotide with said polynucleotide provided in step i),
iii) culturing the cell obtained in step ii) under conditions suitable for hybridization of the PAPP-A2 encoding

polynucleotide provided in step i) to a complementary polynucleotide in said cell, and
iv) inhibiting and/or reducing the expression of PAPP-A2 in said cell.

- 5
27. Method of claim 26, wherein the polynucleotide according to claim 15 and the complementary strand of the polynucleotide according to claim 15 are co-expressed from distinct polynucleotide molecules.
- 10
28. A method for detecting a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2, or measuring the level of PAPP-A2, in a biological sample obtained from an individual, said method comprising the steps of
- 15
i) obtaining a biological sample from said individual,
ii) detecting PAPP-A2 in said sample by detecting
- 20
a) a polypeptide according to any of claims 1 to 14; and/or
b) a polynucleotide in the form of mRNA originating from PAPP-A2 expression using the polynucleotide of any of claims 15-17, and/or
c) PAPP-A2 specific protease activity by detecting cleavage of IGFBP-5.
- 25
29. The method of claim 28 comprising the further step of comparing PAPP-A2 detected in step ii) with a predetermined value selected from the group consisting of
- 30
i) a predetermined amount and/or concentration of PAPP-A2; and/or
ii) a predetermined amount and/or concentration of PAPP-A2 mRNA; and/or
iii) a predetermined PAPP-A2 specific protease activity.
- 35
30. Method of claim 29, wherein said predetermined value is indicative of a normal physiological condition of said individual.
- 30
31. The method of claim 28, wherein said biological sample is selected from the group consisting of blood, urine, pleural fluid, oral washings, tissue biopsies, and follicular fluid.
32. The method of claim 28, wherein said level of PAPP-A2 is measured as PAPP-A2 specific protease activity.
- 35
33. The method of claim 28, wherein said PAPP-A2 is detected as PAPP-A2 monomer.
34. The method of claim 28, wherein said PAPP-A2 is detected as PAPP-A2 dimer.
- 40
35. An *ex vivo* method of diagnosing a clinical condition in an individual, said method comprising the steps of
- 40
i) performing the method of any of claims 28-34 on a biological sample obtained from an individual, and
ii) diagnosing the clinical condition.
- 45
36. Method of claim 35, wherein said clinical condition is a fetal abnormality.
- 50
37. The method of claim 36, wherein said fetal abnormality is selected from the group consisting of Trisomy 21, Trisomy 18, Trisomy 13, and Open Spina Bifida.
- 55
38. The method according to claim 36, wherein said fetal abnormality is ectopic pregnancy, open spina bifida, neural tube defects, ventral wall defects, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Monosomy X or Klinefelter's Syndrome.
39. The method of claim 35, wherein said clinical condition is selected from the group consisting of restenosis, atherosclerosis, wound healing, fibrosis, myocardial infarction, osteoporosis, rheumatoid arthritis, multiple myeloma and cancer.
- 40
40. A method for identifying an agent inhibiting the protease activity of a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2, said method comprising the steps of

- i) incubating a) the polypeptide according to any of claims 1 to 14 and b) a predetermined substrate for said polypeptide, and c) a putative inhibitory agent, and
ii) determining if proteolysis of said substrate is inhibited.

5 **41.** A method for identifying an agent enhancing the protease activity of a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2, said method comprising the steps of

- i) incubating a) the polypeptide according to any of claims 1 to 14 and b) a predetermined substrate for said polypeptide, and c) a putative enhancer agent, and
10 ii) determining if proteolysis of said substrate is enhanced.

42. A method for purification of a polypeptide having the sequence SEQ ID NO:2, which polypeptide is designated as PAPP-A2 or complexes of PAPP-A2 with other proteins, said method comprising the steps of

- 15 i) providing a polyclonal or monoclonal antibody specific against the polypeptides of (a) or (b) according to claim 1, and
ii) purifying PAPP-A2 or complexes of PAPP-A2 with other proteins by means of affinity chromatography.

20 **Patentansprüche**

1. Isoliertes Polypeptid, das

- 25 (a) aus den Resten 234 bis 1791 von SEQ ID NO: 2 besteht und proteolytische Aktivität gegen Insulin Like Growth Factor Binding Protein 5 (IGFBP-5) hat; oder
(b) sich von dem Polypeptid von (a) ausschließlich unterscheidet durch Deletion von 1 bis 10 Aminosäureresten von, oder Addition von 1 bis 10 Aminosäureresten zu, dem Amino-Terminus von dem Polypeptid von (a) und/oder
30 Deletion von 1 bis 10 Aminosäureresten von, oder Addition von 1 bis 10 Aminosäureresten zu, dem Carboxy-Terminus von dem Polypeptid von (a); und/oder
eine oder mehrere konservative Aminosäure-Substitutionen,
wobei das Polypeptid von (b) mindestens 95% identisch zu dem Polypeptid von (a) ist und proteolytische Aktivität gegen Insulin Like Growth Factor Binding Protein 5 (IGFBP-5) hat; oder
35 (c) aus einem Fragment von SEQ ID NO: 2 von mindestens 5 Aminosäuren Länge besteht, das Fragment umfassend eine oder mehrere von den folgenden Regionen von SEQ ID NO: 2:

- Cys-403 bis Cys-499,
Cys-828 bis Cys-881,
Cys-1048 bis Cys-1115,
40 Cys-1390 bis Cys-1396,
Cys-1459 bis Cys-1464,
Cys-1521 bis Cys-1525,
Cys-1590 bis Cys-1595,
Cys-1646 bis Cys-1653,
45 Cys-1729 bis Cys-1733,
wobei das Fragment proteolytische Aktivität gegen Insulin Like Growth Factor Binding Protein 5 (IGFBP-5) hat.

50 **2.** Polypeptid gemäß Anspruch 1, wobei das Polypeptid von (b) mindestens 97% identisch zu dem Polypeptid von (a) ist.

3. Polypeptid gemäß Anspruch 1, wobei das Polypeptid von (b) mindestens 99% identisch zu dem Polypeptid von (a) ist.

4. Polypeptid gemäß Anspruch 1, wobei das Polypeptid von (b) sich von dem Polypeptid von (a) durch eine einzige konservative Aminosäure-Substitutionen unterscheidet.

55 **5.** Polypeptid gemäß Anspruch 1, wobei das Polypeptid von (a) an dem aminoterminalen Ende an das carboxyterminale Ende von Aminosäureresten 1 bis 233 von SEQ ID NO: 2, entsprechend dem prepro-Teil von PAPP-A2, fusioniert ist.

EP 1 346 061 B1

6. Polypeptid gemäß Anspruch 1, wobei das Polypeptid von (a) an dem aminoterminalen Ende an das carboxyterminale Ende von Aminosäureresten 23 bis 233 von SEQ ID NO: 2, entsprechend dem pro-Teil von PAPP-A2, fusioniert ist.
- 5 7. Polypeptid gemäß Anspruch 1, wobei das Polypeptid von (a) oder (b) an dem aminoterminalen Ende an das carboxyterminale Ende von Aminosäureresten 1 bis 22 von SEQ ID NO: 2, entsprechend dem Signal-Peptid von PAPP-A2, fusioniert ist.
- 10 8. Polypeptid gemäß einem der Ansprüche 1 bis 4, wobei das Polypeptid von (a) oder (b) ein rekombinantes Polypeptid ist.
9. Polypeptid gemäß einem der Ansprüche 1 bis 4, wobei das Polypeptid von (a) oder (b) frei von menschlichen Proteinen, oder anderen natürlich mit dem Polypeptid assoziierten Proteinen, ist.
- 15 10. Polypeptid gemäß Anspruch 1, wobei das Fragment von (c) weniger als 250 Aminosäurereste enthält.
11. Polypeptid gemäß Anspruch 1, wobei das Fragment von (c) weniger als 50 Aminosäurereste enthält.
- 20 12. Polypeptid gemäß einem der Ansprüche 1 bis 11, das an eine Polypeptid-Markierung zum Nachweis oder zur Aufreinigung fusioniert ist.
13. Polypeptid gemäß Anspruch 12, wobei die Markierung eine c-myc-Markierung ist.
14. Polypeptid gemäß Anspruch 12, wobei die Markierung eine Histidin-Markierung ist.
- 25 15. Aufgereinigtes Polynukleotid, das das Polypeptid gemäß einem der Ansprüche 1 bis 14 kodiert, oder der komplementäre Strang des Polynukleotids.
- 30 16. Polynukleotid gemäß Anspruch 15, das die Nukleotide 1 bis 5376 von SEQ ID NO: 1, entsprechend der kodierenden Sequenz von PAPP-A2, wie hinterlegt bei der DSMZ unter der Zugangsnummer DSM 13783, umfasst.
- 35 17. Polynukleotid gemäß Anspruch 15, das ein Polypeptid kodiert, das die Aminosäurereste 234 bis 1791 von SEQ ID NO: 2 umfasst.
18. Rekombinantes DNS-Molekül in Form eines Expressionsvektors, umfassend ein Expressionssignal, das funktionsfähig mit dem Polynukleotid gemäß einem der Ansprüche 15 bis 17 verknüpft ist.
- 40 19. Wirtsorganismus, der mit dem Polynukleotid gemäß einem der Ansprüche 15 bis 17 transfiziert oder transformiert ist, oder mit dem rekombinanten DNS-Molekül gemäß Anspruch 18, wobei der Wirtsorganismus kein menschliches Wesen ist.
20. Zusammensetzung, die das Polypeptid gemäß einem der Ansprüche 1 bis 14 in Kombination mit einem physiologisch akzeptablen Träger umfasst.
- 45 21. Pharmazeutische Zusammensetzung, die das Polypeptid gemäß einem der Ansprüche 1 bis 14 in Kombination mit einem pharmazeutisch akzeptablen Träger umfasst.
22. Verfahren zum Herstellen eines Antikörpers, der spezifisch gegen das Polypeptid gemäß einem der Ansprüche 1 bis 14 ist, wobei das Verfahren die Schritte
 - 50 i) Bereitstellen eines Wirtsorganismus, wobei der Wirtsorganismus kein menschliches Wesen ist,
 - ii) Immunisieren des Wirtsorganismus mit einem Polypeptid gemäß einem der Ansprüche 1 bis 14, und
 - iii) Erhalten des Antikörpers umfasst.
- 55 23. Verfahren zum Herstellen des Polypeptids gemäß einem der Ansprüche 1 bis 14, wobei das Verfahren die Schritte
 - i) Bereitstellen eines geeigneten Wirtsorganismus, wobei der Wirtsorganismus kein menschliches Wesen ist,
 - ii) Transfizieren oder Transformieren des Wirtsorganismus bereitgestellt in Schritt i) mit dem Polynukleotid

EP 1 346 061 B1

gemäß einem der Ansprüche 15 bis 17, oder dem Vektor gemäß Anspruch 18,
iii) Kultivieren des in Schritt ii) erhaltenen Wirtsorganismus unter Bedingungen, die für die Expression des Polypeptids kodiert durch das Polynukleotid oder den Vektor, geeignet sind umfasst.

5

24. Verfahren gemäß Anspruch 23, das den weiteren Schritt des Isolierens des Polypeptids von dem Wirtsorganismus umfasst.

10

25. Verfahren gemäß Anspruch 23, wobei der Wirtsorganismus eine Säugetierzelle ist.

26. Verfahren zum Hemmen und/oder Reduzieren der Expression eines Polypeptids mit der Sequenz SEQ ID NO: 2, wobei das Polypeptid in einer Zelle als PAPP-A2 mittels Antisense-Technologie bestimmt wird, wobei das Verfahren die Schritte

15

i) Bereitstellen des komplementären Stranges von dem Polynukleotid gemäß einem der Ansprüche 15 bis 17,
ii) Transfizieren oder Transformieren einer Zelle, die zur Expression eines PAPP-A2 kodierenden Polynukleotids fähig ist, mit dem Polynukleotid bereitgestellt in Schritt i)

20

iii) Kultivieren der in Schritt ii) erhaltenen Zelle unter Bedingungen, die für die Hybridisierung des PAPP-A2 kodierenden Polynukleotids, bereitgestellt in Schritt i), an ein komplementäres Polynukleotid in der Zelle geeignet sind, und

iv) Hemmen und/oder Reduzieren der Expression von PAPP-A2 in der Zelle umfasst.

25

27. Verfahren gemäß Anspruch 26, wobei das Polynukleotid gemäß Anspruch 15 und der komplementären Strang von dem Polynukleotid gemäß Anspruch 15 von unterschiedlichen Polynukleotidmolekülen koexprimiert werden.

28. Verfahren zum Nachweisen eines Polypeptids mit der Sequenz SEQ ID: 2, wobei das Polypeptid als PAPP-A2 bestimmt wird, oder Messen des PAPP-A2-Niveaus, in einer von einem Individuum erhaltenen biologischen Probe, wobei das Verfahren die Schritte

30

i) Erhalten einer biologischen Probe von dem Individuum,
ii) Nachweisen von PAPP-A2 in der Probe durch Nachweisen

35

a) eines Polypeptids gemäß einem der Ansprüche 1 bis 14; und/oder
b) eines Polynukleotids in Form von mRNA, das der Expression von PAPP-A2 bei Verwenden des Polynukleotids gemäß einem der Ansprüche 15 bis 17 entstammt, und/oder
c) der PAPP-A2-spezifischen Proteaseaktivität durch Nachweisen der Spaltung von IGFBP-5 umfasst.

40

29. Verfahren gemäß Anspruch 28 umfassend den weiteren Schritt des Vergleichens von dem in Schritt ii) nachgewiesenen PAPP-A2 mit einem vorausbestimmten Wert, der von der Gruppe bestehend aus

45

i) einer vorausbestimmten Menge und/oder Konzentration von PAPP-A2; und/oder
ii) einer vorausbestimmten Menge und/oder Konzentration von PAPP-A2-mRNA; und/oder
iii) einer vorausbestimmten PAPP-A2-spezifischen Proteaseaktivität, ausgewählt wird.

50

30. Verfahren gemäß Anspruch 29, wobei der vorausbestimmte Wert eine normale physiologische Verfassung des Individuums anzeigt.

31. Verfahren gemäß Anspruch 28, wobei die biologische Probe von der Gruppe bestehend aus Blut, Urin, Pleuraflüssigkeit, Mundspülungen, Gewebebiopsien, und Follikulärflüssigkeit ausgewählt wird.

55

32. Verfahren gemäß Anspruch 28, wobei das PAPP-A2-Niveau als PAPP-A2-spezifische Proteaseaktivität gemessen wird.

33. Verfahren gemäß Anspruch 28, wobei das PAPP-A2 als PAPP-A2-Monomer nachgewiesen wird.

EP 1 346 061 B1

34. Verfahren gemäß Anspruch 28, wobei das PAPP-A2 als PAPP-A2-Dimer nachgewiesen wird.

35. *Ex vivo*-Verfahren zum Diagnostizieren eines klinischen Zustands von einem Individuum, wobei das Verfahren die Schritte

- i) Durchführen des Verfahrens gemäß einem der Ansprüche 28-34 mit einer von einem Individuum erhaltenen biologische Probe, und
- ii) Diagnostizieren des klinischen Zustands umfasst.

36. Verfahren gemäß Anspruch 35, wobei der klinische Zustand eine fetale Auffälligkeit ist.

37. Verfahren gemäß Anspruch 36, wobei die fetale Auffälligkeit von der Gruppe bestehend aus Trisomie 21, Trisomie 18, Trisomie 13, und offener Spina bifida ausgewählt wird.

38. Verfahren gemäß Anspruch 36, wobei die fetale Auffälligkeit ektope Schwangerschaft, offene Spina bifida, Neuralrohrdefekte, Ventralwanddefekte, Edwards-Syndrom, Patau-Syndrom, Turner-Syndrom, Monosomie X oder Klinefelter-Syndrom ist.

39. Verfahren gemäß Anspruch 35, wobei die klinische Verfassung von der Gruppe bestehend aus Restenose, Atherosklerose, Wundheilung, Fibrose, Herzinfarkt, Osteoporose, Gelenkrheumatismus, multiples Myelom und Krebs ausgewählt wird.

40. Verfahren zum Identifizieren eines Stoffes, der die Proteaseaktivität von einem Polypeptid mit der Sequenz SEQ ID NO: 2 hemmt, wobei das Polypeptid als PAPP-A2 bestimmt wird, wobei das Verfahren die Schritte

- i) Inkubieren a) des Polypeptids gemäß einem der Ansprüche 1 bis 14 und b) eines vorher festgelegten Substrates für das Polypeptid, und c) eines mutmaßlich hemmenden Stoffes, und
- ii) Feststellen, ob die Proteolyse des Substrates gehemmt ist umfasst.

41. Verfahren zum Identifizieren eines Stoffes, der die Proteaseaktivität von einem Polypeptid mit der Sequenz SEQ ID NO: 2 verstärkt, wobei das Polypeptid als PAPP-A2 bestimmt wird, wobei das Verfahren die Schritte

- i) Inkubieren a) des Polypeptids gemäß einem der Ansprüche 1 bis 14 und b) eines vorher festgelegten Substrates für das Polypeptid, und c) eines mutmaßlichen Verstärker-Stoffes, und
- ii) Feststellen, ob die Proteolyse des Substrates verstärkt ist umfasst.

42. Verfahren zur Aufreinigung eines Polypeptids mit der Sequenz SEQ ID NO: 2, wobei das Polypeptid als PAPP-A2 oder Komplexe von PAPP-A2 mit anderen Proteinen bestimmt wird, wobei das Verfahren die Schritte

- i) Bereitstellen eines polyklonalen oder monoklonalen Antikörpers, der spezifisch gegen die Polypeptide von (a) oder (b) gemäß Anspruch 1 ist, und
- ii) Aufreinigung von PAPP-A2 oder Komplexen von PAPP-A2 mit anderen Proteinen mittels Affinitätschromatographie umfasst.

Revendications

1. Polypeptide isolé qui

- (a) est constitué des résidus 234 à 1791 de SEQ ID NO : 2 et possède une activité protéolytique contre la protéine 5 de liaison du facteur de croissance de type insulinaire (IGFBP-5) ; ou
- (b) diffère du polypeptide de (a) uniquement par la délétion de 1 à 10 résidus d'acides aminés de, ou l'addition de 1 à 10 résidus d'acides aminés à, l'extrémité amino du polypeptide de (a) et/ou la délétion de 1 à 10 résidus d'acides aminés de, ou l'addition de 1 à 10 résidus d'acides aminés à, l'extrémité

EP 1 346 061 B1

carboxy du polypeptide de (a) ; et/ou
une ou plusieurs substitutions conservatives d'acides aminés,
où ledit polypeptide de (b) est au moins identique à 95 % avec le polypeptide de (a) et possède une activité
protéolytique contre la protéine 5 de liaison du facteur de croissance de type insulinique (IGFBP-5) ; ou
(c) est constitué d'un fragment de SEQ ID NO : 2 d'une longueur d'au moins 5 acides aminés, ledit fragment
comprenant une ou plusieurs des régions suivantes de SEQ ID NO : 2 ;

Cys-403 à Cys-499,
Cys-828 à Cys-881,
Cys-1048 à Cys-1115,
Cys-1390 à Cys-1396,
Cys-1459 à Cys-1464,
Cys-1521 à Cys-1525,
Cys-1590 à Cys-1595,
Cys-1646 à Cys-1653,
Cys-1729 à Cys-1733,

où ledit fragment possède une activité protéolytique contre la protéine 5 de liaison du facteur de croissance
de type insulinique (IGFBP-5).

2. Polypeptide selon la revendication 1, où ledit polypeptide de (b) est au moins identique à 97 % avec le polypeptide de (a).
3. Polypeptide selon la revendication 1, où ledit polypeptide de (b) est au moins identique à 99 % avec le polypeptide de (a).
4. Polypeptide selon la revendication 1, où ledit polypeptide de (b) diffère du polypeptide de (a) par une simple substitution conservative d'acide aminé.
5. Polypeptide selon la revendication 1, où ledit polypeptide de (a) est fusionné à l'extrémité amino-terminale à l'extrémité carboxy-terminale des résidus d'acides aminés 1 à 233 de SEQ ID NO : 2 correspondant à la partie prépro de la PAPP-A2.
6. Polypeptide selon la revendication 1, où ledit polypeptide de (a) est fusionné à l'extrémité amino-terminale à l'extrémité carboxy-terminale des résidus d'acides aminés 23 à 233 de SEQ ID NO : 2 correspondant à la partie pro de la PAPP-A2.
7. Polypeptide selon la revendication 1, où ledit polypeptide de (a) ou (b) est fusionné à l'extrémité amino-terminale à l'extrémité carboxy-terminale des résidus d'acides aminés 1 à 22 de SEQ ID NO : 2 correspondant au peptide signal de la PAPP-A2.
8. Polypeptide selon l'une quelconque des revendications 1 à 4, où ledit polypeptide de (a) ou (b) est un polypeptide recombinant.
9. Polypeptide selon l'une quelconque des revendications 1 à 4, où le polypeptide de (a) ou (b) est dépourvu de protéines humaines, ou d'autres protéines associées naturellement au dit polypeptide.
10. Polypeptide selon la revendication 1, où ledit fragment de (c) contient moins de 250 résidus d'acides aminés.
11. Polypeptide selon la revendication 1, où ledit fragment de (c) contient moins de 50 résidus d'acides aminés.
12. Polypeptide selon l'une quelconque des revendications 1 à 11 fusionné à un marqueur polypeptidique pour la détection ou la purification.
13. Polypeptide selon la revendication 12, où le marqueur est un marqueur c-myc.
14. Polypeptide selon la revendication 12, où le marqueur est un marqueur histidine.
15. Polynucléotide purifié codant pour le polypeptide selon l'une quelconque des revendications 1 à 14, ou le brin

EP 1 346 061 B1

complémentaire dudit polynucléotide.

- 5
16. Polynucléotide selon la revendication 15 comprenant les nucléotides 1 à 5376 de SEQ ID NO : 1, correspondant à la séquence codante de la PAPP-A2, telle que déposée à la DSMZ sous le numéro d'accèsion DSM 13783.
17. Polynucléotide selon la revendication 15 codant pour un polypeptide comprenant les résidus d'acides aminés 234 à 1791 de SEQ ID NO : 2.
- 10
18. Molécule d'ADN recombinant sous la forme d'un vecteur d'expression comprenant un signal d'expression lié de façon fonctionnelle au polynucléotide selon l'une quelconque des revendications 15 à 17.
19. Organisme hôte transfecté ou transformé avec le polynucléotide selon l'une quelconque des revendications 15 à 17, ou molécule d'ADN recombinant selon la revendication 18, où l'organisme hôte n'est pas un être humain.
- 15
20. Composition comprenant le polypeptide selon l'une quelconque des revendications 1 à 14 en combinaison avec un support physiologiquement acceptable.
21. Composition pharmaceutique comprenant le polypeptide selon l'une quelconque des revendications 1 à 14 en combinaison avec un support pharmaceutiquement acceptable.
- 20
22. Procédé de production d'un anticorps spécifique contre le polypeptide selon l'une quelconque des revendications 1 à 14, ledit procédé comprenant les étapes suivantes
- 25
- i) la fourniture d'un organisme hôte, où l'organisme hôte n'est pas un être humain,
 - ii) l'immunisation de l'organisme hôte avec un polypeptide selon l'une quelconque des revendications 1 à 14, et
 - iii) l'obtention dudit anticorps.
23. Procédé de production du polypeptide selon l'une quelconque des revendications 1 à 14, ledit procédé comprenant les étapes suivantes
- 30
- i) la fourniture d'un organisme hôte approprié, où l'organisme hôte n'est pas un être humain,
 - ii) la transfection ou la transformation de l'organisme hôte fourni dans l'étape i) avec le polynucléotide selon l'une quelconque des revendications 15 à 17, ou le vecteur selon la revendication 18,
 - iii) la culture de l'organisme hôte obtenu dans l'étape ii) dans des conditions appropriées pour l'expression du polypeptide codé par le polynucléotide ou le vecteur.
- 35
24. Procédé selon la revendication 23 comprenant l'étape supplémentaire d'isolement du polypeptide de l'organisme hôte.
- 40
25. Procédé selon la revendication 23, où ledit organisme hôte est une cellule de mammifère.
26. Procédé d'inhibition et/ou de réduction de l'expression d'un polypeptide ayant la séquence SEQ ID NO : 2, lequel polypeptide est désigné comme la PAPP-A2 dans une cellule au moyen de la technologie antisens, ledit procédé comprenant les étapes suivantes
- 45
- i) la fourniture du brin complémentaire du polynucléotide selon l'une quelconque des revendications 15 à 17,
 - ii) la transfection ou la transformation d'une cellule capable d'exprimer un polynucléotide codant pour la PAPP-A2 avec ledit polynucléotide fourni dans l'étape i),
 - iii) la culture de la cellule obtenue dans l'étape ii) dans des conditions appropriées pour l'hybridation du polynucléotide codant pour la PAPP-A2 fourni dans l'étape i) à un polynucléotide complémentaire dans ladite cellule, et
 - iv) l'inhibition et/ou la réduction de l'expression de la PAPP-A2 dans ladite cellule.
- 50
27. Procédé selon la revendication 26, dans lequel le polynucléotide selon la revendication 15 et le brin complémentaire du polynucléotide selon la revendication 15 sont coexprimés à partir de molécules distinctes de polynucléotides.
- 55
28. Procédé de détection d'un polypeptide ayant la séquence SEQ ID NO : 2, lequel polypeptide est désigné comme la PAPP-A2, ou de mesure du taux de PAPP-A2, dans un échantillon biologique obtenu à partir d'un individu, ledit

procédé comprenant les étapes suivantes

- i) l'obtention d'un échantillon biologique à partir dudit individu,
- ii) la détection de la PAPP-A2 dans ledit échantillon par détection

5

- a) d'un polypeptide selon l'une quelconque des revendications 1 à 14 ; et/ou
- b) d'un polynucléotide sous la forme d'ARNm provenant de l'expression de la PAPP-A2 en utilisant le polynucléotide selon l'une quelconque des revendications 15 à 17, et/ou
- c) d'une activité protéase spécifique de la PAPP-A2 par détection du clivage de l'IGFBP-5.

10

29. Procédé selon la revendication 28 comprenant l'étape supplémentaire de comparaison de la PAPP-A2 détectée dans l'étape ii) avec une valeur prédéterminée choisie dans le groupe constitué de

- i) une quantité et/ou une concentration prédéterminée de PAPP-A2 ; et/ou
- ii) une quantité et/ou une concentration prédéterminée d'ARNm de PAPP-A2 ; et/ou
- iii) une activité protéase spécifique de la PAPP-A2 prédéterminée.

15

30. Procédé selon la revendication 29, dans lequel ladite valeur prédéterminée indique une condition physiologique normale dudit individu.

20

31. Procédé selon la revendication 28, dans lequel ledit échantillon biologique est choisi dans le groupe constitué de sang, urine, liquide pleural, liquides de lavage oral, biopsies tissulaires, et liquide folliculaire.

32. Procédé selon la revendication 28, dans lequel ledit taux de PAPP-A2 est mesuré comme l'activité protéase spécifique de la PAPP-A2.

25

33. Procédé selon la revendication 28, dans lequel ladite PAPP-A2 est détectée sous la forme de monomère de PAPP-A2.

30

34. Procédé selon la revendication 28, dans lequel ladite PAPP-A2 est détectée sous la forme de dimère de PAPP-A2.

35. Procédé *ex vivo* de diagnostic d'une condition clinique chez un individu, ledit procédé comprenant les étapes suivantes

35

- i) la réalisation du procédé selon l'une quelconque des revendications 28 à 34 sur un échantillon biologique obtenu à partir d'un individu, et
- ii) le diagnostic de la condition clinique.

36. Procédé selon la revendication 35, où ladite condition clinique est une anomalie foetale.

40

37. Procédé selon la revendication 36, dans lequel ladite anomalie foetale est choisie dans le groupe constitué de la trisomie 21, la trisomie 18, la trisomie 13, le spina bifida à moelle ouverte.

38. Procédé selon la revendication 36, dans lequel ladite anomalie foetale est une grossesse ectopique, un spina bifida à moelle ouverte, des anomalies du tube neural, des anomalies de la paroi ventrale, le syndrome d'Edwards, le syndrome de Patau, le syndrome de Turner, la monosomie X ou le syndrome de Klinefelter.

45

39. Procédé selon la revendication 35, dans lequel ladite condition clinique est choisie dans le groupe constitué de resténose, athérosclérose, cicatrisation, fibrose, infarctus du myocarde, ostéoporose, polyarthrite rhumatoïde, myélome multiple et cancer.

50

40. Procédé d'identification d'un agent inhibant l'activité protéase d'un polypeptide ayant la séquence SEQ ID NO : 2, lequel polypeptide est désigné comme la PAPP-A2, ledit procédé comprenant les étapes suivantes

55

- i) l'incubation a) du polypeptide selon l'une quelconque des revendications 1 à 14 et b) d'un substrat prédéterminé pour ledit polypeptide, et c) d'un agent inhibiteur putatif, et
- ii) la détermination si la protéolyse dudit substrat est inhibée.

EP 1 346 061 B1

41. Procédé d'identification d'un agent amplifiant l'activité protéase d'un polypeptide ayant la séquence SEQ ID NO : 2, lequel polypeptide est désigné comme la PAPP-A2, ledit procédé comprenant les étapes suivantes

5 i) l'incubation a) du polypeptide selon l'une quelconque des revendications 1 à 14 et b) d'un substrat prédéterminé pour ledit polypeptide, et c) d'un agent amplificateur putatif, et
ii) la détermination si la protéolyse dudit substrat est amplifiée.

10 42. Procédé de purification d'un polypeptide ayant la séquence SEQ ID NO : 2, lequel polypeptide est désigné comme la PAPP-A2 ou des complexes de la PAPP-A2 avec d'autres protéines, ledit procédé comprenant les étapes suivantes

15 i) la fourniture d'un anticorps polyclonal ou monoclonal spécifique contre les polypeptides de (a) ou (b) selon la revendication 1, et
ii) la purification de la PAPP-A2 ou des complexes de la PAPP-A2 avec d'autres protéines au moyen d'une chromatographie d'affinité.

20

25

30

35

40

45

50

55

Fig. 1a

ATGATGTGCTTAAAGATCCTAAGAATAAGCCTGGCGATTTTGGCTGGGTGGGCACTCTGT M M C L K I L R I S L A I L A G W A L C	50 (20)
TCTGCCAACTCTGAGCTGGGCTGGACACGCAAGAAATCCTTGGTTGAGAGGGAACACCTG S A N S E L G W T R K K S L V E R E H L	120 (40)
AATCAGGTGCTGTTGGAAGGAGAACGTTGTTGGCTGGGGCCAGGTTTCAAGACCCAGA N Q V L L E G E R C W L G A K V R R P R	180 (60)
GCTTCTCCACAGCATCACCTCTTGGAGTCTACCCAGCAGGGCTGGGAACCTAAGG A S P Q H H L F G V Y P S R A G N Y L R	240 (80)
CCCTACCCCGTGGGGAGCAAGAAATCCATCATA CAGGACGCAGCAAAC CAGACTGAA P Y P V G E Q E I H H T G R S K P D T E	300 (100)
GGAAATGCTGTGAGCCTTGTCCCCAGACCTGACTGAAATCCAGCAGGACTGAGGGGT G N A V S L V P P D L T E N P A G L R G	360 (120)
GCAGTTGAGAGCCGGCTGCCCATGGGTAGGGATAGTCTTATGGGCAATCTGAGCTG A V E E P A A P W V G D S P I G Q S E L	420 (140)
CTGGGAGATGATGACGCTTATCTCGGCAATCAAAGATCCAAGGAGTCTCTAGGTGAGGCC L G D D D A Y L G N Q R S K E S L G E A	480 (160)
GGCATTCAGAAAGGCTCAGCCATGGCTGCCACTACTACCACCGCCATTTTACAAACCTG G I Q K G S A M A A T T T T A I F T T L	540 (180)
AACGAACCCAAAC CAGAGACCCAAAGGAGGGCTGGGCCAAGTCCAGG CAGCGTCGCCAA N E R K P E T Q R R G W A K S R Q R R Q	600 (200)
GTGTGGAAGAGGGCGGGGAAGATGGGCAGGAGACTCCGGTATCTCTTACATTTCCAA V W K R R A E D G Q G D S G I S S H F Q	660 (220)
CCTTGGCCCAAGCATTCCCTTAAACACAGGGTCAAAGAGTCCACCGGAGGAAAGCAAC P W P K H S L K H R V K K S P P E E S N	720 (240)
CAAATGGTGGAGAGGGCTCTACCGAGAAGCAGAGACCTTTAACTCCCAAGTAGGACTG Q N G G E G S Y R E A E T F N S Q V G L	780 (260)
CCCATTATACTTCTCTGGGAGGCGGAGCGGCTGCTGCTGCCAGTCCAGAGTCTGGCT P I L Y F S G R R E R L L L R P E V L A	840 (280)
GAGATCCCCGGGAGCGGTTACAGTGAAGCCTGGGTTAAACCGGAGGAGGACAGAAC E I P R E A F T V E A W V K P E G G Q N	900 (300)
AACCCAGCCATCATCGCAGGTGTGTTTGATAACTGCTCCACACTGTCAAGTACAAAGGC N P A I I A G V F D N C S H T V S D K G	960 (320)
TGGCCCTGGGGATCCGCTCAGGGAAGGACAAGGGAAGCGGGATGCTCGCTTCTTCTC W A L G I R S G K D K G K R D A R F F F	1020 (340)
TCCCTCTGCACCGACCGCTGAAGAAAGCCACCATCTTGATTAGCCACAGTCGCTACCAA S L C T D R V K K A T I L I S H S R Y Q	1080 (360)
CCAGGCACATGGACCCATGTGGCAGCACTTACGATGGACGGCACATGGCCCTGTATGTG P G T W T H V A A T Y D G R H M A L Y V	1140 (380)
GATGGCACTCAGGTGGCTAGCAGTCTAGACCAGTCTGGTCCCCTGAACAGCCCTTCATG D G T Q V A S S L D Q S G P L N S P F M	1200 (400)
GCATCTTGGCGCTCTTTGCTCCTGGGGGAGACAGCTCTGAGGATGGGCACTATTCCGT A S C R S L L L G G D S S E D G H Y F R	1260 (420)
GGACACCTGGGCACACTGGTTTTCTGGTTCGACCGCCCTGCCACAAAGCCATTTTCAGCAC G H L G T L V F W S T A L P Q S H F Q H	1320 (440)
AGTTCTCAGCATTCAAGTGGGGAGGGAAGCGACTGACTTGGTCTGACAGCGAGCTTT S S Q H S S G E E E A T D L V L T A S F	1380 (460)
GAGCCTGTGAACACAGAGTGGGTTCCCTTTAGAGATGAGAAGTACCCACGACTTGAGGTT E P V N T E W V P F R D E K Y P R L E V	1440 (480)
CTCCAGGGCTTTGAGCCAGAGCCTGAGATTCTGTGCGCTTTGCAGCCCCCACTCTGTGGG L Q G F E P E P E I L S P L Q P P L C G	1500 (500)
CAAACAGTCTGTGACAAATGTGGAATTGATCTCCAGTACAATGGATACTGGCCCTTCGG Q T V C D N V E L I S Q Y N G Y W P L R	1560 (520)
GGAGAGAGGTGATACGCTACCAGGTGGTGAACATCTGTGATGATGAGGGCCTAAACCC G E K V I R Y Q V V N I C D D E G L N P	1620 (540)
ATTGTGAGTGGAGCAGATTCTGCTGCAGCACGAGGCACTGAATGAGGCCTTCAGCCGC I V S E E Q I R L Q H E A L N E A F S R	1680 (560)
TACAACATCAGCTGGCAGCTGAGCGTCCACCAGGTCCACAATCCACCTGCGACACCGG Y N I S W Q L S V H Q V H N S T L R H R	1740 (580)
GTGTGCTTGTGAACTGTGAGCCAGCAAGATTGGCAATGACCATTGTGACCCCGAGTGT V V L V N C E P S K I G N D H C D P E C	1800 (600)

Fig. 1b

GAGCACCCACTCACAGGCTATGATGGGGTGACTGCCGCTGCAGGGCCGCTGCTACTCC E H P L T G Y D G G D C R L Q G R C Y S	1860 (620)
TGGAACCGCAGGGATGGGCTGTGTACGTTGGAGTGAACAACATGTGAACGACTTTGAC W N R R D G L C H V E C N N M L N D F D	1920 (640)
GACGGAGACTGTGCGACCCCGAGTGGCTGATGTGCGCAAGACCTGTTTACCCCTGAC D G D C C D P Q V A D V R K T C F D P D	1980 (660)
TCACCCAAGAGGGCATAACATGAGTGTGAAGGAGCTGAAGGAGGCCCTGCAGCTGAACAGT S P K R A Y M S V K E L K E A L Q L N S	2040 (680)
ACTCACTTCTCAACATCTACTTTGCCAGCTCAGTCCGGGAAGACCTTGACAGTGTGCC T H F L N I Y F A S S V R E D L A G A A	2100 (700)
ACCTGGCCTTGGGACAAGGACGCTGTCACTCACTGGGTGGCATTGTCTCAGCCCAGCA T W P R D K D A V T H L G G I V L S P A	2160 (720)
TATTATGGGATGCTGGCCACACCGACACCATGATCCATGAAGTGGGACATGTTCTGGGA Y Y G M P G H T D T M I H E V G H V L G	2220 (740)
CTCTACCATGTCTTTAAAGGAGTCACTGAAAGAGAATCCTGCAATGACCCCTGCAAGGAG L Y H V F K G V S E R E S C N D P C K E	2280 (760)
ACAGTGCATCCATGGAACCGGAGACCTCTGTCCGACACCGCCCCACTCCCAAGAGT T V P S M E T G D L C A D T A P T P K S	2340 (780)
GAGCTGTGCCGGGAACCAGAGCCCCTAGTGACACCTGTGGCTTCACTCGCTTCCCAGGG E L C R E P E P T S D T C G F T R F P G	2400 (800)
GCTCCGTTACCAACTACATGAGCTACACGGATGATAACTGCACTGACAACCTTCACTCCT A P F T N Y M S Y T D D N C T D N F T P	2460 (820)
AACCAAGTGGCCGAATGCATGTCTATTTGGACCTAGTCTATCAGCAGTGGACTGAAAGC N Q V A R M H C Y L D L V Y Q Q W T E S	2520 (840)
AGAAAGCCACCCCATCCCATTCACCTATGGTCACTCGGACAGACCAACAAGTCCCTC R K P T P I P I P P M V I G Q T N K S L	2580 (860)
ACTATCCACTGGCTGCCTCCTATTAGTGGAGTTGTATATGACAGGGCCTCAGGCAGCTG T I H W L P P I S G V V Y D R A S G S L	2640 (880)
TGTGGCGCTTGCCTGAAGATGGGACCTTTCGTGATGTGACACAGCTTCTCCCGG C G A C T E D G T F R Q Y V H T A S S R	2700 (900)
CGGGTGTGTGACTCCTCAGGTTATTGGACCCAGAGGAGGCTGTGGGGCCTCCTGATGTG R V C D S S G Y W T P E E A V G P P D V	2760 (920)
GATCAGCCCTGCGAGCAAGCTTACAGGCTGGAGCCCTGAGGTCCACCTGTACCACATG D Q P C E P S L Q A W S P E V H L Y H M	2820 (940)
AACATGACGGTCCCTGCCCCACAGAAGGCTGTAGCTTGGAGCTGCTTCCAACACCCG N M T V P C P T E G C S L E L L F Q H P	2880 (960)
GTCCAAGCCGACACCCTCACCCGTGGGTCACTTCTTCTCATGGAGTCTCGCAGGTC V Q A D T L T L W V T S F P M E S S Q V	2940 (980)
CTCTTTGACACAGATCTTGTCTGAAAACAAGGAGTCACTGACCTGGGCCCTTAGAC L F D T E I L L E N K E S V H L G P L D	3000 (1000)
ACTTCTGTGACATCCCACTCACCATCAAAGTTCACGTTGGATGGGAAGGTTCGGGGGTG T P C D I P L T I K L H V D G K V S G V	3060 (1020)
AAAGTCTACACCTTTGATGAGAGGATAGAGATTGATGCAGCACTCCTGACTTCTCAGCCC K V Y T F D E R I E I D A A L L T S Q P	3120 (1040)
CACAGTCCCTTGTGCTCTGGCTGCAGGCCTGTGAGGTACCAGTTCTCCCGATCCCCCA H S P L C S G C R P V R Y Q V L R D P P	3180 (1060)
TTTGCCAGTGGTTTGGCCGTTGGTGTGACACATTCTCACAGGAAGTTACGGACGTGGAG F A S G L P V V V T H S H R K F T D V E	3240 (1080)
GTCAACCTGGACAGATGTATCAGTACCAAGTTCTAGCTGAAGCTGGAGGAGAAGTGGGA V T P G Q M Y Q Y Q V L A E A G G E L G	3300 (1100)
GAAGCTTCGCTCCTCTGAACCACATTCATGGAGCTCCTTATTGTGGAGATGGGAAGGTG E A S P P L N H I H G A P Y C G D G K V	3360 (1120)
TCAGAGACTGGGAGAAGAGTGTGATGATGGAGACCTTGTGAGCGGAGATGGCTGCTCC S E R L G E E C D D G D L V S G D G C S	3420 (1140)
AAGGTGTGTGAGCTGGAGGAAGTTTCACTGTGTAGGAGAGCCAAGCCTTGTCTACATG K V C E L E E G F N C V G E P S L C Y M	3480 (1160)
TATGAGGGAGATGGCATATGTGAACCTTTTGGAGAAAAACCAGCATTGTAGACTGTGGC Y E G D G I C E P F E R K T S I V D C G	3540 (1180)
ATCTACTCCCAAAGGATACTTGGATCAATGGGCTACCCGGCTTACTCTCTCATGAA I Y T P K G Y L D Q W A T R A Y S S H E	3600 (1200)

Fig. 1c

GACAAGAAAGTGTCTCTGTTTCCCTGGTAACTGGAGAACCCTATTCCCTAATTGGCACA D K K K C P V S L V T G E P H S L I C T	3660 (1220)
TCATACCATCCAGATTTACCCAACCACCGTCCCCCTAACTGGCTGGTTTCCCTGTGTGGC S Y H P D L P N H R P L T G W F P C V A	3720 (1240)
AGTGAAATGAAACTCAGGATGACAGGAGTGAACAGCCAGAAGGTAGCCTGAAGAAAGAG S E N E T Q D D R S E Q P E G S L K K E	3780 (1260)
GATGAGGTTTGGCTCAAAGTGTGTTTCAATAGACCAGGAGAGGCCAGAGCAATTTTATT D E V W L K V C F N R P G E A R A I F I	3840 (1280)
TTTTTGACAACCTGATGGCCTAGTTCGCCGAGAGCATCAGCAGCCGACAGTGACTCTCTAC F L T T D G L V P G E H Q Q P T V T L Y	3900 (1300)
CTGACCGATGTCGGTGAAGCAACCCTCTCTTGGAACCTATGGACTGTCATGCCAGCAT L T D V R G S N H S L G T Y G L S C Q H	3960 (1320)
AATCCACTGATTATCAATGTGACCCATCACCAGAATGTCTTTTCCACCATACCACCTCA N P L I I N V T H H Q N V L F H H T T S	4020 (1340)
GTGCTGTGAATTTCTCATCCCCACGGGTGGCATCTCAGCTGTGGCTCTAAGGACATCC V L L N F S S P R V G I S A V A L R T S	4080 (1360)
TCCCGCATGTGCTTTCGGCTCCAGTAACTGCATCTCAGAGGACGAGGGGCAGAATCAT S R I G L S A P S N C I S E D E G Q N H	4140 (1380)
CAGGGACAGAGCTGTATCCATCGGCCCTGTGGGAAGCAGGACAGCTGTCCGTCTTGTCTG Q G Q S C I H R P C G K Q D S C P S L L	4200 (1400)
CTTGATCATGTGATGTGGTGAACCTGTACCTCTATAGGCCAGGTCTCATGAAGTGTGCT L D H A D V V N C T S I G P G L M K C A	4260 (1420)
ATCACTTGTCAAAGGGGATTTGCCCTCAGGCCAGCAGTGGGCAGTACATCAGGCCCATG I T C Q R G F A L Q A S S G Q Y I R P M	4320 (1440)
CAGAAGGAAATCTGCTCACATGTTCTTCTGGGCACTGGGACCAGAATGTGAGCTGCCTT Q K E I L L T C S S G H W D Q N V S C L	4380 (1460)
CCCGTGGACTGCGGTGTTCCCGACCCGTCTTTGGTGAACCTATGCAAACCTCTCTGCTCA P V D C G V P D P S L V N Y A N F S C S	4440 (1480)
GAGGGAACCAAATTTCTGAAACGCTGCTCAATCTCTTGTGTCCACCAGCCAGCTGCAA E G T K F L K R C S I S C V P P A K L Q	4500 (1500)
GGACTGAGCCCATGGCTGACATGCTTGAAGATGGTCTCTGGTCTTCCCTGAAGTCTAC G L S P W L T C L E D G L W S L P E V Y	4560 (1520)
TGCAAGTGGAGTGTGATGCTCCCCCTATTATTCTGAATGCCAAGTGTCTCTGCCTCAC C K L E C D A P P I I L N A N L L L P H	4620 (1540)
TGCCTCCAGGACAACCACGAGTGGGCACCATCTGCAAATATGAATGCAAACAGGGTAC C L Q D N H D V G T I C K Y E C K P G Y	4680 (1560)
TATGTGGCAGAAAGTGCAGAGGGTAAAGTCAAGAACAAAGCTCCTGAAGATACAATGCCTG Y V A E S A E G K V R N K L L K I Q C L	4740 (1580)
GAAGGTGGAATCTGGGAGCAAGGAGCTGCATTCTCTGTGGTGTGTGAGCCACCCCTCTT E G G I W E Q G S C I P V V C E P P P P	4800 (1600)
GTGTTTGAAGGCATGTATGAATGTACCAATGGCTTCAGCCTGGACAGCCAGTGTGTGCTC V F E G M Y E C T N G F S L D S Q C V L	4860 (1620)
AACTGTAACCAGGAACGTGAAAAGCTTCCCATCCTCTGCCTAAAGAGGGCCTGTGGACC N C N Q E R E K L P I L C T K E G L W T	4920 (1640)
CAGGAGTTTAAGTTGTGTGAGAATCTGCAAGGAGAATGCCACCACCCCTCAGAGCTG Q E F K L C E N L Q G E C P P P P S E L	4980 (1660)
AATTCTGTGGAGTACAAATGTGAACAAGGATATGGGATTGGTGCAGTGTGTTCCCCATTG N S V E Y K C E Q G Y G I G A V C S P L	5040 (1680)
TGTGTAATCCCCCAGTGACCCCGTGTGCTACCTGAGAATATCACTGCTGACACTCTG C V I P P S D P V M L P E N I T A D T L	5100 (1700)
GAGCACTGGATGGAACCTGTCAAAGTCCAGAGCATTGTGTGCACTGGCCGGCGTCAATGG E H W M E P V K V Q S I V C T G R R Q W	5160 (1720)
CACCCAGACCCCGTCTTAGTCCACTGCATCCAGTCAATGTGAGCCCTTCCAAGCAGATGGT H P D P V L V H C I Q S C E P F Q A D G	5220 (1740)
TGGTGTGACACTATCAACAACCGAGCCTACTGCCACTATGACGGGGAGACTGCTGCTCT W C D T I N N R A Y C H Y D G G D C C S	5280 (1760)
TCCCACTCTCTCCAAGAGGTGATTCATTGCTGCTGACTGTGACCTGGATGAGTGC S T L S S K K V I P F A A D C D L D E C	5340 (1780)
ACCTGCCGGGACCCCAAGGCAGAAGAAATCAGTAA T C R D P K A E E N Q *	5376 (1791)

Fig. 2




Fig. 4




Fig. 5




Fig. 6





Fig. 7a

ATGATGTGCT	TAAAGATCCT	AAGAATAAGC	CTGGCGATTT	TGGCTGGGTG	GGCACTCTGT	60
TC TGCCAACT	CTGAGCTGGG	CTGGACACGC	AAGAAATCCT	TGGTTGAGAG	GGAACACCTG	120
AATCAGTGC	TGTTGGAAGG	AGAACGTTGT	TGGCTGGGGG	CCAAGGTTCC	AAGACCCAGA	180
GCTTCTCCAC	AGCATCACCT	CTTTGGAGTC	TACCCACAGCA	GGGCTGGGAA	CTACCTAAGG	240
CCCTACCCCG	TGGGGGAGCA	AGAAATCCAT	CATACAGGAC	GCAGCAAACC	AGACACTGAA	300
GGAAATGCTG	TGAGCCTTGT	TCCCCCAGAC	CTGACTGAAA	ATCCAGCAGG	ACTGAGGGGT	360
GCAGTTGAAG	AGCCGGCTGC	CCCATGGGTA	GGGGATAGTC	CTATTGGGCA	ATCTGAGCTG	420
CTGGGAGATG	ATGACGCTTA	TCTCGGCAAT	CAAAGATCCA	AGGAGTCTCT	AGGTGAGGCC	480
GGGATTGAGA	AAGGCTCAGC	CATGGCTGCC	ACTACTACCA	CCGCCATTTT	CACAACCCCTG	540
AACGAACCCA	AAACCAGAGAC	CCAAAGGAGG	GGCTGGGCCA	AGTCCAGGCA	CGCTCGCCAA	600
GTGTGGGAAG	GGCGGGCGGA	AGATGGGCAG	GGAGACTCCG	GTATCTCTTC	ACATTTCCAA	660
CCTTGGCCCA	AGCATTCCCT	TAAACACAGG	GTCAAAAAGA	GTCCACC CGA	GGAAAGCAAC	720
CAAAATGGTG	GAGAGGGCTC	CTACCGAGAA	GCAGAGACCT	TAACTCCCA	AGTAGGACTG	780
CCCATCTTAT	ACTTCTCTGG	GAGGCGGGAG	CGGCTGCTGC	TGCGTCCAGA	AGTGTCTGGCT	840
GAGATTCCCC	GGGAGGCGTT	CACAGTGGAA	GCCTGGGTTA	AACCGGAGGG	AGCACAGAAC	900
AACCCAGCCA	TCATCGCAGG	TGTGTTTGT	AACTGTCTCC	ACACTGTCTG	TGACAAAGGC	960
TGGGCCCTGG	GGATCCGCTC	AGGGAAGGAC	AAGGGAAAGC	GGGATGCTCG	CTTCTTCTTC	1020
TCCTCTGCA	CCGACCGCGT	GAAGAAAGCC	ACCATCTTGA	TTAGCCACAG	TCGCTACCAA	1080
CCAGGCACAT	GGACCCATGT	GGCAGCCACT	TACGATGGAC	GGCACATGGC	CCTGTATGTG	1140
GATGGCACT	AGGTGGCTAG	CAGTCTAGAC	CAGTCTGGTC	CCCTGAAACAG	CCCCTTCATG	1200
GCATCTTGCC	GCTCTTTGCT	CCTGGGGGGA	GACAGCTCTG	AGGATGGGCA	CTATTTCCGT	1260
GGACACCTGG	GCACACTGGT	TTTCTGGTGC	ACCGCCCTGC	CACAAAGCCA	TTTTCAGCAC	1320
AGTTCTCAGC	ATTCAAGTGG	GGAGGAGGAA	GCGACTGACT	TGGTCTCTGC	AGCGAGCTTT	1380
GAGCCTGTGA	ACACAGAGTG	GGTTCCTTTT	AGAGATGAGA	AGTACCCACG	ACTTGAGGTT	1440
CTCCAGGGCT	TTGAGCCAGA	GCCTGAGATT	CTGTCCGCTT	TGCAGCCCCC	ACTCTGTGGG	1500
CAAACAGTCT	GTGACAATGT	GGAAATGATC	TCCAGTACA	ATGATACTG	GCCCTTCCGG	1560
GGAGAGAAGG	TGATACGCTA	CCAGGTGGTG	AACATCTGTG	ATGATGAGGG	CCTAAACCCC	1620
ATTGTGAGTG	AGGAGCAGAT	TCGTCTGCTG	CACGAGGCAT	TGAATGAGGC	CTTCAGCCCG	1680
TACAACATCA	GCTGGCAGCT	GAGCCTCCAC	CAGGTCCACA	ATTCCACCCT	CGCACACCCG	1740
GTGTGCTTG	TGAACTGTGA	GCCCAGCAAG	ATTGGCAATG	ACCATTGTGA	CCCCGAGGT	1800
GAGCACCCAC	TCACAGGCTA	TGATGGGGGT	GACTGCCGCG	TGCAGGGCCG	CTGCTACTCC	1860
TGGAACCGCA	GGGATGGGCT	CTGTACCGTG	GAGTGTAAAC	ACATGCTGAA	CGACTTTGAC	1920
GACGGAGACT	GCTGCGACCC	CCAGTGGGCT	GATGTGCGCA	AGACCTGCTT	TGACCCCTGAC	1980
TCACCCAAGT	GGGCATACAT	GAGTGTGAAG	GAGCTGAAGG	AGGCCCTGCA	GCTGAACAGT	2040
ACTCACTTCC	TCAACATCTA	CTTTGCCAGC	TCAGTGCGGG	AAGACCTTGC	AGGTGCTGCC	2100
ACCTGGCCTT	GGGACAAGGA	CGCTGTCACT	CACCTGGGGT	GCATTTGCTT	CAGCCCAGCA	2160
TATTATGGGA	TGCCTGGCCA	CACCGACACC	ATGATCCATG	AAGTGGGACA	TGTTCTGGGA	2220
CTCTACCATG	TCTTTAAAGG	AGTCAAGTGA	AGAGAATCCT	GCAATGACCC	CTGCAGAGGAG	2280
ACAGTGCCAT	CCATGGA AAC	GGGAGACCTC	TGTGCCGACA	CCGCCCCAC	TCCCAAGAGT	2340
GAGCTGTGCC	GGGAACCCAGA	GCCCCTAGT	GACACCTGTG	GCTTCACTCG	CTTCCCAGGG	2400
GCTCCGTTCA	CCAACTACAT	GAGCTACACG	GATGATAACT	GCACTGACAA	CTTCACTCT	2460
AACCAAGTGG	CCCCAATGCA	TTGCTATTTG	GACCTAGTCT	ATCAGCAGTG	GACTGAAAGC	2520
AGAAAGCCCA	CCCCCATCCC	CATTCCACCT	ATGGTCACTG	GACAGACCAA	CAAGTCCCTC	2580
ACTATCCACT	GGCTGCCTCC	TATTAGTGGG	GTTGTATATG	ACAGGGCCTC	AGGCAGCTTG	2640
TGTGGCGCTT	GCACTGAAGA	TGGGACCTTT	CGTCAGTATG	TGCACACAGC	TTCTCCCGG	2700
CGGGTGTGTG	ACTCCTCAGG	TTATTGGACC	CCAGAGGAGG	CTGTGGGGCC	TCCTGATGTG	2760
GATCAGCCCT	GCGAGCCRAAG	CTTACAGGCC	TGGAGCCCTG	AGGTCCACCT	GTACCACATG	2820
AACATGACCG	TCCCTTGCCC	CACAGAAGGC	TGTAGCTTGG	AGCTGCTCTT	CCAACACCCG	2880
GTCCAAGCCG	ACACCCCTCAC	CCTGTGGGTC	ACTTCCCTTCT	TCATGGAGTC	CTCGCAGGTC	2940
CTCTTTGACA	CAGAGATCTT	GCTGGA AAC	AAGGAGTCAG	TGCACCTGGG	CCCCTTAGAC	3000
ACTTTCTGTG	ACATCCCACT	CACCATCAA	CTGCACGTGG	ATGGGAAGGT	GTCCGGGGTG	3060
AAAGTCTACA	CCTTTGATGA	GAGGATAGAG	ATTGATGCAG	CACCTCTGAC	TTCTCAGCCC	3120
CACAGTCCCT	TGTGCTCTGG	CTGCAGGCC	GTGAGGTACC	AGGTTCTCCG	CGATCCCCCA	3180
TTTGCCAGTG	GTTTGCCCGT	GGTGGTGACA	CATTCTCACA	GGAAGTTCAC	GGAGTGGAG	3240
GTCACACCTG	GACAGATGTA	TCAGTACCAA	GTCTAGCTG	AAGCTGGAGG	AGA ACTGGGA	3300
GAAGCTTCGC	CTCCTCTGAA	CCACATTCAT	GGAGCTCCTT	ATTGTGGAGA	TGGGAAGGTG	3360
TCAGAGAGAC	TGGGAGAAGA	GTGTGATGAT	GGAGACCTTG	TGAGCCGAGA	TGGCTGCTCC	3420
AAGGTGTGTG	AGCTGGAGGA	AGGTTTCAAC	TGTGTAGGAG	AGCCAAAGCCT	TTGCTACATG	3480
TATGAGGGAG	ATGGCATATG	TGAACCTTTT	GAGAGAAAA	CCAGCATTGT	AGACTGTGGC	3540
ATCTACACTC	CCAAAGGATA	CTTGGATCAA	TGGGCTACCC	GGGCTTACTC	CTCTCATGAA	3600
GACAAGAAGA	AGTGTCTGT	TTCCCTGGTA	ACTGGAGAAC	CTCATTCCTT	AATTTGCACA	3660
TCATACCATC	CAGATTTACC	CAACCACCGT	CCCCTAACTG	GCTGGTTTCC	CTGTGTTGCC	3720
AGTGAAAATG	AAACTCAGGA	TGACAGGAGT	GAACAGCCAG	AAGGTAGCCT	GAAGAAAGAG	3780
GATGAGGTTT	GGCTCAAAT	GTGTTTCAAT	AGACCAGGAG	AGGCCAGAGC	AATTTTATT	3840
TTTTTGACAA	CTGATGGCCT	AGTTCCCGGA	GAGCATCAGC	AGCCGACAGT	GACTCTCTAC	3900
CTGACCGATG	TCCGTGGGAG	CAACCACTCT	CTTGGAACTT	ATGGACTGTC	ATGGCAGCAT	3960
AATCCACTGA	TTATCAATGT	GACCCATCAC	CAGAATGTCC	TTTTCCACCA	TACCACCTCA	4020
GTGCTGCTGA	AITTTCTCATC	CCCAGGGGTC	GGCATCTCAG	CTGTGGCTCT	AAGGCATCC	4080
TCCCGCATTG	GTCTTTCCGC	TCCCAGTAA	TGCATCTCAG	AGGACGAGGG	GCAGAATCAT	4140
CAGGGACAGA	GCTGTATCCA	TGGGCCCTGT	GGGAAGCAGG	ACAGCTGTCC	GTCATTGTCT	4200
CTTGATCATG	CTGATGTGGT	GAACGTGACC	TCTATAGGCC	CAGGTCTCAT	GAAGTGTGCT	4260
ATCACTGTGC	AAAGGGGATT	TGCCCTTCAG	GCCAGCAGTG	GGCAGTACAT	CAGGCCCATG	4320

Fig. 7b

CAGAAGGAAA	TTCTGCTCAC	ATGTTCTTCT	GGGCACTGGG	ACCAGAATGT	GAGCTGCCTT	4380
CCCGTGACT	GCGGTGTTCC	CGACCCGCT	TTGGTGAAGT	ATGCAAACTT	CTCCTGCTCA	4440
GAGGGAACCA	AATTTCTGAA	ACGCTGCTCA	ATCTCTTGTG	TCCCACCAGC	CAAGCTGCAA	4500
GGACTGAGCC	CATGGCTGAC	ATGTCCTGAA	GATGGTCTCT	GGTCTCTCCC	TGAAGTCTAC	4560
TGCAAGTTGG	AGTGTGATGC	TCCCCTATT	ATTCTGAATG	CCAACCTGCT	CCTGCCTCAC	4620
TGCTCCAGG	ACAACCACGA	CGTGGGCACC	ATCTGCAAAT	ATGAATGCAA	ACCAGGGTAC	4680
TATGTGCAG	AAAGTGCAGA	GGGTAAAGTC	AGGAACAAGC	TCCTGAAGAT	ACAATGCCTG	4740
GAAGGTGAA	TCTGGGAGCA	AGGCAGCTGC	ATTCTGTGG	TGTGTGAGCC	ACCCCTCCT	4800
GTGTTTGAAG	GCATGTATGA	ATGTACCAAT	GGCTTCAGCC	TGGACAGCCA	GTGTGTGCTC	4860
AACTGTAACC	AGGAACGTGA	AAAGCTTCCC	ATCCTCTGCA	CTAAAGAGGG	CCTGTGGACC	4920
CAGGAGTTTA	AGTTGTGTGA	GAATCTGCAA	GGAGAATGCC	CACCACCCCC	CTCAGAGCTG	4980
AATTCTGTGG	AGTACAAATG	TGAACAAGGA	TATGGGATG	GTGCAGTGTG	TTCCCATTG	5040
TGTGTAATCC	CCCCAGTGA	CCCCGTGATG	CTACCTGAGA	ATATCACTGC	TGACACTCTG	5100
GAGCACTGGA	TGGAACCTGT	CAAAGTCCAG	AGCATTGTGT	GCACCTGGCCG	GCGTCAATGG	5160
CACCCAGACC	CCGTCTTAGT	CCACTGCATC	CAGTCATGTG	AGCCCTTCCA	AGCAGATGGT	5220
TGGTGTGACA	CTATCAACAA	CCGAGCCTAC	TGCCACTATG	ACGGGGGAGA	CTGCTGCTCT	5280
TCCACACTCT	CCTCCAAGAA	GGTCATTCCA	TTTGCTGCTG	ACTGTGACCT	GGATGAGTGC	5340
ACCTGCCGGG	ACCCCAAGGC	AGAAGAAAAT	CAGTAACTGT	GGGAACAAGC	CCCTCCCTCC	5400
ACTGCCTCAG	AGGCAGTAAG	AAAGAGAGGC	CGACCCAGGA	GGAAACAAG	GGTGAATGAA	5460
GAAGAACAAT	CATGAAATGG	AAGAAGGAGG	AAGAGCATGA	AGGATCTTAT	AAGAAATGCA	5520
AGAGGATATT	GATAGGTGTG	AAC TAGTTCA	TCAAGTAGCC	CAAGTAGGAG	AGAATCATAG	5580
GCAAAAGTTT	CTTTAAAGTG	GCAGTTGATT	AACATGGGAG	GGGAAATATG	ATAGATATAT	5640
AAGGACCTC	CTCCCTCACT	TATATTCTAT	TAAATCCTAT	CCTCAACTCT	TGCCCTGCTC	5700
TCCGCTCCAC	CCCCTGCCAA	CTACTCAGTC	CCACCCAACT	TGTA AACCAA	TACCAAATA	5760
CTAGAGGAGA	AGTTGGCAGG	GATACTGTTA	ATACCCATT	TGAATGGATT	GCCATCTTTC	5820
AGAGCTTGTC	TGCTCTCAAC	TGGCTCTTTT	CTTTTTTGTG	TAGTTTCCCT	TAAATAATGA	5880
AGTTAGTTAT	TAATCTTTA	TAAGTATTTA	AACATAATTA	TATAAATATA	TTATATATAT	5940
TATATTTTTT	GCTGTTTACT	AAGCTAAAA	TTATTCAATG	TTCCACACAT	GCTGCTGTGA	6000
AGTTACATTT	CAAGATGAAT	GTTGAGACTT	TGAGGACAGA	AAGGCAACTT	ATTTTCCCAT	6060
CTTCTATG	ATGCCGATTG	GCAGGTTGAA	TGGGAAGTAC	AGAAGGAGAG	AGAGTAATTA	6120
GATGGAATTC	TGGATGCTAG	CATGTAAGC	TAATCATCTT	TTTTTTTATG	ACCTGGGAGC	6180
TGGGCCCAT	TTATGACCAA	GGAGATGGGG	AGTTGGAATG	GTGGTACTAA	GAGGCATAGG	6240
AAGTTGAGTG	TGAATACCAT	TGGTGATGGG	TCCAGGAGAA	CTAGACTATG	GTCTTGAAT	6300
ATCTGTCCAC	AAAGAATATA	CTAACTTTTG	TCAACTTCTC	AGAACTCCCA	ACTGGAGTCG	6360
GTGAGACCTA	GGATTTTCTG	CAC TPCACA	CATGCCCTGT	CCAAGTGTGG	CTGTCAGCCA	6420
GTCACAAGT	TTG TACTATG	GCCATTCTC	TGATCACCAG	GATTACAGGA	ACTCACACAC	6480
TCCTCATACT	TGGCCTGTAG	TCCTACTTCT	TGTTAGAAGT	CTCCAAGTCT	GGCCAGTCAC	6540
ATGACAAGT	GTTGATTTTT	CTGGAGGAAA	AATTTTTATG	AAATGATATA	GGGGAAGGT	6600
GGGAGGAGAT	GAAAGAACAG	GCAAGAGCTG	TCAGGGTTAA	ATCCAGGCC	GGGCATGAGA	6660
ATGGAAGTGA	TCAGGGAGAC	TCCGTCTCTG	TTCCAAGTCT	CCAAAGAAGA	CCAAAGTGGG	6720
TCCCTTGAGC	AATGAAGAAT	CTGAGATAAA	TTCTCTTCAA	GTATCATGTA	CAAAATCTGT	6780
GAGCCAGAGA	TTTTGACTTG	AGCAAGCCAT	GGAAATGCAT	GGAGCAAGGG	TGACACTCTG	6840
TGGGGAGACA	GAAGAATTTT	AAC TATTTAA	TGTCATTTT	GTTGTTTTTA	CCCTTCTTAA	6900
TCCAATAGAT	GGAAATGCACA	TGAAATGACC	ATATTAAGCC	TCTCTCTATT	TACATCCCAG	6960
GCTCAGTGGG	ATGTGATCTA	CTGCAGTTAC	ATTTTCTTGT	AACGGTTTCT	GGATTAGACC	7020
CTAGGGAAAG	TGAGTAAGGA	GCCAGTTTCT	GTTTAACATT	CTAGTTTTTAC	TCATTTTAGG	7080
AAGGCTGTGA	GTGAGGCTTG	TCTCCTTTAA	AGTTTCTTCT	CCAATGGAAA	CCAAGAACAG	7140
ACAAAATTTA	GAGCTCAGCT	GTGGTCTCTT	CTCATCTTCT	GCTCTTTTGC	TTTGACCACA	7200
GTTTTTCTAC	TCTTCCATC	AACACTAGAG	CAATGGCTGT	GCAATAGGA	ATAGGAAATA	7260
CTACCACAAT	GATAGAAATA	TTATCCACAC	TATCACGTAG	GGAAGAACAA	TATCCTGAAA	7320
GAGAATAAAA	CACGAATAAG	GTGATGTACC	CACATTAATC	TGTGGGTTTG	TGGAATGAGG	7380
GTTGCAAGT	TATTGGGAAA	AGGAAAGAGC	AGAGTTTACC	CATTCAAAAA	AAACCTTTTG	7440
TCTACTAATC	TCTAGTGTAA	AGAAAAATGTA	GTTCAGATAC	CATTCAATTGT	CTGGGTCAT	7500
GCTTAGTGCC	CCCAAGAAGA	CAAACATAAT	TATCTTGGG	ATCTGATAG	GCPTCAATAT	7560
GCAAAGGACA	ATGGA AAAAGT	TTAGACACTC	TATTTTCAAA	ATTTTATAAA	CTGTTTTTAT	7620
TGGGGAAAAAT	GTCCAAATG	CTAGACACAT	TCTAAGTTCT	GCCTTGGAGA	ATCCTACTTT	7680
GTCTGAGATT	GAGGCAGAGG	AAT TGTATC	CTGGGCATTA	CTCAGCTCAG	GAACATGGAG	7740
CCTGTGGTTC	ATGCCAGTGT	GTGTCTTCAT	GCAGTCTCTC	CACAAGAGCA	ACAGTAAGAA	7800
CATTTCTGTT	TTAAATTTCA	TTTTAAAAATA	TTTTATTATC	TGCAATTCAC	CCTGCTCTG	7860
GGAAAGCAAA	AGGAAAGTTT	CTGTTGTGTG	TGAAGAGCCT	CTTAGGCTAT	AAGGCTTCCC	7920
AGCCATAGTC	AGCTATAGCT	ATTCAGAGAC	AGCAGGTTCT	TCCAGTCTTT	GTCTCTGGGA	7980
CCTGATGTTT	TGAGCAACTC	AGGTCACTGA	TAAAGTGGAA	GGACTAAGAC	ACTGTGGTCA	8040
CAGATCCAG	CAACATCAAC	TCACACTCAA	TCCATGTGGT	GGTCCACAT	CTGCTACTCT	8100
TATCCACCCA	TGTGGTCATT	GAGAGCCTTT	CTCAGAGACT	CTTCTGTGTG	TTTGATTGTG	8160
CCCAGTGGC	CCAGGGCTAG	CTGGCTCTAA	CAACTAGCAT	GACAGCCTCC	AATCAGAAAG	8220
GCAGGTAAGG	GGACAGGGTG	AGGAGAATGG	GCAGATACTG	ACAGAAATTA	AAGTAAAGGG	8280
ATTGTGAAAG	TAAAGAGCTC	TTCTGATTC	TCATCTTCTC	TTTTTCTAT	TACAAGGCAT	8340
TGAACTTGGC	ACTTCTGTGA	TTCTTTGTGA	TCACTATTGA	GTGCATTAGT	TAAACCCCAA	8400
GGGGATGGCT	TGATTGGGAA	TGTAGTGAAA	GGAGCTGATC	TACTGTATTG	TAATGTA AAA	8460
CAGCTACAGC	CAGTTATTTT	GTAAGATTAT	AAGTTGTTC	TTAAAAATC	AGCACACAAA	8520
ATATGAA						8527

Fig. 8



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 0054806 A [0024]
- WO 0175067 A [0025]
- WO 0195855 A [0028]
- US 4683195 A [0081]
- US 4965188 A [0081]
- US 5595915 A, Geysen [0179]
- US 6013478 A [0180]
- US 4554101 A, Hopp [0186] [0188]

Non-patent literature cited in the description

- LIN et al. *Am J Obstet Gynecol*, 1974, vol. 118, 223-36 [0005]
- FOLKERSEN et al. *Am J Obstet Gynecol*, 1981, vol. 139, 910-4 [0005]
- OXVIG et al. *J Biol Chem*, 1995, vol. 270, 13645-51 [0005]
- BISCHOF. *Arch Gynecol*, 1979, vol. 227, 315-26 [0005]
- SINOSICH. *Electrophoresis*, 1990, vol. 11, 70-8 [0005]
- OXVIG et al. *J Biol Chem*, 1993, vol. 268, 12243-6 [0005] [0006]
- OVERGAARD et al. *J Biol Chem*, 2000 [0005] [0074] [0260]
- OXVIG et al. *Biochim Biophys Acta*, 1994, vol. 1201, 415-23 [0006] [0007]
- KRISTENSEN et al. *Biochemistry*, 1994, vol. 33, 1592-8 [0006] [0074] [0231] [0233] [0241]
- HAANING et al. *Eur J Biochem*, 1996, vol. 237, 159-63 [0006] [0075] [0231] [0240]
- BODE et al. *FEBS Lett*, 1993, vol. 331, 134-40 [0006] [0074]
- STOCKER et al. *Protein Sci*, 1995, vol. 4, 823-40 [0006] [0074] [0113]
- BARKER et al. *J Exp Med*, 1988, vol. 168, 1493-8 [0007]
- MCGROGAN et al. *J Exp Med*, 1988, vol. 168, 2295-308 [0007]
- OXVIG et al. *J Biol Chem*, vol. 268, 12243-6 [0007]
- OXVIG et al. *Biochem Mol Biol Int*, 1994, vol. 33, 329-36 [0007]
- BONNO et al. *Lab Invest*, 1994, vol. 71, 560-6 [0007]
- OVERGAARD et al. *Biol Reprod*, 1999, vol. 61, 1083-9 [0007] [0242] [0255]
- BRAMBATI et al. *Br J Obstet Gynaecol*, 1993, vol. 100, 324-6 [0008]
- HADDOW et al. *N Engl J Med*, 1998, vol. 338, 955-61 [0008]
- WALD et al. *Bmj*, 1992, vol. 305, 28 [0008]
- WALD et al. *N Engl J Med*, 1999, vol. 341, 461-7 [0008]
- BIAGIOTTI et al. *Prenat Diagn*, 1998, vol. 18, 907-13 [0008]
- SPENCER et al. *Prenat Diagn*, 2000, vol. 20, 411-6 [0008]
- WESTERGAARD et al. *Prenat Diagn*, 1983, vol. 3, 225-32 [0008]
- BAYES-GENIS et al. *Arterioscler Thromb Vasc Biol*, 2000 [0009] [0011]
- CHRISTIANSEN et al. *Prenat Diagn*, 1999, vol. 19, 905-10 [0009]
- LAWRENCE et al. *Proc Natl Acad Sci U S A*, 1999, vol. 96, 3149-53 [0010] [0011] [0074] [0111] [0260]
- FOWLKES. *Trends Endocrinol Metab*, 1997, vol. 8, 299-306 [0010]
- RAJARAM et al. *Endocr Rev*, 1997, vol. 18, 801-31 [0010]
- CONOVER et al. *J Clin Invest*, 1993, vol. 91, 1129-37 [0011] [0254]
- CONOVER et al. *J Clin Endocrinol Metab*, 1999, vol. 84, 4742-5 [0011] [0260]
- HWA et al. *Endocr Rev*, 1999, vol. 20, 761-87 [0012]
- LAWRENCE et al. The Insulin-like growth factor-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. *Proc. Natl. Acad. Sci.*, March 1999, vol. 96, 3149-53 [0013]
- KRISTENSEN et al. Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA. *Biochem.*, 1994, vol. 33, 1592-98 [0014]
- OVERGAARD et al. Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. *The J. of Biol. Chem.*, 06 October 2000, vol. 275 (40), 31128-33 [0015]
- OXVIG et al. Identification of angiotensinogen and compliment C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma. *The J. of Biol. Chem.*, 09 June 1995, vol. 270 (23), 13645-51 [0016]

- **OVERGAARD et al.** Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: Expression in human reproductive and nonreproductive tissues. *Biol. and Reprod.*, 1999, vol. 61, 1083-89 [0017]
- **BONNO et al.** Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. *Lab. Invest.*, 1994, vol. 71 (4), 560-66 [0018]
- **PAGE et al.** The characterization of pregnancy-associated plasma protein-E and the identification of an alternative splice variant. *Placenta*, 2001, vol. 22, 681-87 [0019]
- **OVERGAARD et al.** Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. *The J. of Biol. Chem.*, 16 June 2001, vol. 276 (24), 21849-53 [0020]
- Pregnancy-associated plasma protein-E (PAPP-E); Biochimica ET Bio-physica ACTA. **FARR et al.** Gene Structure and Expression. Elsevier, 02 October 2000, vol. 1493, 356-62 [0021]
- **CHRISTIANSEN et al.** Quantification and characterization of pregnancy-associated complexes of angiotensinogen and the proform of eosinophil major basic protein in serum and amniotic fluid. *Clin. Chem.*, 2000, vol. 46 (8), 1099-1105 [0022]
- **OXVIG et al.** Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. *The J. of Biol. Chem.*, 1993, vol. 268 (17), 12243-12246 [0023]
- **ERICKSON et al.** The physiology of folliculogenesis: the role of novel growth factors. *Fert. and Ster.*, November 2001, vol. 76 (5), 947 [0026]
- **GORDON SMITH et al.** Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth. *The J. of Clin. Endocrinol. & Metab.*, April 2002, vol. 87 (4), 1762-67 [0027]
- **GIUDICE et al.** Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: Evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. *The J. of Clin. Endocrinol. & Metab.*, May 2002, vol. 87 (5), 2359-66 [0029]
- **WALD et al.** First trimester serum screening for down's syndrome. *Prenatal Diag.*, 1995, vol. 15, 1227-40 [0030]
- **WALSH et al.** *PCR Methods Appl*, 1992, vol. 1, 241-50 [0067]
- **RUTHER ; MULLER-HILL.** *Embo J*, 1983, vol. 2, 1791-4 [0093]
- **BITTER et al.** *Methods Enzymol*, 1987, vol. 153, 516-44 [0093]
- **ROSENFELD.** *Methods Enzymol*, 1999, vol. 306, 154-69 [0093]
- **GMUNDER ; KOHLI.** *Mol Gen Genet*, 1989, vol. 220, 95-101 [0094]
- **BROGLIE et al.** *Science*, 1984, vol. 224, 838-43 [0094]
- **SMITH et al.** *Mol Cell Biol*, 1983, vol. 3, 2156-65 [0095]
- **LOGAN ; SHENK.** *Proc Natl Acad Sci U S A*, 1984, vol. 81, 3655-9 [0096]
- **MACKETT et al.** *Proc Natl Acad Sci U S A*, 1982, vol. 79, 7415-9 [0096]
- **CLACKSON et al.** *Nature*, 1991, vol. 352, 624-8 [0105]
- **MARKS et al.** *J Mol Biol*, 1991, vol. 222, 581-97 [0105]
- **SOTTRUP-JENSEN.** *Biochem Mol Biol Int*, 1993, vol. 30, 789-94 [0110]
- **MELDAL.** *Methods Mol Biol*, 1998, vol. 87, 65-74 [0115] [0117]
- **MELDAL.** *Methods Mol Biol*, 1998, vol. 87, 51-7 [0115]
- **MATTHEWS ; WELLS.** *Science*, 1993, vol. 260, 1113-7 [0116]
- **MELDAL.** *Methods Mol Biol*, 1998, vol. 87, 75-82 [0119]
- **SOUTHERN E. M.** *J. Mol. Biol.*, 1975, vol. 98, 503-517 [0155]
- **ALTSCHUL et al.** *J Mol Biol*, 1990, vol. 215, 403-10 [0156]
- **MERRIFIELD.** *J. Am. Chem. Soc.*, 1963, vol. 85, 2149-2146 [0194]
- **NIELSEN et al.** *Protein Eng*, 1997, vol. 10, 1-6 [0231]
- **THOMPSON et al.** *Nucleic Acids Res*, 1994, vol. 22, 4673-80 [0231]
- **KRISTENSE et al.** *Biochemistry*, 1994, vol. 33, 1592-8 [0231]
- **ALTSCHUL et al.** *Nucleic Acids Res*, 1997, vol. 25, 3389-402 [0242]
- **HO et al.** *Gene*, 1989, vol. 77, 51-9 [0246]
- **DUBRIDGE et al.** *Mol Cell Biol*, 1987, vol. 7, 379-87 [0249]
- **PEAR et al.** *Proc Natl Acad Sci U S A*, 1993, vol. 90, 8392-6 [0249]
- **SOTTRUP-JENSEN.** *Anal Biochem*, 1995, vol. 225, 187-8 [0252]
- **NAKAYAMA.** *Biochem J*, 1997, vol. 327, 625-35 [0253]
- **CLAUSSEN et al.** *Endocrinology*, 1994, vol. 134, 1964-6 [0259]
- **LEE et al.** *J Clin Endocrinol Metab*, 1994, vol. 79, 1367-72 [0259]
- **IMAI et al.** *J Clin Invest*, 1997, vol. 100, 2596-605 [0259] [0260]
- **RESNICK et al.** *Endocrinology*, 1998, vol. 139, 1249-57 [0259]
- **CONOVER ; KIEFER.** *J Clin Endocrinol Metab*, 1993, vol. 76, 1153-9 [0259]

- **THRAILKILL et al.** *Endocrinology*, 1995, vol. 136, 3527-33 [0259]
- **BUSBY et al.** *J Biol Chem*, 2000 [0259]
- **BAYES-GENIS, A. ; SCHWARTZ, R. S. ; ASHAI, K. ; LEWIS, D. A. ; OVERGAARD, M. T. ; CHRISTIANSEN, M. ; OXVIG, C. ; HOLMES, D. R., JR. ; CONOVER, C. A.** *Arterioscler. Thromb. Vasc. Biol.* [0260]
- **ALTSCHUL, S. F. ; MADDEN, T. L. ; SCHAFFER, A. A. ; ZHANG, J. ; ZHANG, Z. ; MILLER, W. ; LIPMAN, D. J.** Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res*, 1997, vol. 25, 3389-402 [0261]
- **AUSUBEL, F. M. ; BRENT, R. ; KINGSTON, R. E. ; MOORE, D. D. ; SEIDMAN, J. G. ; SMITH, J. A. ; STRUHL, K.** *Current Protocols in Molecular Biology*. John Wiley & Sons, 1989 [0261]
- **BARKER, R. L. ; GLEICH, G. J. ; PEASE, L. R.** Acidic precursor revealed in human eosinophil granule major basic protein cDNA [published erratum appears. *J Exp Med*, 1988, vol. 170 (3), 1057 [0261]
- *J Exp Med*, vol. 168, 1493-8 [0261]
- **BAYES-GENIS, A. ; SCHWARTZ, R. S. ; ASHAI, K., A., L. D. ; OVERGAARD, M. T. ; CHRISTIANSEN, M. ; OXVIG, C. ; HOLMES JR, D. R. ; CONOVER, C. A.** Insulin-like growth factor binding protein-4 protease produced by arterial smooth muscle cells in vitro is increased in the coronary artery following angioplasty. *Arterioscler Thromb Vasc Biol*, 2000 [0261]
- **BIAGIOTTI, R. ; CARIATI, E. ; BRIZZI, L. ; CAPPELLI, G. ; D'AGATA, A.** Maternal serum screening for trisomy 18 in the first trimester of pregnancy. *Prenat Diagn*, 1998, vol. 18, 907-13 [0261]
- **BISCHOF, P.** Purification and characterization of pregnancy associated plasma protein A (PAPP-A). *Arch Gynecol*, 1979, vol. 227, 315-26 [0261]
- **BITTER, G. A. ; EGAN, K. M. ; KOSKI, R. A. ; JONES, M. O. ; ELLIOTT, S. G. ; GIFFIN, J. C.** Expression and secretion vectors for yeast. *Methods Enzymol*, 1987, vol. 153, 516-44 [0261]
- **BODE, W. ; GOMIS-RUTH, F. X. ; STOCKLER, W.** Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. *FEBS Lett*, 1993, vol. 331, 134-40 [0261]
- **BONNO, M. ; OXVIG, C. ; KEPHART, G. M. ; WAGNER, J. M. ; KRISTENSEN, T. ; SOTTRUP-JENSEN, L. ; GLEICH, G. J.** Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. *Lab Invest*, 1994, vol. 71, 560-6 [0261]
- **BRAMBATI, B. ; MACINTOSH, M. C. ; TEISNER, B. ; MAGUINESS, S. ; SHRIMANKER, K. ; LANZANI, A. ; BONACCHI, I. ; TULUI, L. ; CHARD, T. ; GRUDZINSKAS, J. G.** Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. *Br J Obstet Gynaecol*, 1993, vol. 100, 324-6 [0261]
- **BROGLIE, R. ; CORUZZI, G. ; FRALEY, R. T. ; ROGERS, S. G. ; HORSCH, R. B. ; NIEDERMEYER, J. G. ; FINK, C. L. ; CHUA, N. H.** Light-regulated expression of a pea ribulose-1,5-bisphosphate carboxylase small subunit gene in transformed plant cells. *Science*, 1984, vol. 224, 838-43 [0261]
- **BUSBY, W. H., JR. ; NAM, T. J. ; MORALES, A. ; SMITH, C. ; JENNINGS, M. ; CLEMMONS, D. R.** The Complement Component C1 s is the Protease That Accounts for Cleavage of Insulin-like Growth Factor Binding Protein-5 in Fibroblast Medium. *J Biol Chem.*, 2000 [0261]
- **CHRISTIANSEN, M. ; OXVIG, C. ; WAGNER, J. M. ; QIN, Q. P. ; NGUYEN, T. H. ; OVERGAARD, M. T. ; LARSEN, S. O. ; SOTTRUP-JENSEN, L. ; GLEICH, G. J. ; NORGAARD-PEDERSEN, B.** The proform of eosinophil major basic protein: a new maternal serum marker for Down syndrome. *Prenat Diagn*, 1999, vol. 19, 905-10 [0261]
- **CHRISTIANSEN, M. ; JALIASHVILI, I. ; OVERGAARD, M.T. ; ENSINGER, C. ; OXVIG, C.** Quantitation and characterization of pregnancy-associated complexes between angiotensinogen and the proform of eosinophil major basic protein in serum and amniotic fluid. *Clin. Chem.*, 2000, vol. 46, 1099-1105 [0261]
- **CLACKSON, T. ; HOOGENBOOM, H. R. ; GRIFFITHS, A. D. ; WINTER, G.** Making antibody fragments using phage display libraries. *Nature*, 1991, vol. 352, 624-8 [0261]
- **CLAUSSEN, M. ; ZAPF, J. ; BRAULKE, T.** Proteolysis of insulin-like growth factor binding protein-5 by pregnancy serum and amniotic fluid. *Endocrinology*, 1994, vol. 134, 1964-6 [0261]
- **CONOVER, C. A. ; KIEFER, M. C.** Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. *J Clin Endocrinol Metab*, 1993, vol. 76, 1153-9 [0261]
- **CONOVER, C. A. ; KIEFER, M. C. ; ZAPF, J.** Post-translational regulation of insulin-like growth factor binding protein-4 in normal and transformed human fibroblasts. Insulin-like growth factor dependence and biological studies. *J Clin Invest*, 1993, vol. 91, 1129-37 [0261]
- **CONOVER, C. A. ; OXVIG, C. ; OVERGAARD, M. T. ; CHRISTIANSEN, M. ; GIUDICE, L. C.** Evidence that the insulin-like growth factor binding protein-4 protease in human ovarian follicular fluid is pregnancy associated plasma protein-A. *J Clin Endocrinol Metab*, 1999, vol. 84, 4742-5 [0261]

- ELISA. Theory and Practice, Methods. **CROWTHER, J. R.** Molecular Biology. Humana Press, 1995, vol. 42 [0261]
- **DUBRIDGE, R. B. ; TANG, P. ; HSIA, H. C. ; LEONG, P. M. ; MILLER, J. H. ; CALOS, M. P.** Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol Cell Biol*, 1987, vol. 7, 379-87 [0261]
- **FOLKERSEN, J. ; GRUDZINSKAS, J. G. ; HINDERSSON, P. ; TEISNER, B. ; WESTERGAARD, J. G.** Pregnancy-associated plasma protein A: circulating levels during normal pregnancy. *Am J Obstet Gynecol*, 1981, vol. 139, 910-4 [0261]
- **FOWLKES, J. L.** Insulinlike growth factor-binding protein proteolysis. An emerging paradigm in insulinlike growth factor physiology. *Trends Endocrinol Metab*, 1997, vol. 8, 299-306 [0261]
- **GMUNDER, H. ; KOHLI, J.** Cauliflower mosaic virus promoters direct efficient expression of a bacterial G418 resistance gene in *Schizosaccharomyces pombe*. *Mol Gen Genet*, 1989, vol. 220, 95-101 [0261]
- **HADDOW, J. E. ; PALOMAKI, G. E. ; KNIGHT, G. J. ; WILLIAMS, J. ; MILLER, W. A. ; JOHN-SON, A.** Screening of maternal serum for fetal Down's syndrome in the first trimester. *N Engl J Med*, 1998, vol. 338, 955-61 [0261]
- **HO, S. N. ; HUNT, H. D. ; HORTON, R. M. ; ULLEN, J. K. ; PEASE, L. R.** Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene*, 1989, vol. 77, 51-9 [0261]
- **HWA, V. ; OH, Y. ; ROSENFELD, R. G.** The insulin-like growth factor-binding protein (IGFBP) superfamily. *Endocr Rev*, 1999, vol. 20, 761-87 [0261]
- **HAANING, J. ; OXVIG, C. ; OVERGAARD, M. T. ; EBBESEN, P. ; KRISTENSEN, T. ; SOTTRUP-JENSEN, L.** Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A. Evidence for expression in the brain and induction by cAMP. *Eur J Biochem*, 1996, vol. 237, 159-63 [0261]
- **IMAI, Y. ; BUSBY, W. H., JR. ; SMITH, C. E. ; CLARKE, J. B. ; GARMONG, A. J. ; HORWITZ, G. D. ; REES, C. ; CLEMMONS, D. R.** Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. *J Clin Invest*, 1997, vol. 100, 2596-605 [0261]
- **KRISTENSEN, T. ; OXVIG, C. ; SAND, O. ; MOLLER, N. P. ; SOTTRUP-JENSEN, L.** Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA. *Biochemistry*, 1994, vol. 33, 1592-8 [0261]
- **LAWRENCE, J. B. ; OXVIG, C. ; OVERGAARD, M. T. ; SOTTRUP-JENSEN, L. ; GLEICH, G. J. ; HAYS, L. G. ; YATES, J. R., 3RD ; CONOVER, C. A.** The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. *Proc Natl Acad Sci U S A*, 1999, vol. 96, 3149-53 [0261]
- **LEE, K. O. ; OH, Y. ; GIUDICE, L. C. ; COHEN, P. ; PEEHL, D. M. ; ROSENFELD, R. G.** Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients. *J Clin Endocrinol Metab*, 1994, vol. 79, 1367-72 [0261]
- **LIN, T. M. ; GALBERT, S. P. ; KIEFER, D. ; SPELLACY, W. N. ; GALL, S.** Characterization of four human pregnancy-associated plasma proteins. *Am J Obstet Gynecol*, 1974, vol. 118, 223-36 [0261]
- **LOGAN, J. ; SHENK, T.** Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. *Proc Natl Acad Sci U S A*, 1984, vol. 81, 3655-9 [0261]
- **MACKETT, M. ; SMITH, G. L. ; MOSS, B.** Vaccinia virus: a selectable eukaryotic cloning and expression vector. *Proc Natl Acad Sci U S A*, 1982, vol. 79, 7415-9 [0261]
- **MARKS, J. D. ; HOOGENBOOM, H. R. ; BONNERT, T. P. ; MCCAFFERTY, J. ; GRIFFITHS, A. D. ; WINTER, G.** By-passing immunization. Human antibodies from V-gene libraries displayed on phage. *J Mol Biol*, 1991, vol. 222, 581-97 [0261]
- **MATTHEWS, D. J. ; WELLS, J. A.** Substrate phage: selection of protease substrates by monovalent phage display. *Science*, 1993, vol. 260, 1113-7 [0261]
- **MCGROGAN, M. ; SIMONSEN, C. ; SCOTT, R. ; GRIFFITH, J. ; ELLIS, N. ; KENNEDY, J. ; CAMPANELLI, D. ; NATHAN, C. ; GABAY, J.** Isolation of a complementary DNA clone encoding a precursor to human eosinophil major basic protein. *J Exp Med*, 1988, vol. 168, 2295-308 [0261]
- **MELDAL, M.** Intramolecular fluorescence-quenched substrate libraries. *Methods Mol Biol*, 1988, vol. 87, 65-74 [0261]
- **MELDAL, M.** Introduction to combinatorial solid-phase assays for enzyme activity and inhibition. *Methods Mol Biol*, 1998, vol. 87, 51-7 [0261]
- **MELDAL, M.** The solid-phase enzyme inhibitor library assay. *Methods Mol Biol*, 1998, vol. 87, 75-82 [0261]
- **NAKAYAMA, K.** Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. *Biochem J*, 1997, vol. 327, 625-35 [0261]
- **NIELSEN, H. ; ENGELBRECHT, J. ; BRUNAK, S. ; VON HEIJNE, G.** Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Protein Eng*, 1997, vol. 10, 1-6 [0261]

- **OVERGAARD, M. T. ; HAANING, J. ; BOLDT, H. B. ; OLSEN, I. M. ; LAURSEN, L. ; CHRISTIANSEN, M. ; GLEICH, G. J. ; SOTTRUP-JENSEN, L. ; CONOVER, C. A. ; OXVIG, C.** Expression of Recombinant Human Pregnancy-Associated Plasma Protein-A and Identification of the Proform of Eosinophil Major Basic Protein as its Physiological Inhibitor. *J Biol Chem.*, 2000 [0261]
- **OVERGAARD, M. T. ; OXVIG, C. ; CHRISTIANSEN, M. ; LAWRENCE, J. B. ; CONOVER, C. A. ; GLEICH, G. J. ; SOTTRUP-JENSEN, L. ; HAANING, J.** Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonreproductive tissues. *Biol Reprod*, 1999, vol. 61, 1083-9 [0261]
- **OXVIG, C. ; HAANING, J. ; HOJRUP, P. ; SOTTRUP-JENSEN, L.** Location and nature of carbohydrate groups in proform of human major basic protein isolated from pregnancy serum. *Biochem Mol Biol Int*, 1994, vol. 33, 329-36 [0261]
- **OXVIG, C. ; HAANING, J. ; KRISTENSEN, L. ; WAGNER, J. M. ; RUBIN, I. ; STIGBRAND, T. ; GLEICH, G. J. ; SOTTRUP-JENSEN, L.** Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma. *J Biol Chem*, 1995, vol. 270, 13645-51 [0261]
- **OXVIG, C. ; SAND, O. ; KRISTENSEN, T. ; GLEICH, G. J. ; SOTTRUP-JENSEN, L.** Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. *J Biol Chem*, 1993, vol. 268, 12243-6 [0261]
- **OXVIG, C. ; SAND, O. ; KRISTENSEN, T. ; KRISTENSEN, L. ; SOTTRUP-JENSEN, L.** Isolation and characterization of circulating complex between human pregnancy-associated plasma protein-A and proform of eosinophil major basic protein. *Biochim Biophys Acta*, 1994, vol. 1201, 415-23 [0261]
- **PEAR, W. S. ; NOLAN, G. P. ; SCOTT, M. L. ; BALTIMORE, D.** Production of high-titer helper-free retroviruses by transient transfection. *Proc Natl Acad Sci U S A*, 1993, vol. 90, 8392-6 [0261]
- **PETERS, J. H. ; BAUMGARTEN, H.** Monoclonal Antibodies. Springer-Verlag, 1992 [0261]
- **RAJARAM, S. ; BAYLINK, D. J. ; MOHAN, S.** Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. *Endocr Rev*, 1997, vol. 18, 801-31 [0261]
- **RESNICK, C. E. ; FIELDER, P. J. ; ROSENFELD, R. G. ; ADASHI, E. Y.** Characterization and hormonal regulation of a rat ovarian insulin-like growth factor binding protein-5 endopeptidase: an FSH-inducible granulosa cell-derived metalloprotease. *Endocrinology*, 1998, vol. 139, 1249-57 [0261]
- **ROSENFELD, S. A.** Use of *Pichia pastoris* for expression of recombinant proteins. *Methods Enzymol*, 1999, vol. 306, 154-69 [0261]
- **RUTHER, U. ; MULLER-HILL, B.** Easy identification of cDNA clones. *Embo J*, 1983, vol. 2, 1791-4 [0261]
- **SAMBROOK, J. ; FRITSCH, E. F. ; MANIATIS, T.** Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0261]
- **SCOPES, R. K.** Protein Purification. Principles and Practice. Springer-Verlag, 1987 [0261]
- **SINOSICH, M. J.** Molecular characterization of pregnancy-associated plasma protein-A by electrophoresis. *Electrophoresis*, 1990, vol. 11, 70-8 [0261]
- **SMITH, G. E. ; SUMMERS, M. D. ; FRASER, M. J.** Production of human beta interferon in insect cells infected with a baculovirus expression vector. *Mol Cell Biol*, 1983, vol. 3, 2156-65 [0261]
- **SOTTRUP-JENSEN, L.** Determination of halfcystine in proteins as cysteine from reducing hydrolyzates. *Biochem Mol Biol Int*, 1993, vol. 30, 789-94 [0261]
- **SOTTRUP-JENSEN, L.** A low-pH reverse-phase high-performance liquid chromatography system for analysis of the phenylthiohydantoins of S-carboxymethylcysteine and S-carboxyamidomethylcysteine. *Anal Biochem*, 1995, vol. 225, 187-8 [0261]
- **SPENCER, K. ; ONG, C. ; SKENTOU, H., A. W. L. ; K, H. N.** Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. *Prenat Diagn*, 2000, vol. 20, 411-6 [0261]
- **STOCKER, W. ; GRAMS, F. ; BAUMANN, U. ; REINEMER, P. ; GOMIS-RUTH, F. X. ; MCKAY, D. B. ; BODE, W.** The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. *Protein Sci*, 1995, vol. 4, 823-40 [0261]
- **THOMPSON, J. D. ; HIGGINS, D. G. ; IBSON, T. J.** CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res*, 1994, vol. 22, 4673-80 [0261]
- **THRILKILL, K. M. ; QUARLES, L. D. ; NAGASE, H. ; UZUKI, K. ; SERRA, D. M. ; FOWLKES, J. L.** Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. *Endocrinology*, 1995, vol. 136, 3527-33 [0261]
- **WALD, N. ; STONE, R. ; CUCKLE, H. S. ; GRUDZINSKAS, J. G. ; BARKAI, G. ; BRAMBATI, B. ; TEISNER, B. ; FUHRMANN, W.** First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. *Bmj*, 1992, vol. 305, 28 [0261]
- **WALD, N. J. ; WATT, H. C. ; HACKSHAW, A. K.** Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. *N Engl J Med*, 1999, vol. 341, 461-7 [0261]

EP 1 346 061 B1

- **WALSH, P. S. ; ERLICH, H. A. ; HIGUCHI, R.** Preferential PCR amplification of alleles: mechanisms and solutions. *PCR Methods Appl*, 1992, vol. 1, 241-50 [**0261**]
- **WESTERGAARD, J. G. ; CHEMNITZ, J. ; TEISNER, B. ; POULSEN, H. K. ; IPSEN, L. ; BECK, B. ; GRUDZINSKAS, J. G.** Pregnancy-associated plasma protein A: a possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndrome. *Prenat Diagn*, 1983, vol. 3, 225-32 [**0261**]

专利名称(译)	妊娠相关血浆蛋白-a2 (PAPP-a2)		
公开(公告)号	EP1346061B1	公开(公告)日	2014-12-17
申请号	EP2001978230	申请日	2001-10-19
[标]申请(专利权)人(译)	COMO BIOTECH		
申请(专利权)人(译)	COMO BIOTECH APS		
当前申请(专利权)人(译)	COMO BIOTECH APS		
[标]发明人	OXVIG CLAUS OVERGAARD MICHAEL TOFT		
发明人	OXVIG, CLAUS OVERGAARD, MICHAEL, TOFT		
IPC分类号	C12N9/64 A61K38/00 C07K14/47 C12Q1/37 C12Q1/68 G01N33/68 A01K67/027 A61K31/7088 A61K35/12 A61K45/00 A61K48/00 A61P9/10 A61P19/02 A61P19/10 A61P29/00 A61P35/00 A61P43/00 C07K16/40 C12N1/15 C12N1/19 C12N1/21 C12N5/10 C12N15/09 C12P21/08 C12Q1/02 G01N21/77 G01N21/78 G01N33/15 G01N33/50 G01N33/53 G01N33/566 G01N33/577		
CPC分类号	A61K38/00 A61P9/10 A61P19/02 A61P19/10 A61P29/00 A61P35/00 A61P43/00 C12N9/6489 C07K14/4715 C07K2319/21 C07K2319/41 C12Q1/37 C12Q1/6876 G01N33/689 G01N2333/96486 G01N2500/02		
优先权	200001571 2000-10-20 DK 60/241840 2000-10-20 US		
其他公开文献	EP1346061A2		
外部链接	Espacenet		

摘要(译)	<p>atg atg tgc tta aag atc cta aga ata agc ctg gcg att ttg gct ggg 48 Met Met Cys Leu Lys Ile Leu Arg Ile Ser Leu Ala Ile Leu Ala Gly -230 -225 -220</p> <p>tgg gca ctc tgt tct gcc aac tct gag ctg ggc tgg aca cgc aag aaa 96 Trp Ala Leu Cys Ser Ala Asn Ser Glu Leu Gly Trp Thr Arg Lys Lys -215 -210 -205</p> <p>tcc ttg gtt gag agg gaa cac ctg aat cag gtg ctg ttg gaa gga gaa 144 Ser Leu Val Glu Arg Glu His Leu Asn Gln Val Leu Leu Glu Gly Glu -200 -195 -190</p>
<p>本发明提供了鉴定和编码与妊娠相关的血浆蛋白-A (PAPP-A) 具有同源性的新蛋白质的核苷酸和氨基酸序列。我们表示这种蛋白质PAPP-A2。编码PAPP-A2的cDNA来源于人胎盘。本发明还提供了编码PAPP-A2的核苷酸序列的反义分子，用于产生纯化的PAPP-A2的表达载体，能够特异性结合PAPP-A2的抗体，用于检测PAPP-A2的杂交探针或寡核苷酸。</p> <p>- 编码核苷酸序列，用于表达PAPP-A2的基因工程宿主细胞，使用该蛋白质产生能够与蛋白质特异性结合的抗体，用于筛选怀孕和非怀孕患者中基于检测到的病理学的方法PAPP-A2抗原在人体体液或PAPP-A2编码核酸分子中，使用该蛋白质筛选改变PAPP-A2蛋白酶活性的试剂，使用该蛋白质作为这些试剂的治疗靶标，并使用蛋白质作为相关病理状态的治疗剂。还描述了用于筛选怀孕和/或非怀孕患者中改变的局灶性增殖状态的方法，其包括检测PAPP-A2的水平。本发明还提供了PAPP-A2的天然底物，胰岛素样生长因子结合蛋白 (IGFBP) -5的鉴定。</p>	